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Abstract 
Biological macromolecules such as peptides have a great potential to act as 
therapeutic agents to cure disease. However, they are unable to translocate biological 
membranes and require drug delivery systems (DDSs) for intracellular delivery. In 
order to evaluate the ability of novel DDSs to deliver peptide cargo, it is crucial that 
we are able to assess the functional delivery of the peptide to its intracellular target.   
In this study a technique based on split green fluorescent protein (GFP) has been 
developed to address this. Split GFP consists of two non-fluorescent fragments, 
GFP1-10 and a small peptide fragment called M3. In the presented assay, GFP1-10 
acts as a cytosolic target protein expressed in HeLa cells and M3 mimics the peptide 
cargo that is delivered by a DDS. Upon functional delivery of the M3 peptide by a 
DDS to the cytosol, M3 and GFP1-10 complement to form full length GFP and GFP 
fluorescence is rescued. In this thesis, the development of this split GFP based 
method is described. Furthermore, a stable cell line expressing GFP1-10 was 
generated and we were able to show that our model DDS, the cell penetrating peptide 
octaarginine (R8), functionally delivers M3 to its cytosolic GFP1-10 target in a 
concentration dependent manner. The addition of two Phenylalanine residues to R8-
M3 (FFR8-M3) significantly increases M3 delivery. Furthermore it is shown that M3 
delivery can be investigated in real time using a widefield microscope. Moreover, the 
split GFP complementation assay not only shows if and when the M3 peptide cargo 
is delivered to its intracellular target but also where it localises in the cell. It is 
demonstrated that the subcellular localisation of complemented GFP is dependent on 
the DDS utilised to deliver M3.  A second system has been developed within this 
project where the fluorescent protein mCherry acts as an expression marker of GFP1-
10 expression. This system has the potential to correlate complemented GFP 
fluorescence with the amount of expressed GFP1-10 in order to gain information how 
much M3 peptide has been delivered to the cytosol.  
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1 Introduction 
1.1 The importance of biologics to cure disease 
Biologics include vaccines, therapeutic peptides and proteins, monoclonal 
antibodies and nucleic acids based therapeutics.  They are therapeutic substances 
that are manufactured in living systems or are produced using biotechnology which 
makes use of biological processes, organisms, cells or cellular components in order 
to develop new technologies to treat disease. In contrast, traditional pharmaceuticals 
like small molecule drugs are chemically manufactured. Biologics are of growing 
importance for the pharmaceutical industry to act as novel therapeutics to cure 
disease and their development has revolutionized the pharmaceutical industry 
(Stockwin and Holmes 2003; Vlieghe et al. 2010; Lundin et al. 2015).  
In the year 2000, the main reasons for attrition of drugs in the clinic was lack of 
clinical safety and toxicology as well as a lack of efficiency of drugs (Kola and Landis 
2004). A study between the years 1991 to 2000 that investigated the top 10 drug 
companies' success and failure rates from across different therapeutic areas showed 
that attrition mainly occurs in Phase II and Phase III clinical trials (Kola and Landis 
2004). Biologics brought a big change into the pharmaceutical industry with the 
prospect to cure disease with higher specificity and less side effects compared to 
small molecule drugs. In fact, it can be shown that the likelihood of moving from Phase 
I clinical trial to launch has been higher for biologics compared to small molecules 
from 1996 to 2014 (Figure 1-1 a). Between 2012 and 2014 it was even twice as likely 
for biologics (18%) to move from Phase I clinical trial to launch compared to small 
molecules (9%). Furthermore it was shown that the success rate was increased for 
biologics to move to the next phase of clinical trials between 2012 and 2014 (Figure 
1-1 b) (Smietana et al. 2016).  Thus, biologics have been shown to be more 
successful to act as therapeutics than small molecules.  
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The impact of biologics to act as therapeutics is also reflected in an overview of 
best-selling drugs in 2016 where top-selling drugs were ranked based on sales or 
revenue reported for 2016 by biopharma companies in press announcements, annual 
reports, investor materials, and/or conference calls. Eight of the ten best selling drugs 
were biologics (genengnews.com).  
 
 
 
 
Figure 1-1 Comparison of success rates of small molecules and biologics in clinical 
trials.  
(a) Comparison of the cumulative success rates of small molecules and biologics to move 
from Phase I clinical trial to launch 1996-2014. (b) Success of small molecules and biologics 
to move to the next phase 2012-2014. Figure obtained from (Smietana et al. 2016). 
Permission for reprint: license number 4270770091808. 
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1.1.1 Extracellular targets of biologics 
Thus far biologics have been successful to act as therapeutics to target 
extracellular receptors that trigger an intracellular response or extracellular factors 
such as antigens or cytokines. 
The top-selling drug shown in the overview of best-selling drugs in 2016 is 
Humira (AbbVie) (genengnews.com). Humira is a therapeutic monoclonal antibody 
(MAb) that targets the extracellular soluble cytokine TNF alpha in order to treat the 
autoimmune disease rheumatoid arthritis. MAb are complex macromolecules that are 
highly specific to their antigens and bind these with high specificity and high affinity. 
In 2015, 47 approved MAb products were on the market. All targeting strategies of 
these products to treat disease involved the targeting of extracellular factors such as 
cell surface antigens, cytokines and extracellular receptors with the most successful 
strategies for marketed MAb products being cytokine binding to treat autoimmune 
diseases and extracellular receptor binding in order to treat cancer (Doig Alfred 2015).  
Monoclonal antibodies are just one example of approved biologics that have 
extracellular targets. A second type of biologics are therapeutic peptides. Peptide 
therapeutics are macromolecules of a size of up 50 amino acids. The majority of 
therapeutic peptides on the market act as receptor agonists to trigger an intracellular 
response (Vlieghe et al. 2010; Kaspar and Reichert 2013). One class of receptors 
that are a popular target for peptide therapeutics are G protein coupled receptors 
(GPCRs). In 2003 peptides targeting GPCRs accounted for the biggest class of 
therapeutic peptides on the market (almost 50%) (Pichereau 2005). One example is 
the Gonadotropin-Releasing-Hormone (GNRH) agonists Leuprolide (Lupron1; Abbott 
Laboratories) which is used to treat prostate cancer. It achieved global sales of over 
US$2 billion in 2011: the second best-selling peptide therapeutic drug between 2009 
and 2011 out of 25 US-approved products (Kaspar and Reichert 2013). Another 
peptide therapeutic which targets a GPCR is the glucagon-like peptide 1 (GLP-1) 
receptor agonist for the treatment of type 2 diabetes. The glucagon-like peptide 
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1(GLP-1) receptor presented the biggest class of G-protein coupled receptor targets 
of peptides in clinical studies in 2012 (Kaspar and Reichert 2013). 
 
1.1.2 Intracellular targets of biologics 
Extracellular targets are the low hanging fruits in the development of biologic 
therapeutics as these targets do not require the macromolecules to pass the plasma 
membrane. A new promising area for biologic drugs is to carry out their function at 
intracellular targets. Intracellular targets include cytoplasmic (e.g. kinases and other 
enzymes), mitochondrial (e.g. pro or anti-apoptotic factors) or nuclear targets (e.g. 
transcription factors) (Mitragotri et al. 2014).  
One major therapeutic area that requires the access of therapeutics to 
intracellular targets is gene therapy. Nucleic acid based therapeutics can be utilised 
for gene therapy that allows the specific targeting of genes that are responsible for 
causing disease and control their expression. Popular approaches in order to achieve 
this are antisense oligonucleotides (ASOs) or small interfering RNAs (siRNA). Both 
of these strategies are induce targeted downregulation of gene expression post 
transcriptional through Watson-Crick base pairing with the complementary mRNA. 
ASOs are single stranded and inhibit gene expression by binding to mRNA thereby 
blocking access of ribosomes the mRNA, modulate splicing or recruit cleaving 
enzymes to the complex. In contrast, siRNA is double stranded consisting of a 
passenger and a guide strand. While the passenger strand is released in the process 
of gene silencing, the guide strand ensures the recruitment of degrading protein 
complexes to the complementary mRNA strand (reviewed in (Watts and Corey 
2012)). Nucleic acid based therapeutics are especially promising therapeutics for 
cancer therapy where cells undergo numerous genetic changes which lead to tumour 
cell growth (reviewed in (Devi 2006; Young et al. 2016).  
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Antibodies have been shown to be successful therapeutic agents to act at 
extracellular targets. They are also believed to have a great potential to act 
intracellularly in order to target protein-protein interactions, protein-nucleic acid 
interactions or even relocation of their antigens to subcellular locations (reviewed in 
(Lobato and Rabbitts 2003)).  
Another group of therapeutics promising to target intracellular protein-protein 
interactions are therapeutic peptides (Nevola and Giralt 2015; Doak et al. 2016).The 
advantage of peptides therapeutics compared to antibodies is that they have a lower 
manufacturing cost because they can be manufactured synthetically (compared to 
recombinant production of antibodies), show high biological activity associated with 
low toxicity (reviewed in (Ladner et al. 2004), (Pichereau 2005)). In addition, peptides 
have a potential to penetrate further into tissues compared to antibodies due to their 
smaller size (McGregor 2008). 
 
Despite this great potential of biologics such as therapeutic peptides, antibodies 
and nucleic acid derivatives to cure disease, their poor absorption and permeability 
across biological barriers and delivery to their intracellular targets largely limits their 
therapeutic use.  
 
1.2 Requirements for intracellular delivery  
Absorption, distribution, metabolism and excretion (ADME) processes in the 
body are critical when developing drugs. Especially cell permeability of a drug in order 
to reach its intracellular target is critical to the successful development of drugs. 
Factors that play a key role in the absorption of drugs are solubility and permeability. 
For small molecule drugs the chemical properties to achieve optimal solubility 
and permeability are well defined. Christopher Lipinski and his colleagues proposed 
the key chemical criteria to achieve optimal solubility and permeability of a drug in 
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1997 (Lipinski et al. 1997). Lipinski’s Rule of Five implies that poor absorption and 
permeation of a drug is more likely if it meets the following criteria: the number of 
groups that donate hydrogen to form a hydrogen bond is more than five (sum of 
hydroxyl and amine groups); the number of groups that accept hydrogen to form a 
hydrogen bond is more than 10 (sum of oxygen and nitrogen atoms); the molecular 
weight is greater than 500 Daltons and the calculated Log P (logarithm of the partition 
coefficient between water and 1-octanol) is greater than 5 (Lipinski et al. 1997). These 
rules apply to the absorption by passive diffusion of drugs and are used as criteria to 
determine the overall ‘drug-likeliness’ of small molecule drugs rule and has led to the 
decrease in attrition rates of drugs (Leeson 2012). Lipinski’s observations show that 
oral bioavailability and cell permeability is mainly dependent on molecular weight and 
polarity and is increased for small lipophilic molecules.  
 
1.2.1 Inability of biologics to pass the plasma membrane 
Lipinski’s Rule of Five defines the optimal characteristic of a drug in order to 
permeate the plasma membrane. Key characteristics are molecular weight and 
polarity. Investigating the characteristics regarding molecular weight and polarity of 
the small molecule drug aspirin compared to biologics sheds light on as to why 
biologics do not comply with the rule of five and have a poor permeability across 
biological membranes.  Figure 1-2 shows the structure and molecular weight of the 
small molecule drug Aspirin as well as three examples of biologics, Glucagon-like 
peptide 1, Insulin and a monoclonal antibody. Aspirin consists of 21 atoms with a 
molecular mass of 0.18 kDa. In contrast, biologics are complex macromolecules with 
increased molecular weight; Glucagon-like peptide 1 with 3.27 kDa; Insulin with 5.8 
kDa or a monoclonal antibody with 26 kDa. The molecular weight of biologics 
compared to aspirin is increased by 18.1 times for Glucagon-like peptide 1, 32.2 times 
for Insulin and 144.4 times for a monoclonal antibody. This increased molecular 
weight limits their ability to passively diffuse across the plasma membrane. 
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Furthermore, aspirin is lipophilic in the acidic environment of the stomach which 
allows absorption of the drug by diffusion across the plasma membrane (Gutknecht 
and Tosteson 1973). Therapeutic proteins and peptides are of hydrophilic nature 
which makes them impermeable to the lipidic plasma membrane.  
 
The rule of five not only defines the ‘drug-likeliness’ of small molecule drugs but 
also allows to predict small molecule ‘druggable’ protein targets. These are limited to 
proteins where ligand and substrate binding pockets are solvent-accessible and 
susceptible to small molecule interaction (e.g. inhibition) (Naylor et al. 2017). Due to 
the small size of a small molecule drug (<0.5 kDa) it has a limited surface area and 
the interaction site with its target protein represents no more that 2-5% of the surface 
area of the protein (Lazo and Sharlow 2016). The classes of proteins that were 
defined as ‘druggable’ targets of small molecules are mainly enzymes and G protein 
coupled receptors (Hopkins and Groom 2002). However, these targets only reflect a 
small portion of the interactions mapped in the human genome (Venkatesan et al. 
2009). Especially targets like protein-protein interactions are important novel targets 
in drug discovery (McFedries et al. 2013). With their large interaction surface that 
contain few opportunities for molecular interaction, these targets do not comply with 
Lipinski’s Rule of Five and were therefore believed to be ‘undruggable’.  (Doak et al. 
2016).  In contrast, biologics are macromolecules (>0.5 kDa) that do not comply with 
Lipinski’s Rule of Five which limits their permeability across the plasma membrane.  
However, their large surface area and biological activity offers novel possibilities of 
molecular interaction with their targets beyond ‘Rule of five drugs’ (Doak et al. 2016; 
Lazo and Sharlow 2016).  
Hence, in order to make use of the full potential of biologics to cure disease, drug 
delivery systems are needed that facilitate the delivery of biological macromolecules 
across that plasma membrane to their intracellular targets.  
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Figure 1-2 Comparison of the size of a small molecule drug and biologics.  
Aspirin represents a small molecule drug. The structure was obtained from the PubChem website (CID 2244). Carbon molecules are shown in black, Hydrogen 
molecules are shown in dark grey and Oxygen molecules are shown in red. Glucagon like peptide 1 (GLP-1) receptor agonist is a popular choice for peptide 
therapeutics (Kaspar and Reichert 2013). Presented here is the structure of Glucagon-like peptide 1 (PDB ID: 1D0R) (Chang 2001) . Furthermore, structures 
of Insulin (PDB ID: 3I40) (Timofeev et al. 2010) and an IgG2a monoclonal antibody (PDB ID 1igt) (Harris et al. 1997) are shown as an example for biologics. All 
structures were modelled using Chimera.
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1.3 Cell penetrating peptides for delivery of biologics 
1.3.1 Natural peptides 
Cell penetrating peptides (CPPs) are currently attracting a lot of interest in the 
drug delivery field, as it is hoped they can be exploited as a novel drug delivery system 
for macromolecular delivery (Foged and Nielsen 2008; Munyendo et al. 2012).  
As their name suggests, CPPs have the ability to penetrate the cell membrane 
and gain access into the cell. CPPs are short peptide sequences, usually consisting 
of no more than 30 residues and were first found in organisms that are known to be 
able to penetrate membranes (e.g. viruses). These sequences are also called protein 
transduction domains (PTD).  The best characterised examples are the human 
immunodeficiency virus (HIV) derived CPP Tat which plays a major role in the virus 
transduction into cells (Fawell et al. 1994; Vives et al. 1997), or the amphipathic 
Antennapedia homeobox protein, penetratin which was discovered in Drosophila 
where it acts as a transcription factor that can translocate between cells (Derossi et 
al. 1994). The amphipathic character of penetratin is revealed upon interaction with 
the plasma membrane when there is a structural change in the peptide conformation 
(helix formation) and insertion into the membrane (Dom et al. 2003; Ziegler 2008) .  
In contrast, the Tat peptide is classed a non-amphipathic peptide and binds to 
plasma membranes with a high local concentration of anionic lipids (Madani et al. 
2011). The cell penetrating character of Tat is attributed to its charge as the peptide 
consists of mainly basic amino acids; predominantly Arginine and Lysine residues, 
giving the peptide a cationic character that allows the peptide to bind and translocate 
through the membrane (Vives et al. 1997). 
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1.3.2 Synthetic peptides 
Based on these natural examples highly positively charged synthetic peptides 
were generated to test their cell penetrating ability. Potential peptides for this were 
polymers consisting of the basic amino acids Histidine, Lysine and Arginine. It was 
found that peptides with a length of less than 6 amino acids are ineffective to enter 
the cell. Furthermore, a comparison of polypeptide sequences consisting of Arginine, 
Lysine or Histidine residues revealed that (L-or D-) Arginine is the most efficient to 
enter cells (Mitchell et al. 2000).  
In a study by Gisela Tuennemann the penetration ability of polyarginines was 
further investigated. It was shown that the cell penetrating character is dependent on 
the length of the polyarginine chain and successful cell penetration requires a 
minimum of 7 Arginine residues. The transduction efficiency of polyarginines 
increases with increasing number of arginine residues and concentration. This effect 
however is accompanied with increased toxicity (Tunnemann et al. 2008). Peptides 
between 8 and 10 arginine residues are commonly used to study uptake of 
polyarginines into cells (Futaki et al. 2003; Tunnemann et al. 2008).   
The chemically synthesised peptide Octaarginine, R8, is of special interest for 
this study. For this reason uptake mechanisms and cargo delivery are discussed 
focused on R8 or arginine rich peptides.  
 
1.3.3 The uptake of CPPs 
1.3.3.1 Methods to study the uptake of CPPs 
A popular strategy in order to investigate the uptake of CPPs like R8 into cells is 
the attachment of a fluorophore to the CPP and quantification using fluorescent 
microscopy or flow cytometry. Commonly used methods included methanol or 
paraformaldehyde fixation of cells after incubation with the fluorophore tagged CPP 
and microscopic analysis of the localisation of the fluorophore. However microscopic 
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analysis showed that fixation introduced an artificial redistribution of arginine rich 
CPPs to the nucleus compared to live cells where the fluorescence was located in 
vesicular structures throughout the cytosol (Lundberg and Johansson 2002; Richard 
et al. 2003). Due to these experimental artefacts, it is critical to perform uptake studies 
of cell penetrating peptides and quantify cellular fluorescence using live cells.  
Furthermore it is important to be able discriminate between fluorescently tagged 
CPP that is bound to the cell surface and CPP that has internalised into the cell. 
Richard and colleagues have demonstrated in their studies that fluorescently tagged 
CPPs are associated to the plasma membrane and quantification using flow 
cytometry measurement not only measures the fluorescence of internalised CPPs but 
also extracellular CPP bound to the plasma membrane (Richard et al. 2003). For this 
reason it is important to remove extracellular membrane bound CPP. Methods to 
achieve this are treatment of cells with trypsin in order to digest the membrane bound 
CPP without damaging the plasma membrane (Richard et al. 2003) or heparin 
washing of the cells which competitively removes CPPs bound to heparan sulfates 
on the plasma membrane (Lundberg et al. 2003). Utilising these improved methods it 
is possible to quantify the uptake of fluorescently tagged CPPs using microscopy or 
flow cytometry measurement (Fretz et al. 2007; Tunnemann et al. 2008; Sayers et al. 
2014). Attachment of fluorescent probes to the CPP, however have been shown to 
influence the uptake of CPPs into cells. Depending on the charge of the fluorescent 
probe itself it can increase the uptake of CPPs into cells (Jones and Sayers 2012; 
Hyrup Moller et al. 2015). An alternative to the attachment of fluorescent probes to 
CPPs in order to monitor their uptake into cells is quantification using mass 
spectrometry where molecules can be analysed according to their mass. This 
technique however requires the lysis of cells and does not allow to monitor the 
subcellular distribution of CPPs in live cells (Burlina et al. 2005).  
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1.3.3.2 L and D amino acid enantiomers 
When CPPs are synthesised, they can be chemically synthesised using L or D 
amino acids, however, the choice of the L or D isoform has an effect on uptake 
dynamics into cells. The human body only produces and recognises L-amino acid 
isoforms. Thus, CPPs that are produced as an L-amino acids isoforms can be 
recognised by cellular proteases and are at risk of degradation. In contrast, it has 
been shown that CPPs composed of the D-isoform were more stable in HeLa cells 
than CPPs composed of L-amino acids because they are not recognised by cellular 
proteases (Derek S. Youngblood et al. 2006). This could lead to the assumption that 
CPPs composed of the D-isoform should be utilised over the L-isoform. However, due 
to the fact that the D-isoform is foreign to the body, it was also demonstrated that the 
uptake of D-CPPs was decreased compared to L-CPPs (Verdurmen et al. 2011). For 
this reason it is preferred use L-CPPs compared to D-CPPs even though this is 
associated with an increased susceptibility to protease degradation once internalised.  
How CPPs enter the cell is widely discussed and an ongoing field of CPP 
research. Thus far, two modes of cell entry are considered for cationic CPPs, direct 
translocation of the plasma membrane and uptake via endocytosis (reviewed in 
(Koren and Torchilin 2012; Layek et al. 2015)) (Figure 1-3).  
 
1.3.3.3 Direct translocation 
One mechanism for arginine rich peptides to gain entry to the cytosol is direct 
penetration of the plasma membrane (Figure 1-3 A) and this process has been found 
to be concentration dependent (Tunnemann et al. 2008). Once the peptides reach a 
threshold concentration, direct translocation across the plasma membrane can occur 
(Fretz et al. 2007; Jones 2007). When the direct translocation efficiency of 
polyarginines into cells was assessed it was found that the threshold started at 
concentrations as low as 5 µM. However, only a low proportion of cells was seen to 
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be positive for translocation (<5%). Direct translocation for this study was considered 
to occur when the fluorescent signal of the fluorophore tagged CPP is distributed 
within the whole cytosol and not seen as punctate structures enclosed in vesicles, 
where the uptake would be classed as occurring via endocytosis (Tunnemann et al. 
2008).  
 Direct penetration of the cell by positively charged CPPs involves interaction 
with the negatively charged components of the plasma membrane like proteoglycans 
and phospholipids that leads to destabilisation of the membrane (reviewed in (Layek 
et al. 2015)). The mode by which penetration of lipid membranes by Arginine residues 
occurs was shown to be due to the formation of stable arginine-phosphate clusters 
that were formed in the membrane. This leads to binding, membrane perturbations 
and can result in pore formation in the membrane (Li et al. 2013). However, even 
though direct penetration of the plasma membrane is seen from a concentration of 5 
µM (<5% transduced cells), it was shown that this was not associated with toxicity up 
to a concentration of 50 µM (35% of transduced cells) when polyarginines (R7-R9) 
were incubated with HeLa cells (Tunnemann et al. 2008).  
There is evidence that damage to the membrane caused by the entry of CPPs 
trigger cellular repair mechanisms that involve internal vesicles being mobilized to the 
site of the disrupted plasma membrane resealing it to prevent leakage of intracellular 
molecules (Palm-Apergi et al. 2009). 
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Figure 1-3 Mode of uptake 
of  Cell penetrating 
peptides. 
(A) Cell penetrating peptides 
can enter the cell through 
direct penetration of the 
plasma membrane (direct 
translocation).  
(B) A second way of uptake is 
via endocytic pathways like 
macropinocytosis or clathrin 
dependent endocytosis. Once 
CPPs are internalised they 
are enclosed in an 
endosome/macropinosome.  
R8 is shown as an example 
for CPP uptake.  
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1.3.3.4 Endocytic uptake  
A second mechanism by which Arginine rich CPPs can enter the cells is through 
endocytosis (Figure 1-3 B). Endocytosis is a process where membrane impermeable 
molecules are internalized into the cell by engulfing them with plasma membrane in 
order to form vesicles. Through this process, the molecule is enclosed in a membrane 
vesicle that buds inside the cell to form an endosome. Hence, the endocytic process 
leads to internalisation of membranes originating from the plasma membrane bilayer. 
It can be dependent on different co-factors defining several endocytic pathways 
(reviewed in (Doherty and McMahon 2009)). Endocytic uptake of CPPs is usually 
studied in low concentrations ranging from 1 µM to 10 µM (Ikuhiko Nakase et al. 2006; 
Sayers et al. 2014; Kawaguchi et al. 2016). 
CPPs like Tat and R8 were shown to be taken up by an endocytic process called 
macropinocytosis (Kaplan et al. 2005; Ikuhiko Nakase et al. 2006). Macropinocytosis 
is a process of ruffling of the plasma membrane to engulf fluid and cargo into 
macropinosomes (Figure 1-3 B). This fluid phase uptake process was first described 
in 1931 by Warren Lewis in rat macrophages (Lewis 1931). Macropinocytosis can be 
initiated by signalling molecules like epidermal growth factor (EGF). Stimulation with 
EGF leads to reorganisation of the actin skeleton and ruffling of the plasma 
membrane which leads to internalisation of EGF receptor (Orth et al. 2006).  
Uptake of R8 through macropinocytosis was shown to be dependent on 
interaction with heparan sulfate proteoglycans, negatively charged components of the 
plasma membrane,  and it was suggested that interaction with these components 
activates signals that lead to actin organisation and macropinocytosis (Ikuhiko 
Nakase et al. 2006). Knockdown of macropinocytosis by an actin cytoskeleton 
inhibitor was also shown to significantly suppress uptake of R8 into HeLa cells. 
(Nakase et al. 2004).  
A second endocytic mechanism for the CPP Tat was shown to be clathrin 
mediated endocytosis (CME) (Richard et al. 2005) ((Figure 1-3 B). CME is a process 
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of the cell used in order to internalise receptors from the cell surface. One example is  
the internalisation of transferrin receptor (TR) which leads to uptake of iron into the 
cell through the TR bound ligand transferrin (Dautry-Varsat et al. 1983). Clathrin 
mediated endocytosis characteristically involves the formation of a clathrin coated pit. 
This coat forms at the cytoplasmic face of the plasma membrane and consists of the 
scaffold protein clathrin and adaptor protein complexes such as the adaptor protein 
AP-2 (Pearse 1976). Inhibition of this pathway can be achieved by utilising siRNA 
knockdown of the AP-2 subunit involved in the clathrin coat formation (Motley et al. 
2003). In a study by Shiru Futaki’s lab, syndecan-4, a heparin sulfate proteoglycan, 
was most recently identified to act as an receptor for R8 and that mediates uptake via 
clathrin mediated endocytosis (Kawaguchi et al. 2016).  
 
Independent of which endosomal mechanism uptake occurs, it is important to 
consider that once a CPP has been taken up it is enclosed in a vesicle 
(endosome/macropinosome) and has not yet entered the cytosol (Figure 1-3 B). In 
order to understand the fate of a CPP enclosed in an endocytic vesicle it is important 
to outline the pathways and function of the endolysosomal system (Figure 1-4). The 
endolysosomal system carries out important functions such as recycling plasma 
membrane and their back to the cell surface (Steinman et al. 1983) as well as 
internalisation of receptors and targeting of specific cargo to the lysosome in order 
degrade it.  
Once a cargo has entered the cell via an endocytic pathway it is enclosed in an 
endosome. Endosomes will fuse to form the first compartment of the endocytic 
pathway, the early endosome (Gruenberg et al. 1989). From this compartment cargo 
can be recycled back to the cell surface via recycling endosomes (van IJzendoorn 
and Hoekstra 1999). One example of a cargo that utilises this pathway is the 
transferrin receptor that is internalised via CME. This receptor is constitutivly 
internalised (Hopkins et al. 1985) and when bound to its ligand transferrin it transports 
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iron into the cell. Endocytic recycling can be as fast as 8-15 min (Huotari and Helenius 
2011) and is not only important in order to maintain the presence of this receptor at 
the cell surface but also to recycle plasma membrane material back to the cell 
surface. Another example is the EGFR that is internalised via CME when bound to its 
EGF ligand and recycled back to the cell surface in order to achieve prolonged 
signalling (Sigismund et al. 2008).  
However, this receptor can also be internalised via other endocytic routes which 
will lead degradation of the receptor (Figure 1-4). This is an important pathway in 
order to downregulate the presence of receptors on the cell surface. When cargo is 
targeted for degradation in the lysosome (ubiquitination of the cytosolic domain of 
EGFR) the cargo resides in the early endosome which matures into a late endosome. 
Characteristic of this maturation is a drop in pH in the late endosomal compartment 
(Maxfield and Yamashiro 1987). These late endosomal compartments then fuse with 
lysosomes in order to degrade the cargo material. Lysosomes are cellular organelles 
that contain enzymes that can break down proteins and other organic materials. 
These enzymes only function at acidic pH for which reason it is important to maintain 
the acidic pH (pH 5) in the lysosome.  
 
Thus, CPPs that enter the cell through endocytic pathways largely remain 
trapped in the endolysosomal system where they recycle back to the cell surface or 
reside in the endosome to undergo degradation in the lysosome. However, in order 
to function as novel DDSs to facilitate uptake and delivery of target molecules to their 
intracellular targets it is critical that the CPP and its cargo escape the endosome. 
Endosomal escape of CPPs will further be discussed with their function as 
macromolecular drug delivery systems.  
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Figure 1-4 The 
endolysosomal system 
Cargo can enter the 
endolysosomal system 
through various endocytic 
pathwyas like clathrin 
mediated endocytosis or 
macropinocytosis. 
Endosomes fuse together to 
an organelle called the early 
endosome. From this location 
the receptor can undergo 
different fates; it can recycle 
back to the cell surface 
through a recycling 
endosome or remain in the 
early endosome, which 
matures into a late endosome 
and will be degraded in the 
lysosome.  
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1.3.3.5  Macromolecular cargo delivery and endosomal escape  
Due to their cell penetrating ability, CPPs are a popular choice for the delivery of 
biological macromolecules such as peptides that cannot pass the plasma membrane 
by themselves (Foged and Nielsen 2008; Munyendo et al. 2012). CPPs are also 
termed ‘Trojan horses’ because they have the ability to facilitate the uptake of 
macromolecules into the cell that would not gain access to the cell by itself. They 
have been shown to be able to facilitate the uptake of macromolecular cargo such as 
peptide, proteins, nucleic acids and nanoparticles by covalent conjugation of the 
cargo to the peptide or by complexation with the peptide. Uptake of cargo molecules 
by CPPs can be shown by conjugation of a fluorescent label to the cargo and 
measurement of fluorescent intensity of the cell. Using this method the uptake of 
siRNA can be shown by Tat when the nucleic acid is labelled with the fluorescent 
probe Cy5 (Arthanari et al. 2010). Penetratin has been shown to facilitate the uptake 
of BSA into cells when complexed with the protein; in the same study it has been 
demonstrated that R8 can facilitate the uptake of quantum dots into cells. 
Interestingly, the uptake of quantum dots dots as well as BSA was enhanced when a 
Phenylalanine residue was substituted for the Glycine residue in the N-terminal 
GSGSGSGSG linker sequence attached to the CPP (Sayers et al. 2014). The uptake 
was validated through attachment of the fluorophore Alexa647 to BSA or by utilising 
the optical properties of quantum dots.  Investigating the uptake of these fluorescently 
tagged cargos through CPPs by microscopy, it can be seen that the fluorescence is 
mainly localised in endosomes and the concentration of CPP used in this study (2 
µM) suggest endosomal uptake of the CPP and its cargo (Sayers et al. 2014).  
 
It has been shown that a macromolecular cargo influences uptake of the CPP-
cargo complex and can be different as seen with the CPP alone. Uptake is dependent 
on the size and the charge of the cargo if uptake is facilitated through direct 
translocation or via an endocytic mechanism (Maiolo et al. 2005; Tunnemann et al. 
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2006). Large cargos like globular proteins remain trapped in endocytic vesicles and 
smaller cargos like non globular peptides are to some extent internalised by 
endocytosis but can also enter the cell through direct penetration (Tunnemann et al. 
2006). Thus, macromolecular cargo is likely to be internalised through endocytic 
mechanisms.  
 
When investigating intracellular cargo delivery by CPPs it is critical to 
differentiate between uptake and functional delivery of the cargo to its intracellular 
target. A cell penetrating peptide can facilitate uptake of cargo via direct translocation 
or endocytosis (Figure 1-5). When the CPP-cargo complex enters the cell via direct 
translocation, it has direct access to its intracellular target (Figure 1-5 A). However, if 
it utilises the endocytic route it is at risk to recycling back to the cell surface or 
degradation in the lysosome (Figure 1-5 B). In order to function at its intracellular 
target, the cargo has to reach the cytosol through endosomal escape.  
Hence, endosomal escape is critical for the cargo in order to reach its intracellular 
target (Figure 1-5 B). Endosomal escape of CPPs and other novel drug delivery 
vectors and their cargos is highly inefficient and is believed to be the limiting factor 
for cargo delivery to their intracellular targets (El-Sayed et al. 2009; Erazo-Oliveras et 
al. 2012). Hence, the cargos remain trapped in the endosome are recycled back to 
the cell surface or undergo degradation in the lysosome and will therefore not be able 
to function at their intracellular targets (Sahay et al. 2013).  
 
For this reason novel DDSs are needed that not only facilitate uptake of their 
cargo, but also deliver it to its intracellular target.  
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Figure 1-5 Delivery of 
macromolecular cargo by R8. 
Macromolecular therapeutics 
are too large to cross the 
plasma membrane by 
themselves.  
Their delivery across the plasma 
membrane can be facilitated by 
drug delivery systems such as 
the cell penetrating peptide R8. 
Delivery to intracellular targets 
can be achieved through direct 
translocation (A) or endocytosis 
followed by endosomal escape 
(B) to avoid recycling to the cell 
surface or degradation in the 
lysosome.  
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In order to pursue this strategy CPPs are being modified to enhance endosomal 
escape mechanisms by endosomal leakage. For Tat it has been shown that 
dimerization of the peptide increases endsosomal escape which was shown by 
attatchment of the fluorescent probe rhodamine to the CPP. Tat monomer was mainly 
localised in endosomes when incubated at 20 µM whereas the fluorescently labelled 
dimer was distributed across the cytosol of the whole cell. Other endosomal escape 
mechanisms include fusion of the CPP to membrane lytic peptides (Arthanari et al. 
2010). These lytic peptides can make use of the acidification of the endosome during 
its maturation process. Recently it has been shown that even macromolecules like an 
Alexa 488 labelled IgG antibody can be delivered with the help of lytic peptides. 
Critical residues of this peptide consisted of glutamic acid which is negatively charged 
in the extracellular region and does not penetrate membranes. When it is entrapped 
in the endosome with the antibody cargo, acidification of the maturing endosome 
causes protonation of glutamic acid which allows the less charged peptide to form a 
helical structure that pertubs the endosomal membrane (Akishiba et al. 2017).  
 
Attachment of a fluorescent probes in order to investigate the location of a cargo 
inside the cell is an effective technique in order to differentiate between cargos 
trapped in endosomes and cytosolic distribution of the cargos (Fretz et al. 2007; 
Tunnemann et al. 2008; Sayers et al. 2014). However, fluorophores where shown to 
influence uptake dynamics of CPPs (Jones and Sayers 2012) and utlising this method 
does not answer an important question when delivering biological macromolecules: 
 
Is the cargo still functional once it reaches the cytosol? 
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When fluorescently tagged splice correcting oligonucleotides were delivery by 
CPPs it was shown that intracellular fluorescence did not correlate with splice 
correcting activity of the oligonucleotides (Hassane et al. 2011). This study shows 
that simple attachment of a fluorophore to a CPP-cargo complex does not sufficiently 
represent its delivery or biological activity and this method is not suitable to investigate 
cargo delivery into the cell. For this reason, techniques are needed that not only prove 
cytosolic delivery of biologics but also assess their functionality.  
It is also important to consider that covalent attachment of a cargo to CPPs can 
change the intracellular localization of the cargo. It has been demonstrated that CPPs 
with positively charged amino acids like TAT or R8 accumulate at the nucleolus of 
cells (Tunnemann et al. 2006; Martin et al. 2007). Covalent attachment of a cargo to 
these CPPs can result in the localisation of cargo in the nucleolus and is therefore 
not able to carry out its function at a target located in the cytosol of the cell. 
 
For this reason it is not only important to develop techniques that assess the 
functionality of the cargo but more importantly techniques that assess the biological 
function of the cargo at its intracellular target.  
 
1.3.4 Strategies to investigate the delivery of biologics 
Promising biologics that carry out their function at intracellular targets are 
therapeutic peptides or proteins, antibodies and nucleic based therapeutics. In order 
to characterise novel DDSs that facilitate the functional delivery of these biologics to 
their intracellular targets, robust methods have to be in place to assess the biological 
activity of the delivered cargo.  
The biological activity of delivered nucleic acids such as ASO or siRNA can easily 
be determined using splice correction assays or by testing gene silencing (Hassane 
et al. 2011). Popular gene silencing targets for colorimetric assays are proteins that 
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are introduced to the cell to be stably expressed such as green fluorescent protein 
(GFP) or luciferase. Gene silencing of GFP can be determined in live cells by 
monitoring the decrease of the fluorescence of the expressed protein (Kim et al. 
2006). 
In order to investigate the delivery of therapeutic proteins such as enzymes, 
several methods are available. These include the delivery of enzymes such as RNAse 
A, Luciferase or beta lactamase and measuring their enzymatic activity as an 
indication for delivery (D'Astolfo et al. 2015; Niikura et al. 2015). However, these 
methods cannot be assessed in live cells. Delivery of molecules such as RNAse 
requires further RNA purification steps to obtain a quantitative readout of delivery. 
The delivery of luciferase involves lysis of cells and preparation for luciferase 
measurement. When beta lactamase is delivered into cells its activity is measured by 
a shift of a fluorescent signal of a compound that requires cellular treatment with that 
compound (D'Astolfo et al. 2015; Niikura et al. 2015). Protein delivery into live cells 
can be investigated by the delivery of the protein GFP into cells, however this does 
not include assessment of therapeutic activity of the protein cargo (Erazo-Oliveras et 
al. 2014).  The functional delivery of small cell penetrating antibodies (nanobodies) 
into cells has recently been shown by targeted relocation of their specific antigen from 
the cytosol to the nucleolus (Herce et al. 2017). This was shown by the change of the 
location of GFP fom the cytosol to the nucleolus. Binding of GFP was facilitated by 
the anti GFP binding nanobody, penetration into the cell as well as relocation of the 
GFP cargo-nanobody complex was facilitated by cyclic decarginine attachted to the 
nanobopdy. 
 Another class of therapeutics that have potential to act at intracellular targets 
are therapeutic peptides. Therapeutic peptides have a lower manufacturing cost 
compared to antibodies and show high biological activity associated with low toxicity. 
However, it is more challenging to determine the functional delivery of a peptide in 
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order to assess the DDS delivering the peptide. Hence, we require a method in order 
to assess functional delivery of a peptide to its intracellular target.  
 
1.3.5 Requirements for a method to determine functional peptide delivery 
A method to determine functional delivery of a peptide in order to evaluate their 
DDSs should be a robust and reproducible method. The method has to give 
information about the delivery of a peptide to its intracellular target as well as its 
biological activity at its target. The delivery of enzymes are great methods to 
determine functional delivery of macromolecules, however, these methods do not 
give a direct readout of engagement with their target or their functionality because of 
further purification and cell preparation steps.  
Hence, when developing a method to investigate functional delivery of a peptide, 
a direct correlation of targeted engagement and biological activity would be desirable. 
Especially obtaining a readout of delivery in a live cell would be advantageous. 
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1.4 Green fluorescent protein (GFP) 
As previously mentioned, GFP is a popular tool to be utilised to prove the delivery 
of various biologics into live cells. These include siRNA delivery resulting in gene 
silencing of GFP expression; GFP delivery representing a 27 kDa protein cargo; and 
anti GFP nanobody delivery which leads to GFP antigen binding which allows us to 
investigate the subcellular localisation of the antibody-antigen complex (Kim et al. 
2006; Erazo-Oliveras et al. 2014; Herce et al. 2017). Furthermore, GFP has found a 
wide range of applications in cells such as protein labelling, defining subcellular 
localisations of proteins within cells, acting as biosensors, cell and tissue labelling, 
DNA and RNA labelling or studying protein-protein interactions (reviewed in 
(Chudakov et al. 2010)). It is a powerful tool because of its ability to give a readout 
without the need of additional cofactors or substrates and allows us to visualise the 
spatial and temporal patterns of GFP tagged targets in live cells.  
 
1.4.1 History of GFP 
The discovery of GFP was a Nobel Prize winning finding and a major discovery 
in the last century. Osam Shimura, Martin Schalfie and Roger Y. Tsien contributed to 
the discovery and characterisation of GFP and were awarded the Nobel Prize in 
chemistry in 2008 (Nobelprize.org Last accessed 07/2017). 
GFP was first described in 1955 as yellow-green fluorescent masses appearing 
in the marginal canal of the jellyfish Aequorea Victoria upon mechanical stimulation 
(Davenport and Nicol 1955). In 1962 Osamu Shimomura discovered GFP while he 
was studying and isolating the photoprotein aequorin from Aequorea Victoria that 
emits light in the presence of calcium ions. During the purification process of aequorin 
a second protein was identified that is known as GFP today (Shimomura et al. 1962; 
Shimomura 2009). Over 30 years later the DNA of the 238 amino acid protein was 
first cloned (Prasher et al. 1992) and then introduced as a tool in molecular biology to 
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monitor gene expression and protein localisation in living cells by Martin Chalfie. 
Using GFP, gene expression could be detected in the prokaryotic organism E.coli and 
the sensory neurons of the eukaryotic organism C.elegans (Chalfie et al. 1994). GFP 
was then further characterised with respect to the process of chromophore formation, 
fluorescent properties and its structure. 
 
1.4.2 Structure of GFP 
The crystal structure of the protein was obtained by Ormo and colleagues 1996 
(Ormo et al. 1996) (Figure 1-6). It revealed that the protein consists of 11 beta sheets 
with a central coaxial alpha-helix inserted between the 3rd and the 4th beta strand 
which contains the chromophore (star in Figure 1-6 A). In the 3 dimensional structure 
of GFP, the beta sheets build a barrel surrounding the central alpha helix (Figure 1-6 
B). 
 
 
 
 
Figure 1-6 Structure of GFP 
(A) Two dimensional structure of GFP showing 11 beta sheets (β1 – β11) and the central 
alpha helix containing the chromophore (pink star). (B) Three dimensional structure of GFP. 
The structure was modelled using Chimera (PDB ID: 1EMA) (Ormo et al. 1996). 
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It was found that the chromophore of wild type GFP is formed by an autocatalytic 
cyclisation of the three amino acids Ser65-Tyr66-Gly67 (Cody et al. 1993). It was 
identified that this reaction consists of three steps: cyclisation, oxidation and 
dehydration (Heim et al. 1994; Rosenow et al. 2004). For these steps, not only the 
three amino acids that form the chromophore, but also surrounding amino acids within 
the GFP structure play a key role in the maturation of the chromophore. Highly 
conserved residues are Arg96 and Glu222 which act as catalysts for the chromophore 
formation and are therefore in close proximity of the central helix (Sniegowski et al. 
2005). Roger Y. Tsien not only contributed to the understanding how GFP fluoresces 
but also identified key residues that could be mutated in order to improve the 
properties of GFP for scientific applications. 
 
1.4.3 Mutations of GFP 
Wildtype GFP is a protein consisting of 238 residues, 27 kDa in size, with two 
excitation peaks at 395 and 475 nm and a single emission peak at 509 nm 
wavelength. The two excitation peaks represent two different states of the 
chromophore. The larger excitation peak at 395 nm wavelength light is found in a 
neutral chromophore (protonated) and the minor excitation peak at 475 nm 
wavelength light is caused by an anionic chromophore (deprotonated) (Heim et al. 
1994; Brejc et al. 1997).  
Major drawbacks of GFP for scientific use were the low maturation at 37 °C and 
its low fluorescent intensity when excited with blue light due to the low excitation peak 
at 475 nm wavelength light. Substitution of Phenylalanine to Leucine at position 64 
(F64L) resulted in a protein with greater stability and therefore rate of fluorophore 
generation at 37°C (Cormack et al. 1996). Mutation of Ser65 to Thr65 (S65T), 
contained in the chromophore, suppresses the 395nm excitation peaks and leads to 
increased brightness and with a single excitation peak at 488 nm wavelength 
(emission 512nm) (Heim et al. 1995). The protein with improved folding and 
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brightness was named enhanced GFP (EGFP) (Heim et al. 1995; Cormack et al. 
1996). Further mutations lead to the generation of colour variants of GFP such as 
yellow (T203Y) or cyan (Y66W) fluorescent proteins (Heim et al. 1994; Heim and 
Tsien 1996; Ormo et al. 1996).  
An improvement to live cell imaging to track dynamics of proteins in cells was 
made by introducing photoactivatable GFP (PA-GFP). PA-GFP was developed based 
on GFP carrying two excitation peaks. Introduction of a Thr203His mutation, produces 
mostly neutral chromophore form of GFP with its main excitation peak at 400 nm 
wavelength light (Patterson and Lippincott-Schwartz 2002). This is termed the low 
fluorescent state of the fluorophore when excited with 488 nm wavelength light. 
Photoactivatable GFP relies on a conversion from the fluorescent protein from a low 
fluorescent state to a higher fluorescent state. This is achieved by irradiation of the 
fluorophore in the low fluorescent state with 413 nm wavelength light which shifts the 
excitation wavelength from 400 nm of the neutral form to the anionic form of the 
fluorophore which absorbs at 507 nm. This leads to an irreversible photoactivation of 
the fluorophore with a 100 times increase in fluorescence of the higher fluorescent 
state to the lower fluorescent state when excited with 488 nm wavelength light. This 
conversion can be achieved selectively for the protein of interest which can be tracked 
and imaged over the low GFP fluorescent background. Further improvement was the 
photoconversion from cyan fluorescent protein to green fluorescent protein in 
response to 405 nm wavelength light irradiation termed photoswitching (PS) 
(Chudakov et al. 2004).  
Improvements to expression of GFP in E.Coli were made with the generation of 
folding reporter GFP. Wild type GFP missfolds when expressed in E.Coli and is 
expressed in inclusion bodies. Folding reporter GFP includes the improvements that 
were previously made for EGFP, the S65T and F64L mutation in order to ensure the 
maturation at 37 °C and the brightness of the protein as well as three additional 
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mutations (F99S, M153T, V163A). This folding reporter had improved brightness as 
well as improved solubility when expressed in E.Coli (Crameri et al. 1996).  
GFP and its variants have found useful applications as fusion proteins, however, 
the fluorescence and folding of the protein is susceptible to the ability of their fusion 
partners to fold correctly. Their folding can decrease the folding yields of GFP and its 
brightness. Bright fluorescence is only seen when GFP is expressed as a fusion 
protein to well folded proteins (Waldo et al. 1999). For this reason, Waldo and 
colleagues generated a new GFP mutant, superfolder GFP (sfGFP), with improved 
folding characteristics that even folds well when fused to poorly folding polypeptides. 
This mutant was based on a previously generated well-folding variant of GFP, folding 
reporter GFP (Crameri et al. 1996). In addition to the mutations present in folding 
reporter GFP sfGFP contained six new mutations (S30R, Y39N, N105T, Y145F, 
I171V and A206V). sfGFP folds well and is bright fluorescent even when expressed 
as a fusion to poorly folded polypeptides (Pedelacq et al. 2006).  
 
1.4.4 Disadvantages of GFP 
It is also important to mention that using GFP can have disadvantages. GFP as 
a protein label is expressed as a C- or N-terminal fusion protein to its protein target. 
However, the addition of a 27kDa fluorescent protein to a protein can impair its 
biological function. It is therefore critical to not only study the fusion protein but also 
to obtain data from the endogenous protein without a fluorescent protein tag 
(Michaelson and Philips 2006). In addition to that, GFP tagging as well as the choice 
of C- or N-terminal fusion to the target protein can have an influence of its subcellular 
localisation (Palmer and Freeman 2004). However, an analysis of the localisation of 
>500 human proteins showed that 80% of proteins had the same localisation when 
expressed as fluorescent protein fusions compared to the localisation of an 
endogenous protein that was shown using immunofluorescence (Stadler et al. 2013).  
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Another factor to be considered when performing expreiments where 
endogenous DNA is expressed is the change of localisation of the protein by its 
overexpression. GFP fusion proteins are generally expressed by introduction of an 
expression plasmid encoding for the exogenous fusion protein. Protein expression 
from an expression plasmid can lead to overexpression of the protein introducing 
overexpression artifacts compared to the endogenous protein.  
 
Another disadvantage is that the emission spectrum of GFP lies within the 500 – 
600 nm spectral region where autofluorescence is detected in cultured mammalian 
cells. The source of this autofluorescence are endogenous fluorophores like 
nicotinamide adenine dinucleotide (NADH) or flavins like flavin adenine dinuclotide 
(FAD) which were shown to be localised in the perinuclear region (Aubin 1979; 
Benson et al. 1979). Their fluorescent excitation/emission spectra are 350/460 nm for 
NADH and 450/535 nm for FAD (Ramanujam et al. 1994). Because NADH and FAD 
are important cofactors in the mitochondrial electron transport chain where they 
function as coenzymes for cell metabolism and energy production, it was shown that 
their fluorescent properties can be utilised to develop an imaging technique 
investigating cellular metabolic activity or using it to determine mitochondrial 
cytotoxicity of chemical compounds (Skala and Ramanujam 2010; Bednarkiewicz et 
al. 2011; Rodrigues et al. 2011). FAD with its emission spectrum of 535 nm lies within 
the spectral range that is collected when GFP emission is measured. Thus, the 
autofluorescence of cells can create a fluorescent background signal when choosing 
GFP as a fluorescent protein for imaging. 
 
Nevertheless, GFP and its derivatives have turned out to be a very powerful tool 
for live cell imaging to determine protein localization or to study dynamic events inside 
cells using a fluorescent microscope.  
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1.4.5 Split GFP to show protein-protein interaction  
To test the delivery of biologics by DDSs, GFP can serve as a 27 kDa model 
protein cargo. Its fluorescence will give information about its subcellular localisation 
as well as if the protein is intact at this localisation. However, this does not give 
information about the engagement of the cargo with an intracellular target. When 
developing a new method to investigate functional delivery of a therapeutic peptide 
by DDSs, not only the success of delivery is important but it would also be a major 
improvement to be able to show its biological activity at its intracellular target.  
One technology where GFP fluorescence is utilised as a biosensor for the 
readout of the biological engagement of two proteins is split GFP (Hu and Kerppola 
2003; Cabantous and Waldo 2006).  
The idea of split GFP was first mentioned in 2000. GFP was divided into two 
large parts between residues 157 and 158 to create two non fluorescent fragments, 
CGFP and NGFP containing 157 and 81 residues, respectively. The chromophore 
was contained on NGFP. Both fragments were connected to antiparallel leucine 
zippers via a flexible linker. The fragments connected to the designed leucine zippers 
were termed NZGFP and CZGFP respectively.  Reassembly of NZGFP and CZGFP 
to from full length fluorescent GFP was achieved by the non-covalent association of 
the two leucine zippers and reassembly was shown to be dependent on the leucine 
zippers in vitro and in vivo (Ghosh et al. 2000).  
Based on this leucine zipper mediated reassembly split fluorescent proteins were 
used to study protein-protein interactions inside cells (bimolecular fluorescence 
complementation (BiFC) (Hu et al. 2002). The broad range of GFP variants that were 
split using leucine zipper mediated re-association allowed the visualisation of multiple 
interaction events in the same cell (Hu and Kerppola 2003). For this application it was 
important that the re-association of the two fragments found not to be spontaneously 
initiated by the split fragments but dependent on the protein-protein interaction (e.g. 
leucine zipper association) of the fusion proteins (Chudakov et al. 2010).  
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Waldo and colleagues wanted to utilise this split GFP system as a folding 
reporter for proteins and detect soluble or insoluble proteins in living cells and cell 
lysates. However existing split GFP could not be utilised because of insufficient 
folding when expressed as fusion proteins as well as the dependence of fusion protein 
interaction in order to achieve GFP complementation. Thus, they improved this 
system and designed split GFP fragments that were able to self-assemble 
independent of a fusion proteins and fragments with improved folding (Cabantous et 
al. 2005). In order to improve the folding of split GFP fragments, experiments were 
based on the two well-folding GFP variants, folding reporter GFP (Crameri et al. 1996) 
and superfolder GFP (Pedelacq et al. 2006). They split both GFP variants 
assymatrically into two non fluorescent split GFP fragments, a large fragment 
consisting of amino acids 1-214 termed GFP1-10 and the small fragment, GFP11, 
comprising amino acids 215-230. When they coexpressed both fragments in E.Coli 
only coexpression of the superfolder fragments led to complementation of the 
fragments and rescued GFP fluorescence. However superfolder GFP1-10 was 
insoluble. In a stepwise improvement through introduction of mutations they designed 
two fragments with maximal solubility and brightest in vitro complementation. They 
named these split GFP variants GFP1-10 OPT and GFP11 M3 (containing 16 amino 
acids). GFP1-10OPT contains all amino acid substitutions found in superfolder GFP 
and seven additional mutations (N39I, T105K, E111V, I128T, K166T, I167V and 
S205T).  
In vitro complementation of both fragments to form full length GFP was shown to 
occur shortly after incubation of the fragments and saturation of GFP 
complementation of 50 pmol GFP11 M3 with 800 pmol GFP 1–10 OPT was reached 
after ~400 min (Cabantous et al. 2005). 
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Figure 1-7 Split GFP 
(A) Key components of GFP (pink) are 
the chromophore located on the 
central alpha helix consisting of the 
amino acids Thr65-Tyr66-Gly67 as 
well as the highly conserved residue 
glutamic acid (GLU222) which is 
located on the 11th beta sheet of the 
beta barrel. (B) GFP can be split into 
two non- fluorescent fragments, 
GFP1-10 OPT containing the 
chromophore and GFP11 M3 
containing GLU222. These fragments 
can complement to form full length 
GFP and the green fluorescence of 
the protein is rescued (Kent et al. 
2008).  
The structures are based on the 
crystal structure of superfolder GFP 
(PDB ID: 2B3P) (Pedelacq et al. 
2006). All structures were modelled 
using Chimera.  
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The underlying mechanism of split GFP generated by Waldo and colleagues is 
shown in Figure 1-7. Key components of GFP that are important to the fluorescence 
of the protein are the chromophore located on the central alpha helix consisting of the 
amino acids Thr65-Tyr66-Gly67 as well as the highly conserved glutamic acid residue 
(GLU222) which is located on the 11th beta sheet of the beta barrel (Figure 1-7 A). 
These can be separated to obtain two non- fluorescent fragments, GFP1-10 OPT 
containing the chromophore and GFP11 M3 containing GLU222. These fragments 
can complement to form full length GFP and the green fluorescence of the protein is 
rescued (Figure 1-7 B) (Kent et al. 2008).   
 
Furthermore it was shown that in vitro complementation was linear to the 
concentration of the fragments when 0.1 to 200 pmol of GFP11 M3 was mixed with 
800 pmol GFP1-10 OPT. Moreover the complementation of the split GFP fragments 
was analysed regarding pH dependency. It was found that complementation below a 
pH of 6.5 was inefficient (Cabantous et al. 2005). 
Investigation of absorption and excited-state proton transfer dynamics revealed 
that complemented GFP (not containing the S65T mutation) had identical 
characteristics to the full length protein. It was also noted that complemented GFP 
can be separated by denaturation and the GFP1-10 fragment containing the matured 
chromophore emits weak fluorescence (Kent et al. 2008).  
With the development of spontaneously assembling split GFP fragment a new 
powerful tool has been created to investigate intracellular processes.   
 
Importantly, split GFP allows us to investigate functional complementation of a 
large protein fragment, GFP1-10OPT and a small peptide fragment, GFP11 M3 which 
has a great potential to investigate a functional biological interaction of a cargo 
(GFP11 M3) at its intracellular target (GFP1-10OPT).  
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One key publication that has led to the development of the split GFP based 
method presented in this study utilised split GFP for the selective detection of single 
biomolecules using complementation-activated light microscopy (CALM). It was 
shown that split GFP complementation can be directly imaged when the M3 peptide 
conjugated to biotin was fixed to an avidin-functionalized coverslip and subsequently 
incubated with GFP1-10. GFP complementation occurred within 10 minutes and 
lasted for 2 hours until it reached saturation. Importantly, they also showed that 
extracellular membrane proteins on live cells fused with GFP1-10, complemented to 
full length GFP upon incubation with the M3 peptide. Complementation was achieved 
by incubation of M3 peptide (50 µM) with live cells within 45-60 min.  Furthermore, 
intracellular GFP complementation was investigated by microinjection of M3 to an 
intracellular expressed GFP1-10 target.  Importantly, it was briefly described that 
short amphipathic peptide carrier, Pep-1 was used to deliver M3 across the 
membrane by co-incubation to complement with its intracellular target as an 
alternative to microinjection (Pinaud and Dahan 2011).  
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1.5 Hypothesis and aims 
1.5.1 Utilising split GFP to show functional peptide delivery by DDSs 
Because of insufficient delivery of macromolecular therapeutics such as peptides 
across the plasma membrane, there is a need for novel DDSs that facilitate uptake of 
these macromolecules. Hence, novel DDSs have to be assessed regarding their 
delivery efficiency of peptides. For this reason methods need to be developed to 
evaluate and quantify the functional delivery of their functional peptide cargo across 
biological barriers. 
The split GFP system by Waldo and colleagues holds great potential in order to 
achieve this. The idea for the development of a method to investigate functional 
peptide delivery utilising the Split GFP is shown in Figure 1-8. Non-fluorescent GFP1-
10OPT (named GFP1-10 in this thesis) (Cabantous et al. 2005), is expressed in the 
cytosol of HeLa cells and mimics an intracellular target protein. The M3 peptide 
consisting of 16 amino acids as described (GFP11 M3)  (Cabantous et al. 2005) acts 
as a peptide cargo that cannot pass the plasma membrane. Attatchment of a drug 
delivery system (DDS) (e.g. octaarginine) to M3 can facilitate its uptake through direct 
translocation across the plasma membrane or via endocytic pathways. The M3 
peptide only reaches the cytosol by direct entry or endosomal escape, avoiding 
recycling back to the cell surface or degradation in the lysosome. If the M3 peptide 
enters the cytosol, GFP1-10 and M3 are localised in the same cellular compartment 
and can undergo spontanous complementation to form full length GFP.  This implies 
that the M3 peptide is fully functional and has not been degraded before reaching its 
intracellular GFP1-10 target. Hence, intracellular GFP fluorescence is a proof of the 
delivery of functional M3 peptide cargo by the DDS.  1
                                                          
1 This idea was first described within my Master’s project that preceded this project  
(Riester P., Characterising the cellular uptake and targeting of novel drug delivery  
systems, 2014, Department of Biology, Universitaet Konstanz.).  
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Figure 1-8 Split GFP 
complementation assay to 
determine functional delivery 
of a peptide by DDSs 
GFP1-10 is expressed in the 
cytosol of HeLa cells and 
mimics an intracellular target 
protein. The M3 peptide 
consisting of 16 amino acids 
acts as a model peptide cargo 
that cannot pass the plasma 
membrane. Attachment of the 
drug delivery vector R8 to M3 
can facilitate its uptake through 
direct translocation across the 
plasma membrane or via 
endocytic pathways. The M3 
peptide only reaches the 
cytosol by direct entry or 
endosomal escape, avoiding 
recycling back to the cell 
surface or degradation in the 
lysosome. If the M3 peptide 
enters the cytosol, GFP1-10 
and M3 undergo spontaneous 
complementation to form full 
length GFP. Functional peptide 
delivery can be measured by 
GFP fluorescence upon 
illumination with 490 nm 
wavelength light,  
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R8 has been extensively investigated by our research group and will act as a 
model DDS for the development of this assay (Fretz et al. 2007; Sayers et al. 2014). 
However, this method has the potential to can act as a platform to evaluate any 
peptide delivery vector regarding its efficiency to funtionally deliver peptide cargo.   
The advantage of this technique over commonly used techniques (e.g. 
measurement of enzymatic activity of delivered enzyme) is that functional delivery to 
an intracellular target can be visualized in live cells in real time upon illumination of 
the cells with 490 nm wavelength light.  
 
1.5.2 Existing Split GFP complementation assays to prove functional peptide 
delivery 
Split GFP complementation assays utilising the method described above to 
determine the functional delivery of the M3 peptide by CPPs were published by other 
research groups after 1.5 years into the development of the assay presented in this 
work (Milech et al. 2015; Schmidt et al. 2015b). 
Schmidt et al. first published the split GFP complementation assay using the CPP 
nonarginine (R9) to deliver the small fragment of split GFP (called GFP11 in that 
study) to its cytosolic GFP1-10 target. In this publication it was shown that the CPP 
conjugated GFP11 peptide as well as the pure GFP11 peptide can be introduced to 
the cytosol of the cell by electroporation to complement with GFP1-10 resulting in 
green fluorescence. Furthermore, Schmidt et al. demonstrated that R9 functionally 
delivers GFP11 to cells transiently expressing GFP1-10 along with the co-expression 
marker mCherry in a concentration dependent manner (Schmidt et al. 2015b). The 
majority of this work, however, is presented from two independent experiments only.  
Shortly after the first publication, Milech et al. published the same split GFP 
complementation approach to prove the functional delivery of the short fragment of 
GFP (called S11 in that study) to its intracellular GFP1-10 target. In this study the 
delivery efficiency of a large range of different CPPs to facilitate functional S11 
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delivery is compared. Concentration dependent delivery of S11 is shown for the CPPs 
Tat, R9 and penetratin (Milech et al. 2015). In both papers analysis of functional 
peptide delivery resulting in GFP complementation was detected by flow cytometry 
and it was not utilised as a microscopy based technique. Microscopy images were 
shown in the paper by Schmidt et al. but solely to identify if the peptide fragment of 
GFP was delivered to the cytosol. Using microscopy has the huge potential to gain 
additional information from the assay such as time dependent delivery of the M3 
peptide as well as assessment of the subcellular localisation of delivered peptide.  
 
1.5.3 Aims of this work.  
The aim of this project is to develop and characterise a method to investigate 
functional peptide delivery by DDSs based on split GFP technology. This method will 
enable us to determine the functional cytosolic delivery of a peptide thereby 
evaluating different drug delivery systems regarding their efficiency to functionally 
deliver peptide cargo. The assay will be developed in the well characterised model 
cell line HeLa due to its ease of manipulation and well characterised cell biology. 
Once the system is verified in this cell model it can further be applied to detect delivery 
of peptides into pharmaceutically relevant endothelial barriers (e.g. intestine, lung, 
skin, and blood-brain-barrier) or utilized in vivo to investigate functional delivery into 
target tissues. Furthermore, it is important to be able to assess M3 peptide delivery 
by a DDS in a concentration dependent manner in order to determine effective 
concentrations for peptide delivery. Analysis of concentration dependent delivery of 
the M3 peptide by different DDSs by flow cytometry will be comparable to split GFP 
complementation assays shown by Milech et al and Schmidt et al..  
In this work, however, the focus is to develop the split GFP complementation 
assay to be utilised as a microscopy based technique and detailed characterisation 
of the split GFP system on a fluorescent widefield microscope will be performed. 
Detection of split GFP complementation upon M3 delivery to the cytosol using a 
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microscope allows us to visualize real time delivery of a functional peptide cargo to 
its intracellular target. Fluorescent microscopy on a widefield microscope will ensure 
the visualisation of live cell processes with sufficient speed.   
In addition to this, microscopic analysis of M3 delivery will also elucidate the 
subcellular localisation of the complemented target-cargo complex once delivered 
into the cell. This will emphasize the influence of the DDS on intracellular localisation 
of the cargo.  
 
The additional information gained in this work by analysing when a peptide is 
delivered to its intracellular target as well as where it is located inside the cell will go 
above and beyond what has been published previously and add valuable information 
to the characterisation of drug delivery systems.   
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2 Materials and Methods 
2.1  Consumables 
Tissue culture plastic-ware and laboratory disposables were obtained from 
Fisher Scientific. General usage chemicals and reagents were supplied by Sigma-
Aldrich.  
 
2.2 Peptides 
All peptides were obtained from EZBiolabs. Peptides were synthesised of L-
amino acids and were obtained at >95% purity and aliquoted to 1 mg as lyophilized 
powder. When necessary, peptides were modified with an acetylation (Ac-) at the N-
terminus or an amidation (-NH2) at the C-terminus. Peptides were resuspended in 
DMSO to a final concentration of 10 mM. Lyophilized powder was stored at -20˚C, 
once resuspended in DMSO, peptides were stored in 5 µl aliquots at -80˚C. Table 2-1 
shows an overview of peptides used in this study and the volume of DMSO that was 
used to dilute peptides to obtain a final concentration on 10 mM.  
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Table 2-1 List of peptides used in this study. 
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2.3 Tissue culture methods and cell preparation for microscopy 
2.3.1 Cell culture  
The human cervical cell line HeLa was obtained from the American Type Culture 
Collection (ATCC) and had been Mycoplasma tested. Cells were cultured at 5% CO2 
and 37˚C in a humidified incubator. Their growth was monitored every day using 
brightfield microscopy. Cells were grown in a cell culture petri dish with 55 cm2 growth 
area.  
 
2.3.1.1 Media 
Cells were maintained in Minimal Essential Medium (MEM) containing 
GlutaMAX(TM) (Thermofisher) which was additionally supplemented with 10% Foetal 
Bovine Serum (FBS) (Thermofisher), 1X Non Essential Amino Acids (NEAA) and 1 
mM Sodium Pyruvate to be used as complete medium. Cells were grown in absence 
of antibiotics. When serum free conditions were required for experiments MEM 
containing GlutaMAX(TM) was supplemented with 1X Non Essential Amino Acids 
(NEAA) and 1 mM Sodium Pyruvate only. For generation of stable cell lines, selection 
media containing 400 mg/ml G418 (Geneticin®) was used. Table 2-2 displays an 
overview of the types of media used in this study.  
 
Table 2-2: Media composition.  
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2.3.1.2 Routine Cell culture 
Cells were passaged every 3-4 days when cells had reached 75% confluency. 
All solutions were pre-warmed to 37˚C in a water bath and passaging was performed 
in a sterile cell culture hood which was disinfected with 70% Industrial Methylated 
Spirit (IMS) prior to and following use. For passaging, cells were washed once with 
Phosphate Buffered Saline (PBS) (Thermofisher) and incubated with 1 mL 0.25% 
Trypsin/EDTA (Thermofisher) for 5 min at 37˚C. Detachment of cells was confirmed 
using a brightfield microscope. The detached cells were resuspended using 9 mL of 
culture Media and transferred into a 15 mL falcon tube. Cell suspension was 
centrifuged at 250x g for 4 min and supernatant discarded. The remaining pellet was 
resuspended in 10 mL of fresh cell culture media. Cell number per mL was 
determined using a Hemacytometer and 0.37 x 104 cells per cm2 were plated into a 
new cell culture dish. Cells were passaged to a maximum passage number of 30.  
 
Number of Cells per ml was determined using the following equation: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑝𝑒𝑟 𝑚𝐿 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑝𝑒𝑟 𝑠𝑞𝑢𝑎𝑟𝑒  
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒 𝑖𝑛 𝑚𝐿 ∗
 
* Vol. of square = W x H x D = 1 mm x 1mm x 0.1 mm = 0.1 mm3 = 0.0001 mL 
The volume of cell suspension required for seeding cells was determined using 
the following equation: 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑖𝑛 𝑚𝐿 =
𝑅𝑒𝑞𝑢𝑖𝑟e𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑝𝑒𝑟 𝑚𝐿
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2.3.2 DNA transfection of cells 
DNA transfection was performed using Fugene6 (Promega). This method 
describes volumes and quantities for transfections per well of a 6-well plate (Corning) 
or a single MatTek dish with 35 mm2 growth area (Mattek Corporation). For the 
transfection mix 3 µl of Fugene6 was added to of 100 µl Optimem (Thermofisher), 
mixed and incubated for 5 min at room temperature. Then 1000 ng of DNA was 
added, mixed and incubated for 25 min. After incubation, 94 µl of transfection mix 
was pipetted into the cell culture media of the cells. When co-expression experiments 
were performed in which multiple DNA types were co-transfected, a total amount of 
1000 ng DNA consisting of equal amounts of the different types of DNA was added. 
For Mock transfections, no DNA was added to the transfection mix. The transfection 
mix was incubated with the cells in 2 mL complete media overnight (~16 h) at 37˚C.  
 
2.3.2.1 DNA constructs for DNA transfection 
Plasmids used in DNA transfections are listed in Table 2-3.  
 
2.3.3 Paraformaldehyde (PFA) fixation and triton-X100 permeabilisation of 
cells 
Prior to fixation of cells, 4%PFA/PBS (Affymetrix) was warmed to 37˚C. For 
fixation, cell culture media of cells was removed and replaced with 4% PFA/PBS for 
20 min. Fixed wells were incubated with 30mM Glycine/PBS for 5 min to quench the 
active groups of PFA and washed once in PBS. If permeabilisation was required, PBS 
was removed and the plasma membrane was pemeabilised with 0.1% Triton-X-
100/PBS for 4 min and washed once with PBS.  
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Table 2-3 Plasmids for DNA transfection. 
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2.3.4 Widefield fluorescence Microscopy 
Fluorescence microscopy was carried out using an inverted Olympus IX73 
widefield fluorescent microscope.  Images were collected with an Orca flash 4.0 
camera (Hamamatsu) using HCImaging software and a Prior Lumen200Pro light 
source. Fluorescence emission was separated by a multiband dichroic emission filter 
set #69002 (Chroma). For live cell imaging, cells were kept at 37˚C and 5% CO2 
throughout the imaging process. Microscopy and settings were kept consistent within 
each experiment. Excitation and emission filter settings as well as type of objectives 
are listed in Table 2-4 and Table 2-5 below. 
 
Table 2-4 Excitation and emission filter settings. 
 
Table 2-5 Objectives used in this study. 
 
2.3.4.1 Image processing 
Images were processed using ImageJ adjusting the brightness and contrast 
settings and applying a scale bar on images. Merged images were separated to 
obtain single images representing the green, red and blue channel. Brightness and 
contrast settings were kept consistent between images derived from the same 
experiment.  
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2.4 Investigation of GFP1-10 expression and testing of the 
complementation of GFP1-10 with M3 
2.4.1 Immunofluorescent staining to detect GFP1-10 expression 
For immunofluorescent staining, 1.0x105 cells were seeded in 6 well plates 
(Corning) and grown on No. 1.5 coverslips, 25 mm in diameter (VWR) in complete 
medium (Table 2-2). When DNA transfection was needed cells were transfected with 
a DNA construct coding for GFP1-10/mCherry-GFP1-10/GRASP65-GFP1-10 (Table 
2-3) one day after seeding as described previously (2.3.2). Cell lines stably 
expressing GFP1-10 or mCherry-GFP1-10 were left untreated. The next day cell were 
PFA fixed and Triton-X-100 permeabilised (2.3.3). For immunofluorescent staining, 
cells were blocked for non-specific anti body binding in 3% BSA/PBS (Sigma) for 30 
min. Then cells were incubated with an anti-GFP antibody (Vector Laboratories) in 
3% BSA/PBS (1:500) for 1h, followed by three washes in PBS for 5 min each. Next, 
cells were stained with secondary anti-goat-647 antibody (Invitrogen) in 3% BSA/PBS 
(1:300) for 1h and washed twice with PBS for 5 min each. For secondary antibody 
controls, cells were only stained with the secondary anti-goat-647 antibody in 3% 
BSA/PBS (1:300) for 1h after cells were blocked in 3% BSA/PBS for 30 min. Finally 
the nucleus was stained with DAPI/PBS (1:10,000) for 5 min, washed in PBS and 
mounted on glass slides using 15 ul Mowiol (Appendix 9.1). Antibodies are listed in 
Table 2-6. All steps were carried out at room temperature. Antibody staining was 
investigated using microscopy (2.3.4).   
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Table 2-6 Antibodies used for Immunofluorescence 
 
 
Quantification of Antibody stain 
Microscopy images of antibody staining were analysed with ImageJ. Single cells 
were encircled at their cell membrane using the brightfield image. The integrated 
density (Area of the cell * mean fluorescence within that area) of red fluorescence 
representing total protein levels of the antibody stain was measured within this area 
using the image obtained in the Alexa647 channel. On the same image, two 
measurements were taken of the background without cells. The mean fluorescence 
was measured and the average of two mean fluorescence measurements 
represented the red fluorescence of the average background. The corrected total cell 
fluorescence (CTCF) was calculated with the following formula:  
CTCF= Integrated density - (Area of the cell * Average background) 
 
2.4.2 Western Blot analysis of GFP and GFP1-10 expression 
For Western Blot analysis 1x105 cells were seeded two days before the 
experiment. The next day cells were transiently transfected with plasmids coding for 
EGFP or GFP1-10 expression (2.3.2). On the day of the experiment cells were 
washed with ice cold PBS once, then cells were lysed using ice cold non-denaturing 
lysis buffer (Appenidx, 9.1). Cells were scraped off the dish and the suspension was 
transferred into an Eppendorf tube and kept at 4˚C for 30 min. Cell suspension was 
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pelleted using a microcentrifuge and the supernatant was placed into a new tube and 
placed on ice for further analysis. For western blot analysis of cell lysates, a 4-12% 
Bis-Tris Gel (Invitrogen) with 1x MOPS running Buffer (Invitrogen) was used. Samples 
were prepared following the Bis-Tris Mini Gels Electrophoreses Protocol for reduced 
samples. Gel was run at 200V for 70 minutes. Proteins were transferred on a 
membrane using 1x NuPage Transfer Buffer (Invitrogen) supplemented with 20% 
Methanol at 30V for 1h. For antibody detection, membrane was blocked in 5% Marvel 
in PBS/0.05% Tween20 for 1 hour. Membrane was incubated with 1ug/mL anti-GFP 
(Vectorlabs) in 5% Marvel in PBS/0.05% Tween20 at room temperature overnight. 
The next day membrane was washed with PBS/0.05% Tween20 for 3 times for 5 
minutes before the secondary (anti goat-HRP) was incubated in 5% milk in 
PBS/0.05% Tween20 for 1 hour at room temperature and washed with PBS/0.05% 
Tween20 for 3 times for 5 minutes. Antibodies are listed in Table 2-7. Membrane was 
incubated with Enhanced Chemiluminescent Substrate (Invitrogen) for 5 minutes. 
Luminescence was detected using the ChemiDoc (BioRad) detection system.  
 
Table 2-7 Antibodies used for Western Blotting 
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2.4.3 GFP complementation using co-transfection 
2.4.3.1 Investigation of GFP complementation using microscopy 
To investigate GFP complementation using co-transfection 1x105 cells were 
seeded in 6 well plates on 25 mm coverslips in complete medium and left to adhere 
overnight. The next day cells were transfected with indicated DNA constructs using 
Fugene6 (2.3.2) and incubated overnight. The next day cells were fixed using PFA 
(2.3.3).  Nuclei were stained with DAPI/PBS (1:10,000) for 5 min and washed in PBS 
once. Coverslips were mounted on glass slides using Mowiol and analysed by 
microscopy (2.3.4).  
 
2.4.3.2 Investigation of GFP complementation using a microplate reader 
To investigate GFP complementation using a microplate reader, 1x105 cells were 
seeded in 6 well plates in complete medium and left to adhere overnight. The next 
day cells were transfected with indicated DNA constructs using Fugene6 (2.3.2). On 
the day of the experiment, transfected cells were detached using 250 µl 0.25% 
Trypsin/EDTA per well of a 6 well plate. Cells were left to detach for 4min at 37˚C. 
Detached cells were resuspended in 750 µl PBS and transferred into eppendorf 
tubes. Cells were pelleted at 250xg for 4 min. The supernatant was discarded and 
the cell pellet was washed in PBS and pelleted at 250x g for 4 min. The washing step 
was performed twice and the pellet containing transfected cells was resuspended in 
a final volume of 350 µl PBS. The cells in suspension were plated in triplicates (100 
µl each, containing ~ 100,000 cells) into a clear bottom, black walled 96 well plate 
(Greiner) and immediately analysed on a microplate reader.  
 
Settings and analysis on the microplate reader 
Green fluorescence was detected using the microplate reader FLUOstar 
OPTIMA (BMG Labtech). The reader was set to measure fluorescent intensity. The 
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dimensions of the plate to be measured were set to Greiner 655096 Uclear96. The 
lid of the 96 well plate was removed before measurements and the sample was 
excited from the top and emitted fluorescence was detected from the top. Excitation 
and emission filters for GFP detection were set as 485 nm and 520 nm, respectively. 
The gain was adjusted to reach 88% for the co-transfection positive control and kept 
constant between experiments. The well scanning mode was set as orbital 
measurements.  
 
Data processing 
In order to display green fluorescence in a graph, all fluorescent values obtained 
from the plate reader were background subtracted. Values obtained from mock 
transfected cells, served as background readings. Readings are displayed in relative 
fluorescent units (RFU).  
 
2.4.4 GFP complementation with a synthetic peptide 
2.4.4.1 Microscopy approach: ‘Fix and stain‘ 
To test complementation of expressed GFP1-10 with the M3 peptides (Table 
2-1), 1x105 cells were seeded on 25 mm coverslips two days prior the experiment and 
left to adhere overnight in complete media. Cells were transfected with DNA 
constructs coding for GFP1-10 or GRASP65-GFP1-10 one day after seeding as 
described previously (2.3.2). On the day of the experiment cells were PFA fixed and 
permeabilised (2.3.3). Cells with permeabilised plasma membrane were then 
incubated with 20 µm of M3 containing peptide in PBS for 1h at room temperature. 
Cells were washed once in PBS. Finally the nucleus was stained with DAPI/PBS 
(1:10,000) for 5 min, washed in PBS and mounted on glass slides using 15 µL Mowiol. 
GFP complementation was analysed by microscopy (2.3.4).  
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2.4.4.2 Improved in vitro GFP complementation using cell lysate and detection 
with a microplate reader 
To investigate reassembly of GFP1-10 and M3 peptides in vitro, M3 containing 
peptides were diluted in 30 µl PBS to a concentration of 80 µM or 20 µM. Stable cells 
or transiently transfected cells expressing GFP1-10 or mCherry-GFP1-10 were grown 
in 10 cm dishes until they had reached 80% confluency. For the experiment cells of 
two 10 cm dishes were detached using 0.25% Trypsin/EDTA and incubated for 4 min 
at 37˚C. Cells were resuspended in PBS and pooled in a 15 mL falcon tube. The cell 
suspension was centrifuged at 250x g for 4 min and supernatant discarded. The 
remaining pellet was resuspended in 10 mL of fresh PBS. Cell number per mL was 
determined using a Haemocytometer (2.3.1.2). Then the volume was calculated that 
was needed to obtain a cell suspension of 26.6x105 cells per mL. The cells in solution 
were pelleted at 250x g for 4 min and the cell pellet was resuspended in the calculated 
volume of 0.1% Triton-X-100/PBS. Cells were left to lyse for 4 min at RT.  
To test GFP complementation in vitro, 30 µl of 80 µM /20 µM M3 containing 
peptides were mixed with 30 µl of cell lysate containing ~ 0.8 x 105 cells to obtain a 
final concentration of 40 µM /10 µM M3 containing peptides respectively. The mixture 
was transferred into a clear bottom, black walled 96 well plate (Greiner) and GFP 
fluorescence was monitored using a microplate reader. GFP fluorescence was 
detected after 5 min and then every hour. The plate was kept under constant agitation 
at the indicated temperature (4˚C or room temperature). The gain was set to 2750 
unless indicated otherwise. All other settings of the microplate reader were kept as 
previously described (2.4.3.2).  
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Data processing 
In order to display green fluorescence in a graph, all fluorescent values obtained 
from the plate reader were background subtracted. Values obtained from DMSO 
treated cells served as background readings. Readings are displayed in relative 
fluorescent units (RFU).  
 
2.5 Live uptake assay for GFP complementation by M3 delivery 
2.5.1 Microscopic analysis of M3 delivery into cells  
For the live GFP complementation assay using transient transfected cells, 1x 105 
cells were seeded on 35 mm MatTek dishes (Mattek Corporation) with a 10 mm glass 
bottom two days prior to the experiment and left to adhere overnight. Cells were 
transfected to express GFP1-10 or mCherry-GFP1-10 on the next day using Fugene6 
(2.3.2). For the live GFP complementation assay using stable cell lines, 1.8x 105 cells 
were seeded on 35 mm MatTek dishes (MatTek Corporation) with a 10 mm glass 
bottom one day prior the experiment and left to adhere overnight. On the day of the 
experiment M3 containing peptides were diluted in serum free media (see Table 2-2) 
to the indicated concentration (10-40 µM). Cells were washed with prewarmed serum 
free media once. Serum free media was aspirated off and central glass bottom ring 
of cells was incubated with 100 µl of peptides in serum free media for 2 hours at 5% 
CO2 and 37˚C in a humidified incubator. Cells were washed with phenol red free 
RPMI once and incubated with Hoechst (1:2000) in RPMI for 5 minutes at 37°C, 
washed twice in RPMI and left in RPMI for imaging. 
Imaging was performed on a widefield fluorescent microscope. GFP 
complementation was imaged using the following settings: 100x Oil objective, 2x 
binning, 500ms exposure time on GFP excitation and emission filter settings (see 
2.3.4). 
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Quantification 
When microscopy images were quantified, imaged were acquired randomly. 
Images were analysed using ImageJ. Single cells were encircled at their cell 
membrane using the brightfield image. The integrated density of green fluorescence 
representing total protein levels of complemented GFP was measured within this area 
using the image from the GFP channel. Then the mean fluorescence of two 
background measurements were taken on the same image where no cells were 
present. The average of those two measurements represented the average 
background fluorescence. The corrected total cell fluorescence (CTCF) was 
calculated with the following formula:  
CTCF= Integrated density - (Area of the cell * Average background) 
 
When uptake of Rhodamine labelled R8-M3 peptide was measured, the CTCF 
of the red channel was calculated from the same images where GFP 
complementation was assessed.   
 
2.5.2 Flow cytometry analysis  
2.5.2.1 Detection of morphologically intact cells and cell characterisation 
In order to define FSC and SSC gating for morphologically intact cells, Hela cells, 
SCL1 cells and mCherry-SCL1 cells were grown in 10 cm dishes to 75% confluency 
and detached from the dish using 1 mL prewarmed 0.25% Trypsin/EDTA for 4 min at 
5% CO2 and 37˚C in a humidified incubator. To prepare cells for flow cytometry 
measurement, cells were resuspended in 9 mL ice cold PBS and transferred into an 
Eppendorf tube. Cells were pelleted at 300x g for 4 min, washed once in 5 mL PBS 
and pelleted again at 300x g for 4 min. To investigate the viability of these cells, cells 
were mixed with LIVE/DEAD™ Violet Stain (Invitrogen L34963) according to the 
manufacturer’s protocol and incubated on ice for 30min. Cells were washed once in 
PBS and final cell pellet was resuspended in 500 µl PBS. Flow cytometry 
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measurement of FSC, SSC and cell viability was performed using FACSCanto II (BD 
Biosciences). Cells were mixed by flicking the tube before the measurement. To 
detect viable cells, samples were excited with 405 nm wavelength and emitted 
fluorescence was collected using the Pacific Blue filter (425 - 475 nm). Green and red 
fluorescence of untreated cells were measured using the 488nm excitation laser and 
FITC (515-545 nm wavelength) and PerCP-Cy5-5 (670 – 753 nm) emission filters, 
respectively. Fluorescence of a total of 50,000 per sample. Samples were measured 
in duplicates. Voltage settings were the following: FSC-A: 100 V; SSC-A 320 V; pacific 
blue 200 V; FITC: 400 V 
 
Data processing 
Data was analysed using the FlowJo software (V10) gating of cells was 
performed using FSC-A and SSC-A measurements. Single cells were gated using 
according to FSC-A and FSC-H measurements. Within the single cell population, 
fluorescence of GFP, mCherry and LIVE/DEAD™ Violet Stain was determined and 
shown as a histogram. FSC and SSC gating for morphologically intact cells was set 
where cells were negative for LIVE/DEAD™ Violet Stain fluorescence.  
 
2.5.2.2  Flow cytometry analysis of M3 delivery into cells 
For Flow cytometry analysis of M3 delivery into cells, 0.7x 105 SCL1 or mCherry-
SCL51 cells were seeded into each well of a 12 well plate (Corning) and left to adhere 
for 48 hours. On the day of the experiment M3 containing peptides were diluted in 
serum free media (see Table 2-2) to the indicated concentration (10-40 µM). Cells 
were washed with prewarmed serum free media once and incubated in 300 µl 
prewarmed peptide solution in serum free media for 2 hours at 5% CO2 and 37˚C in 
a humidified incubator. After the incubation time the peptide solution was aspirated 
off and cells were washed twice with ice cold 0.5 mg/mL Heparin/PBS to remove 
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bound R8 containing peptides from the plasma membrane. Cells were washed once 
with PBS at room temperature and detached from the dish using 250 µl prewarmed 
0.25% Trypsin/EDTA that was incubated with the cells for 4 min at 5% CO2 and 37˚C 
in a humidified incubator. The cell suspension was resuspended in 750 µl ice cold 
PBS and transferred into an Eppendorf tube. Cells were pelleted at 300x g for 4 min, 
washed once in 1000 µl PBS and pelleted again at 300x g for 4 min. Cells were 
resuspended in 500 µl PBS and transferred into round-bottom polystyrene tubes 
(Corning) for flow cytometry analysis and kept on ice.  
Flow cytometry measurement of GFP complementation was performed using a 
BD FACSCanto II. Cells were mixed by flicking the tube before the measurement. 
Samples were excited with 488 nm wavelength and emitted fluorescence was 
collected using the FITC filter (515-545 nm wavelength). When mCherry-SCL51 was 
measured on the flow cytometer, red fluorescence was collected in addition to the 
FITC signal using the PerCP-Cy5-5 emission filter (670 – 753 nm). Green 
fluorescence of a total of 20,000 cells (SCL1) or 10,000 cells (mCherry-SCL51) was 
measured. Voltage settings were the following: FSC: 100 V; SSC 320 V; FITC 400 V; 
PerCP-Cy5-5 500 V. 
 
Data processing 
Data was analysed using the FlowJo software (V10) gating of morphologically 
intact cells was performed using FSC-A and SSC-A measurements. Single cells were 
gated using FSC-A and FSC-H measurements. The geometric mean of GFP 
fluorescence was determined within the single cell population. When fold change of 
GFP fluorescence is shown, geometric mean of the DMSO control was set to a value 
of 1 and all samples were normalised to the DMSO control. Percentage of GFP 
positive cells was determined using the population comparison tool in the FlowJo 
software using the Overton % Positive algorithm.  
 
59 
 
2.6 Spectral detection of green fluorescence of GFP1-10  
Spectral detection of green fluorescence was performed using a Zeiss LSM 880 
confocal microscope. 1.0x105 HeLa cells and SCL1 cells were grown on  No. 1.5 
coverslips, 25 mm in diameter (VWR) in complete medium (Table 2-2) two days 
before the experiment.  HeLa cells were transfected with DNA coding for EGFP, 
GFP1-10 expression or Mock transfected (2.3.2). SCL1 cells were left untreated. On 
the day of the experiment, coverslips were transferred into an imaging chamber and 
the fluorescent signal of HeLa cells transfected with EGFP, GFP1-10 or mock 
transfected cells as well as green fluorescence of untreated SCL1 cells was analysed.  
The green fluorescent signal of a chosen region of interest was analysed regarding 
its emission spectrum. The emitted fluorescent signal was collected on 22 detectors 
dividing the fluorescent signal between 495 nm 682 nm wavelength light with a 
collection range of 8-9 nm wavelength light for a single detector. Values were then 
plotted in Excel to obtain the full emission spectrum of each sample.  
 
2.7 Confocal analysis of localisation of complemented GFP 
For the analysis of the localisation of complemented GFP, 1.0X 105 HeLa cells 
were seeded on 35 mm MatTek dishes (MatTek Corporation) with a 10 mm glass 
bottom two days prior to the experiment and left to adhere overnight. HeLa cells were 
transfected the next day with with DNA coding for GFP1-10 expression (2.3.2). On 
the day of the experiment M3 containing peptides were diluted in serum free media 
(see Table 2-2) to 40 µM. Cells were washed with prewarmed serum free media once. 
Serum free media was aspirated off and the central glass bottom ring of cells was 
incubated with 100 µl of peptides in serum free media for 2 hours at 5% CO2 and 
37˚C in a humidified incubator. Cells were washed with phenol red free RPMI once 
and incubated with Hoechst (1:2000) in RPMI for 5 minutes at 37°C, washed twice in 
RPMI and left in RPMI for imaging. Confocal analysis of complemented GFP was 
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performed using the Leica TCS SP2 AOBS confocal system using the inverted (Leica 
DMIRE2) microscope and the HCX PL APO 63x oil objective.  
 
2.8 Generation of stable cell lines  
2.8.1 Determination of the concentration of selection antibiotics 
Before generating the stable cell line, the concentration for Geneticin (G418) 
(Invitrogen) selection was detected on untransfected HeLa cells. The optimal dose 
for antibiotic selection was defined when 90% cell death occurred after 7 days and 
corresponded to 400 µg/mL G418.  
 
2.8.2 Generation of stable cell lines  
To generate the stable cell lines SCL1 and mCherry-SCL51, HeLa cells were 
transfected with the DNA coding for GFP1-10 or mCherry-GFP1-10 and the 
Neomycine gene using Fugene6. Transfection was carried out when cells were ~60% 
confluent in a 10 cm cell culture dish (55 cm2 growth area). The transfection mix 
consisted of 700 µl Optimem, 21 µl Fugene6 and 7000 ng DNA. Cells were 
maintained in complete media for 48 h to allow expression of the Neomycine gene for 
G418 resistance. Cell were then passaged (see 2.3.1.2) and divided into new dishes 
in the different dilutions 1:2, 1:5, 1:10, 1:20 and 1:40 containing selection media 
supplemented with 400 mg/ml G418. The media was changed regularly for 14 days. 
After 14 days the dish containing the highest number of clearly separated cell colonies 
was chosen for limiting dilution. To perform limiting dilution, cells were seeded into 96 
well plates at a concentration of 0.5 cells/well or 2 cells/well to increase the chances 
of the cell colonies growing up from a single cell clone to obtain a monoclonal cell 
line. Selection media was regularly changed until cells had grown to confluence.  
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2.8.2.1 Selection of a colony expressing GFP1-10: SCL1  
When cells had grown to confluency in a 96 well plate, cells were replica plated 
to maintain growth of the colonies and cells were additionally plated into a screening 
plate. This plate was used to screen colonies for expression levels of GFP1-10 by 
immunohistochemistry (2.4.1). Selection criteria to reduce number of colonies to the 
most promising clones were even antibody staining across the cell population. Most 
promising colonies were then tested for GFP complementation using co-transfection 
of DNA coding for M3 (0) and reassembly with M3 peptides (2.4.4.1). The colony 
expressing highest and even levels of GFP1-10 that was able to complement using 
co-transfection and reassembled with M3 peptides was chosen as the most promising 
colony and was named Split Cell Line 1 (SCL1). After selection of SCL1, cells were 
cultured in selection media for another 4 weeks until cultured in non-selective media. 
Expression of GFP1-10 was confirmed again when cells were cultured in complete 
media using immunohistochemistry (2.4.1).  
 
2.8.2.2 Generation of stable cell line expressing mCherry-GFP1-10: mCherry-
SCL51  
When cells had grown to confluency in a 96 well plate, cells were replica plated 
to maintain growth of the colonies and cells were additionally plated into a screening 
plate. The screening plate was then imaged on a widefield fluorescent microscope 
(2.3.4) to investigate mCherry fluorescence in live cells. Selection criteria to reduce 
number of colonies to the most promising clones were even expression of mCherry 
across the cell population. Most promising colonies were then tested for GFP1-10 
expression using immunofluorescence (2.4.1). When GFP1-10 expression was 
confirmed in these colonies, GFP complementation using co-transfection of DNA 
coding for M3 (0) and reassembly with M3 peptides (2.4.4.1). In the first round of 
limiting dilution it was not possible to obtain a monoclonal stable cell line. Hence 
another round of limiting dilution and screening as described above was performed. 
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The cell line that was obtained was named mCherry-SCL51 and was the cell line with 
the highest amount of mCherry-GFP1-10 expression cells. However, it is also a 
polyclonal cell line.  
 
2.8.3 Freezing stable cell lines  
For long-term storage, 75% confluent stable cells lines were detached from the 
cell culture dish and pelleted following the protocol for routine cell culture (2.3.1.2). 
Pellet containing ~1 x 106 cells was resuspended in 1mL freezing mix containing 50% 
complete media, 40% FBS and 10% DMSO and transferred into a cryovial. Cells were 
frozen in a temperature controlled freezing container to -80˚C and transferred to liquid 
nitrogen for long-term storage.  
2.9 Statistical analysis 
Statistical analysis was performed using R Statistical Software. Statistical 
examination of two populations was first performed by testing for normality of the data. 
This was performed by investigating the distribution of the data in a histogram as well 
as performing a Shaipiro-Wilk-Test. If p<0.05, the data was not normally distributed 
and data was further tested for significant difference using a Mann–Whitney-U-Test 
for nonparametric data.  
When multiple conditions were compared, data was tested using a One-Way-
Annova. If residuals were normally distributed multiple condition were compared 
using a Turkey honest significant difference (HSD) test. If residuals were not normally 
distributed, data was tested using a Kruskal-Wallis test for nonparametric data and a 
Benjamini Hochberg test for multiple comparison. Significance levels are indicated 
the following *: p<0.05, **: p<0.01, ***: p<0.001, n.s.: not significant. 
 
  
63 
 
2.10 Molecular biological techniques 
2.10.1 Restriction digest 
For DNA restriction digests the appropriate restriction enzymes were used and 
their according buffers to ensure optimal performance. Components were defrosted 
on ice. The volumes for the restriction digest were the following:  
 
Component Volume 
DNA 1-5 µg 
10X NEBuffer 5µl  
Restriction Enzyme 10 Units per µg of DNA 
Nuclease free water to 50 µl 
 50 µl 
 
The restriction digest was mixed by pipetting up and down incubated at 37˚C for 
1 h. The restriction digest was analysed using agarose gel electrophoresis (2.10.6) 
or cleared from restriction enzymes using QiaexII Gel extraction kit (2.10.7). When a 
test digest was performed, a total volume of 20 µl was used and volumes of reagents 
were adjusted accordingly.   
 
2.10.2 Ligation using T4 DNA Ligase 
When a traditional cloning technique was used, DNA fragments were ligated 
following the T4 DNA ligase protocol. Components were defrosted at room 
temperature. The volumes for the ligation were the following:  
Component Volume 
10X T4 Ligase Buffer 2 µl 
Vector DNA x µl (50 ng) 
Insert DNA* x µ (x ng) 
Nuclease free water to 20 µl 
T4 ligase 1 µl 
 20 µl 
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* The amount of insert that was added to the ligation mix was in a molar ratio of 1:3 
(Vector:Insert) and calculated using the following formula: 
𝑛𝑔 𝑜𝑓 𝐼𝑛𝑠𝑒𝑟𝑡 =
3 𝑥 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑝 𝑜𝑓 𝐼𝑛𝑠𝑒𝑟𝑡 𝑥 𝑛𝑔 𝑜𝑓 𝑉𝑒𝑐𝑡𝑜𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑝 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟
 
 
The ligation mix was mixed by pipetting up and down incubated at room temperature 
for 1 h. 1-5 µl were added to the transformation mix of Top10 chemically competent 
cells. 
 
2.10.3 Ligation using Seamless cloning technique 
New constructs were obtained following the GeneArt® Seamless Cloning and 
Assembly protocol. This technique relies on homologues recombination of DNA. In 
order to utilize this technique, Genestrings were designed, containing the genes of 
interest. These genestrings contained homologue regions to their linearised receiving 
vector at their N- and C-terminus (15 bp each).  All genestrings that were utilised 
within this work were generated within the Master’s Thesis: Riester P., Characterising 
the cellular uptake and targeting of novel drug delivery systems, 2014, Department of 
Biology, Universitaet Konstanz. Cloning of constructs was performed within this PhD 
thesis. 
 
2.10.4 Transformation of bacteria 
E.Coli were transformed using the heat shock method. The E.Coli strands that 
were used are listed below.  
Table 2-8 E.Coli strands 
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For transformations, bacteria were defrosted on ice for 30 min and 50-400 ng of 
DNA was added to the tube and mixed. DNA was incubated with the bacteria on ice 
for 30 min. Then bacteria were heat-shocked for 45 seconds at 42°C followed by an 
incubation on ice for 2 minutes. 250 µl of SOC media (Invitrogen) was added and 
bacteria were incubated shaking at for one hour at 37°C to allow expression of the 
antibiotic resistance. Then 80 µl were plated out on LB-Agar plates containing the 
appropriate antibiotics and incubated at 37°C overnight.  
 
2.10.5 Polymerase Chain reaction (PCR) 
PCR was used to screen bacterial colonies or to amplify DNA sequences for 
cloning. PCR primers used in this study can be found in Table 2-9. Primers were 
obtained from eurofins genomics and diluted in nuclease free water to a final 
concentration of 100 pmol/ µl.  
Table 2-9 List of primers 
 
2.10.5.1 PCR for screening bacterial colonies  
In order to investigate if bacterial colonies had amplified DNA containing the 
correct insert resulting from molecular cloning, PCR was used to screen for positive 
colonies. Single colonies were picked from the LB agar plate and diluted in 100 µl 
nuclease free water and mixed well. To screen bacterial colonies, Taq Polymerase 
was used. Per PCR a PCR mix of a total volume of 10 µl was prepared. An example 
is shown below when PCR mix was prepared to screen 10 colonies. The template 
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DNA was added individually for every PCR by adding 1 µl of the bacterial colony mix 
in nuclease free water to 9 µl of PCR mix.  
 
Component 100 µl Final concentration 
10X Standard Taq Reaction Buffer 10 µl 1x 
10 mM dNTPs 2 µl 200 µM 
10 µM Forward Primer 2 µl 0.2 µM 
10 µM Reverse Primer 2 µl 0.2 µM 
Taq DNA Polymerase 0.25 µl 1.25 U/50 µl PCR 
Template DNA 1 µl  -  
Nuclease-free Water to 100 µl  
 100 µl  
 
The thermocycling conditions were the following: 
 
 
The Annealing temperature was adjusted depending on the melting temperature (Tm) 
of the used primers. A list of primers used in this study can be found in Table 2-9. 
PCR products were visualised using Gel electrophoresis (2.10.6).  
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2.10.5.2 PCR to generate gene constructs for cloning 
In order to amplify DNA sequences used for cloning, Phusion DNA polymerase 
was chosen exhibiting a proof reading function. Per sample a 50 µl reaction volume 
was used. An example for a 50 µl PCR mix is shown below.  
Component 50 µl Final concentration 
5X Phusion HF buffer 10 µl 1x 
10 mM dNTPs 1 µl 200 µM 
10 µM Forward Primer 2.5 µl 0.5 µM 
10 µM Reverse Primer 2.5 µl 0.5 µM 
Phusion DNA Polymerase 0.5 µl 1.0 U/50 µl PCR 
Template DNA variable  ~ 20ng  
Nuclease-free Water to 50 µl  
 50 µl  
 
The thermocycling conditions were the following: 
 
The Annealing temperature was adjusted depending on the melting temperature (Tm) 
of the used primers. PCR products were visualised using Gel electrophoresis (2.10.6) 
and DNA was purified using Gel extraction (2.10.7). 
 
2.10.6 Agarose gel electrophoreses  
DNA fragments from restriction digests and PCR products were separated and 
analysed by Gel electrophoresis. Therefore a 1.5 % Agarose gel was prepared by 
boiling Agarose in Tris-acetate- EDTA buffer (TAE-buffer). After cooling down, 
ethidiumbromide to a final concentration of 0.5 µg/mL was added. The gel was left to 
polymerise. Once gel was set it was placed in an electrophoresis tank and filled with 
TAE buffer. DNA samples were loaded using 10x loading buffer (Appendix 9.1). Gel 
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ran for at 90 V until bands were sufficiently separated and visualized under UV light 
using a GelDoc UV transilluminator (Bio-Rad).  
 
2.10.7 Gel extraction 
Gel extraction of DNA was carried out using a Qiaquick Gel extraction kit 
(Qiagen). If high yields of extracted DNA were required or restriction digests were 
purified from restriction enzymes, QiaexII Gel extraction kit (Qiagen) was used. Both 
gel extractions were performed following the manufacturer’s protocol. 
 
2.10.8 Plasmid preparation 
A single colony of bacteria was picked and cultured in LB-media containing the 
appropriate antibiotics overnight shaking at 37°C. For minipreps a 5 mL overnight 
culture was grown; for a plasmid midiprep a 5 mL day culture was grown and 1 mL 
was transferred into 50 mL of fresh LB media containing the appropriate antibiotics 
for an overnight culture.  Plasmid DNA was isolated following the manual of 
PureLink™ Quick Plasmid Miniprep or Midiprep Kit (Invitrogen).  
 
2.10.9 Quantification of DNA 
The concentration and purity of DNA obtained from plasmid preparations was 
determined using a NanoDrop2000 (Thermo Scientific).  
 
2.10.10 Sequencing of DNA constructs 
Purified plasmid DNA was submitted for sequencing with appropriate sequencing 
primers. Sequencing was carried out by Eurofins Genomics. 
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2.11 Generation of expression plasmids 
2.11.1 Generation of pGRASP65-GFP1-10-N2 
pGRASP65-GFP1-10-N2 was generated by using the seamless cloning 
technique (2.10.3) using a genestring carrying the DNA for GFP1-10 expression. This 
genestring was designed for mammalian expression of GFP1-10. The GFP1-10 
sequence used was based on the GFP1-10(h) sequence, optimized for human codon 
usage (Pinaud and Dahan 2011) but still encoding the 16 mutations that are 
necessary for split GFP1-10 OPT (Cabantous et al. 2005). The genestring (Figure 
2-1) was designed to be cloned into the multiple cloning site of pEGFP-N2 
(Appendix9.2 Figure 9-1) when this vector was linearised by digest with the restriction 
enzymes XmaI and XbaI. Therefore, the genestring contained N- and C-terminal 
homologous regions to linearised pEGFP-N2, XmaI and XbaI restriction sites to 
restore restriction sites in the resulting plasmid and GFP1-10. This genestring was 
designed within a previous Master’s project (Riester P., Characterising the cellular 
uptake and targeting of novel drug delivery systems, 2014, Department of Biology, 
Universitaet Konstanz.) 
 
Figure 2-1 Genestring for GFP1-10 expression 
DNA sequence of genestring coding for GFP1-10 expression is shown. Homologous base 
pairs to linearised pEGFP-N2 when digested with XmaI and XbaI are underlined. XmaI 
restriction site (red), XbaI restriction site (blue), GFP1-10 coding region (green) and the start 
of transcription is marked with an arrow.  
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To perform cloning, a plasmid encoding GRASP65 in the background vector 
pEGFP-N2 was received as a kind gift from Dr. John D. Lane (pGRASP65-EGFP-N2) 
(Lane et al. 2002). The plasmid was amplified in a DAM- bacterial strain to prevent 
methylation of the XbaI site. Full length EGFP was removed by restriction digest of 
XmaI and XbaI sites. The linearised vector was purified by agarose gel 
electrophoresis (2.10.6.) followed by gel extraction (2.10.7). In order to insert the DNA 
encoding for GFP1-10 following the GeneArt® Seamless Cloning and Assembly 
protocol, a genestring was synthesised with a 15 bp overhang at the N- and C-
terminus homologous to the linearized vector (2.11.1 ). Using the seamless cloning 
technology the genestring was ligated with the linearised vector via homologous 
recombination to obtain pGRASP65-GFP1-10-N2 (Figure 2-2). This was achieved 
following GeneArt® Seamless Cloning and Assembly ligation protocol. The ligation 
mix was transformed into Top10 chemically competent bacteria (2.10.4) and plated 
onto LB-Agar plates containing kanamycin. The next day four colonies were grown 
on the LB-Agar plates. Clones1-4 were picked and DNA was obtained using a 
PureLink™ Midiprep Kit (see 2.10.8). All clones were test digested with XmaI and 
BsrGI. The digest products were analysed using gel electrophoresis and visualised 
using a GelDoc UV transilluminator (Figure 2-3). The expected size for a GFP1-10 
insert was 475 bp and 736 bp if the DNA was derived from the original plasmid 
pGRASP65-EGFP-N2. All clones (1-4) showed a correct sized insert and sent off for 
sequencing. Sequencing results were correct and clone 1 was selected to be used 
for GRASP65-GFP1-10 expression. 
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Figure 2-2 Cloning strategy to obtain pGRASP65-GFP1-10-N2 
pGRASP65-EGFP-N2 was amplified in a DAM- bacterial strain to prevent methylation of the 
XbaI site. Full length EGFP was removed by restriction digest of XmaI and XbaI sites. Using 
the seamless cloning technology a genestring coding for GFP1-10 with homologous 
sequences to the linearised vector was ligated with the vector to obtain pGRASP65-GFP1-10-
N2. 
 
 
 
Figure 2-3 Test digest to identify pGRASP65-GFP1-10-N2 
All clones as well as the original plasmid pGRASP65-EGFP-N2 were test digested with XmaI 
and BsrGI. Samples were run on a 1.5% agarose gel in TAE buffer. In addition to the samples, 
1kb DNA ladder and 100 bp DNA (NEB) were run on the gel. Expected sizes were 475 bp 
when GFP1-10 has inserted correctly and 736 bp when EGFP was inserted back into the 
vector.  
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2.11.2 Generation of pGFP1-10-N1 
The plasmid pCav1-GFP1-10(h)-N1 coding for caveolin-GFP1-10 expression was 
received as a kind gift from F. Pinaud/ M. Dahan (Pinaud and Dahan 2011). Caveolin-
1 was removed by double digest with BglII and BamHI. The digest was purified from 
restriction digest enzymes using QiaexII Gel extraction Kit (see 2.10.2). The digest 
with BglII and BamHI resulted in compatible cohesive ends that were religated 
following the T4 DNA ligase protocol (see 2.10.2) in frame to obtain pGFP1-10-N1 
(Figure 2-4). The ligation mix was transformed into Top10 chemically competent 
bacteria (2.10.4) and plated onto LB-Agar plates containing kanamycin. The next day 
clones were screened using PCR (2.10.5.1) to identify clones where the DNA had 
religated to pCav1-GFP1-10-N1 and clones that contained the DNA for pGFP1-10-
N1. PCR primers that were used were CMV forward and EGFPC1 reverse primer. 
Annealing temperature was 55°C annealing and elongation time 1min. The PCR 
products were analysed using gel electrophoresis and visualised using a GelDoc UV 
transilluminator (Figure 2-5). The expected size for a religated vector with GFP1-10 
insert only was ~700 bp. When the vector had religated with the original Caveolin-
GFP1-10 DNA, PCR product was expected to be a size of ~1300 bp. Clones 118, 121 
and 122 showed the correct size of PCR product on the gel. Clone 118, 121 were 
mini prepped and sent off for sequencing. Sequencing results were correct and clone 
121 was selected to be used for GFP1-10 expression.  
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Figure 2-4 Cloning strategy to obtain pGFP1-10-N1 
pCav1-GFP1-10(h)-N1 was digested with BglII and BamHI to remove  Caveolin-1. Digest with 
BglII and BamHI resulted in compatible cohesive ends that were religated using T4 DNA 
ligase.  
 
Figure 2-5 Screening of PCR products to identify pGFP1-10-N1. 
Clones from bacterial colonies were screened using PCR to identify pCav1-GFP1-10-N1. PCR 
primers used were CMV forward and EGFPC1 reverse primer. Annealing temperature was 
55°C annealing and elongation time 1min. Samples were run on a 1.5% agarose gel in TAE 
buffer. In addition to the samples, 1kb DNA ladder (NEB) were run on the gel. Expected sizes 
were ~700 bp when GFP1-10 has inserted correctly and ~1300 bp when Caveolin-GFP1-10 
was inserted back into the vector.  
 
 
        
2.11.3 Generation of pET3A-H6-Xa-R8-M3 
pET3A-H6-Xa-R8-M3 was generated by using the seamless cloning technique 
(2.10.3) using a genestring carrying the DNA for H6-Xa-R8-M3 expression. The 
genestring was designed with the Master’s thesis: Riester P., Characterising the 
cellular uptake and targeting of novel drug delivery systems, 2014, Department of 
Biology, Universitaet Konstanz. This DNA construct was generated and served as a 
precursor for a mammalian DNA construct coding for H6-Xa-R8-M3. The genestring 
was designed to be cloned into the multiple cloning site of pET3A when this vector is 
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by digest with the restriction enzymes NdeI and BamHI.  To perform seamless 
cloning, the genestring contained N- and C-terminal homologous regions to linearised 
pET3A and a coding region carrying the DNA for H6-Xa-R8-M3 expression. 
Furthermore, the genestring was designed to restore NdeI and BamHI restriction sites 
(Figure 2-6). The full sequence of the genestring is shown in Figure 2-7. The 
sequence of M3 was based on the published GFP11 M3 sequence (Cabantous et al. 
2005) and the flexible linker between octaarginine (R8) and M3 was used as 
described by (Pinaud and Dahan 2011). 
 
 
Figure 2-6 Cloning strategy to obtain pET3A-H6-Xa-R8-M3 
 
Digest of pET3a with the restriction enzymes NdeI and BamHI leads to linearization of the 
vector.  A genestring containing N- and C-terminal homologue regions to linearised pET3A 
and a coding region carrying the DNA for H6-Xa-R8-M3 expression can then be ligated into 
the vector using the seamless cloning technique.  
 
 
 
Figure 2-7 Genestring for H6-Xa-R8-M3 cloning into pET3a.  
DNA sequence of genestring coding for H6-Xa-R8-M3 expression expression is shown. 
Homologue base pairs to linearised pET3a when digested with NdeI and BamHI are 
underlined. NdeI restriction site (blue), BamHI restriction site (orange), coding region for H6 in 
brown, Xa cleavage site in grey, R8 in blue, M3 in green and the start of transcription is marked 
with an arrow.  
 
 
To perform the cloning, the bacterial expression plasmid pET3a was linearized 
using the restriction sites NdeI and BamHI. The digest was purified from restriction 
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digest enzymes using QiaexII Gel extraction Kit (see 2.10.2). Making use of the 
seamless cloning technology the linearized vector and the homologous sequences of 
the genestring were recombined. The ligation mix was transformed into Top10 
chemically competent bacteria (2.10.4) and plated onto LB-Agar plates containing 
Ampicillin. The next day clones on LB plates were screened using PCR (2.10.5.1) to 
identify clones where the DNA coding for H6-Xa-R8-M3 had inserted into pET3A. 
PCR primers that were used were T7 forward and T7 reverse. The PCR products 
were analysed using gel electrophoresis and visualised using a GelDoc UV 
transilluminator (Figure 2-5). The expected size for a vector with correct H6-Xa-R8-
M3 insert only was ~300 bp. When the vector had religated to the original pET3a 
vector, PCR product was expected to be a size of ~100 bp. Figure 2-8 shows that 
clone 84, 85 and 86 had the correct size insert. All clones were sent off for 
sequencing. Sequencing results were correct and clone 86 was selected to be used 
for bacterial H6-Xa-R8-M3 expression. 
 
Figure 2-8 Screening of PCR products to identify pET3a-H6-Xa-R8-M3. 
Clones from bacterial colonies were screened using PCR to identify pET3a-H6-Xa-R8-M3. 
PCR primers used were T7 forward and T7 reverse primer. Samples were run on a 1.5% 
agarose gel in TAE buffer. In addition to the samples, 1kb DNA ladder (NEB) were run on the 
gel. Expected sizes were ~300 bp when H6-Xa-R8-M3 has inserted correctly and ~100 bp 
when pET3a had not inserted DNA.  
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2.11.4 Generation of pH6-Xa-R8-M3-N2 
For further subcloning of H6-Xa-R8-linker-M3 into the mammalian expression 
plasmid pEGFP-N2, H6-Xa-R8-linker-M3 was PCR amplified and inserted into the 
vector EGFP-N2 through restriction digest of both, vector an insert at the XmaI and 
XbaI restriction sites followed by ligation (Figure 2-9).  
To perform the subcloning, the XmaI-H6-Xa-R8-linker-M3-XbaI insert was PCR 
amplified from pET3a-H6-Xa-R8-M3 using Phusion polymerase (2.10.5.2).  Forward 
primer and reverse primer used were T7 forward and T7 reverse, respectively.  The 
PCR product was purified and digested with XmaI and XbaI restriction enzymes. The 
insert was purified from restriction enzymes using the QiaexII Gel extraction Kit 
(2.10.7). The plasmid pEGFP-N2 was amplified in a DAM- bacterial strain to avoid 
methylation of restriction sites. The plasmid was linearised by restriction digest with 
XmaI and XbaI and EGFP was removed. The vector was purified using gel 
electrophoresis (2.10.6) followed by gel extraction (2.10.7). Then H6-Xa-R8-M3 and 
pEGFP-N2 were ligated using T4 ligase (2.10.2) to obtain mammalian expression 
construct pH6-Xa-R8-M3-N2. The ligation mix was transformed into Top10 chemically 
competent bacteria (2.10.4) and plated onto LB-Agar plates containing Kanamycin. 
The next day clones on LB plates were screened using PCR (2.10.5.1) to identify 
colonies where the DNA coding for H6-Xa-R8-M3 had inserted into pEGFP-N2. 
Colonies were screened using CMV forward and EGFPC1 reverse primers and an 
annealing temperature of 55°C. The PCR products were analysed using gel 
electrophoresis and visualised using a GelDoc UV transilluminator (Figure 2-10). The 
expected size for a vector with correct H6-Xa-R8-M3 insert only was ~300 bp.  Figure 
2-10 shows that all clones (1-5) show different sized inserts below 500 bp. All clones 
were sent off for sequencing. Sequencing results were correct for clone 1 which was 
selected to be used for mammalian H6-Xa-R8-M3 expression.  
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Figure 2-9 Cloning strategy to obtain pH6-Xa-R8-M3-N2.  
The XmaI-H6-Xa-R8-linker-M3-XbaI insert is amplified using PCR from the vector pET3a-H6-
Xa-R8-M3 and T7 forward and reverse primers. The mammalian expression pEGFP-N2 and 
the XmaI-H6-Xa-R8-linker-M3-XbaI insert are digested using restriction enzymes XmaI and 
XbaI and vector and insert a ligated to obtain p-H6-Xa-R8-M3.  
 
Figure 2-10 Screening of PCR products to identify pH6-Xa-R8-M3-N2. 
Clones from bacterial colonies were screened using PCR to identify pH6-Xa-R8-M3-N2. PCR 
primers that were used were CMV forward and EGFPC1 reverse primer. Samples were run 
on a 1.5% agarose gel in TAE buffer. In addition to the samples, 100 bp DNA ladder (NEB) 
was run on the gel. Expected sizes were ~300 bp when H6-Xa-R8-M3 has inserted correctly. 
Samples were run on the same gel as the 100 bp DNA ladder but samples that were not 
relevant to this experiment were removed from the gel.   
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2.11.5 Generation of pcDNA3.1-mCherry-H6-Xa-R8-M3 
To have a fluorescent readout of H6-Xa-R8-M3-N2 expression, another 
mammalian expression construct was generated where H6-Xa-R8-M3-N2 was 
introduced as a C-terminal fusion to mCherry using XhoI and XbaI restriction sites 
available in vector and insert (Figure 2-11). The plasmid pcDNA3.1 encoding mCherry 
was given as a kind gift from D. Dafydd Jones laboratory (Nasu et al. 2015). Both 
plasmids, pcDNA3.1.-mCherry and pH6-Xa-R8-M3-N2 were amplified in a DAM- 
bacterial strain to obtain a non-methylated XbaI site and digested with XbaI and XhoI. 
Digested vector and insert were purified (2.10.7) and the insert H6-Xa-R8-M3 was 
ligated (2.10.2) into the linearised vector pcDNA3.1.-mCherry to obtain a new 
mammalian expression construct, pcDNA3.1.-mCherry-H6-Xa-R8-M3. The ligation 
mix was transformed into Top10 chemically competent bacteria (2.10.4) and plated 
onto LB-Agar plates containing Ampicillin. The next day clones on LB plates were 
screened using PCR (2.10.5.1) to identify colonies where the DNA coding for H6-Xa-
R8-M3 had inserted into pCDNA3.1-mCherry. Colonies were screened using 
pcDNA3.1 forward and pcDNA3.1 reverse primers and an annealing temperature of 
55°C. The PCR products were analysed using gel electrophoresis and visualised 
using a GelDoc UV transilluminator (Figure 2-10). The expected size for a vector with 
correct H6-Xa-R8-M3 insert only was ~1200 bp.  Figure 2-12 shows that clone 217 
shows a bigger size insert than all other clones screened. All other clones show the 
same size as original pcDNA3.1-mCherry construct.  Clone 217 was sent off for 
sequencing. Sequencing results were correct and clone 217 was selected to be used 
for mCherry-H6-Xa-R8-M3 expression. 
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Figure 2-11 Cloning strategy to obtain pcDNA3.1-mCherry-H6-Xa-R8-M3.  
To obtain pcDNA3.1-mCherry-H6-Xa-R8-M3, pcDNA3.1-mCherry and pH6-Xa-R8-M3-N2 
were digested using XhoI and XbaI restriction sites. Vector and insert were then ligated using 
T4 ligase.  
  
Figure 2-12 Screening of PCR products to identify pCDNA3.1-mCherry-H6-Xa-R8-M3. 
Clones from bacterial colonies were screened using PCR to identify pCDNA3.1-mCherry-H6-
Xa-R8-M3. PCR primers that were used were pcDNA3.1 forward and pcDNA3.1 reverse 
primer. Samples were run on a 1.5% agarose gel in TAE buffer. In addition to the samples a 
1kb DNA ladder (NEB) was run on the gel. Expected sizes were ~1200 bp when H6-Xa-R8-
M3 has inserted correctly.  
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2.11.6 Generation of pcDNA3.1-mCherry-GFP1-10 
For the generation of a mammalian mCherry-GFP1-10 expression construct, a 
GFP1-10 insert was PCR amplified including restriction sites XhoI and XbaI and 
inserted into pcDNA3.1-mCherry (Figure 2-13).  
To perform the cloning, GFP1-10 was PCR amplified from pGFP1-10-N1 using 
phusion polymerase (2.10.5.2). Primers used were GFP1-10 forward and GFP1-10 
reverse primers. These primers ensured amplification of a XhoI and a XbaI site in 
addition to the GFP1-10 insert and an overhang sequence. PCR products were 
purified using the QiaexII purification kit (Qiagen). pcDNA3.1.-mCherry was amplified 
in a DAM- bacterial strain to obtain a non-methylated XbaI site. The purified GFP1-
10 PCR product and the plasmid pcDNA3.1-mCherry encoding mCherry were cut 
with XhoI and XbaI, purified and the GFP1-10 insert was ligated C terminally to 
mCherry into pcDNA3.1 (2.10.2). The ligation mix was transformed into Top10 
chemically competent bacteria (2.10.4) and plated onto LB-Agar plates containing 
Ampicillin. The next day clones on LB plates were screened using PCR (2.10.5.1) to 
identify colonies where the DNA coding for GFP1-10 had inserted into pcDNA3.1-
mCherry. Colonies were screened using pcDNA3.1 forward and pcDNA3.1 reverse 
primers. The PCR products were analysed using gel electrophoresis and visualised 
using a GelDoc UV transilluminator (Figure 2-14). The expected size for a vector with 
correct GFP1-10 insert only was ~1700bp. Figure 2-14 shows that clone 322 was the 
correct size on the gel. Clone 322 was sent off for sequencing. Sequencing results 
were correct and clone 322 was selected to be used for mCherry-GFP1-10 
expression. 
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Figure 2-13 Cloning strategy to obtain pcDNA3.1-mCherry-GFP1-10. 
To obtain pcDNA3.1-mCherryGFP1-10, pcDNA3.1-mCherry a PCR amplified insert XhoI-
GFP1-10-XbaI were digested using XhoI and XbaI restriction sites. Vector and insert were 
then ligated using T4 ligase.  
 
 
Figure 2-14 Screening of PCR products to identify pCDNA3.1-mCherry-GFP1-10. 
Clones from bacterial colonies were screened using PCR to identify pCDNA3.1-mCherry-
GFP1-10. PCR primers that were used were pcDNA3.1 forward and pcDNA3.1 reverse 
primer. Samples were run on a 1.5% agarose gel in TAE buffer. In addition to the samples a 
1kb DNA ladder (NEB) was run on the gel. Expected sizes were ~1700 bp when H6-Xa-R8-
M3 has inserted correctly.  
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2.11.7 Generation of pcDNA3.1-mCherry-GFP 
For the generation of a mammalian mCherry-GFP expression construct, a GFP1-
10 insert was PCR amplified including restriction sites XhoI and XbaI and inserted 
into pcDNA3.1-mCherry (Figure 2-15).  
To perform the cloning, GFP was PCR amplified from pEGFP-C1 using Phusion 
polymerase (2.10.5.2). Primers used were GFP forward and GFP reverse primers. 
These primers ensured amplification of a XhoI and a XbaI site in addition to the GFP 
insert and an overhang sequence. PCR products were purified using the QiaexII 
prurification kit (Qiagen). pcDNA3.1.-mCherry was amplified in a DAM- bacterial 
strain to obtain a non-methylated XbaI site. The purified GFP1-10 PCR product and 
the plasmid pcDNA3.1-mCherry encoding mCherry were cut with XhoI and XbaI, 
purified and the GFP insert was ligated C terminally to mCherry into pcDNA3.1 
(2.10.2). The ligation mix was transformed into Top10 chemically competent bacteria 
(2.10.4) and plated onto LB-Agar plates containing Ampicillin. The next day clones on 
LB plates were screened using PCR (2.10.5.1) to identify colonies where the DNA 
coding for GFP had inserted into pCDNA3.1-mCherry. Colonies were screened using 
pcDNA3.1 forward and pcDNA3.1 reverse primers. The PCR products were analysed 
using gel electrophoresis and visualised using a GelDoc UV transilluminator (Figure 
2-14). The expected size for a vector with correct GFP insert only was ~1770 bp. 
Figure 2-16 shows that clone 327 and clone 331 were correctly sized. Clone 327 and 
clone 331 were sent off for sequencing. Sequencing results were correct and clone 
327 was selected to be used for mCherry-GFP expression. 
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Figure 2-15 Cloning strategy to obtain pcDNA3.1-mCherry-GFP. 
To obtain pcDNA3.1-mCherryGFP, pcDNA3.1-mCherry a PCR amplified insert XhoI-GFP1-
XbaI were digested using XhoI and XbaI restriction sites. Vector and insert were then ligated 
using T4 ligase.  
 
 
Figure 2-16 Screening of PCR products to identify pCDNA3.1-mCherry-GFP. 
Clones from bacterial colonies were screened using PCR to identify pCDNA3.1-mCherry-
GFP. PCR primers that were used were pcDNA1.3 forward and pcDNA3.1 reverse primer. 
Samples were run on a 1.5% agarose gel in TAE buffer. In addition to the samples a 1kb DNA 
ladder (NEB) was run on the gel. Expected size was ~1770 bp when GFP has inserted 
correctly.  
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3 Development of a spit GFP assay to detect 
functional cytosolic delivery of a peptide 
3.1 Introduction 
The success of the proposed method (1.5.1) to evaluate the efficiency of drug 
delivery systems to functionally deliver M3 peptide cargo to the cytosol of target cells 
that express GFP1-10 relies on three important factors. Firstly, that GFP1-10 can be 
expressed in the cytosol of HeLa cells and remain non-fluorescent. Secondly, GFP1-
10 and M3 are able to complement to form full length GFP in the cytosolic 
environment of HeLa cells. Thirdly, the chemically synthesised DDS conjugated M3 
peptide (R8-M3) as well as the M3 peptide alone can complement with GFP1-10 of 
cellular origin in an in vitro system where direct access of the two fragments is 
guaranteed, and complementation is not dependent on delivery of M3 across a 
biological membrane.   
The primary focus of this chapter lies on the development of appropriate methods 
to prove that non-fluorescent GFP1-10 can be expressed in target cells and is able to 
complement with M3 in the cytosolic environment as well as in vitro with synthetic M3 
peptide. Moreover, one of the main benefits of this assay will be to monitor peptide 
delivery in live cells in real time using fluorescent widefield microscopy. Hence, it is 
important to develop this assay and its methods to prove GFP complementation using 
a fluorescent widefield microscope to ensure that its sensitivity is adequate for it to be 
utilised as a detection platform to observe GFP complementation.  
A second aim of this chapter is to demonstrate that the proposed split GFP assay 
can be utilised to show functional M3 peptide delivery by the drug delivery system R8 
in live cells and that this delivery is indeed drug delivery system dependent.  
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3.2 Assay development 
3.2.1 Cytosolic expression of the intracellular GFP1-10 target  
The first aim in the development of an assay to determine the functional delivery 
of the M3 peptide to its cytosolic GFP1-10 target was to ensure that GFP1-10 can be 
expressed in the cytosol of HeLa cells (Henrietta Lacks). HeLa cells were chosen for 
the development of this assay because it is a well characterised cervical carcinoma 
cell line in which gene expression can be easily manipulated. To be able to transfect 
HeLa cells with the DNA coding for GFP1-10, the expression plasmid pGFP1-10-N1 
was generated (2.11.2). To further prove that GFP1-10 can be expressed in the 
cytosol, HeLa cells were transiently transfected with pGFP1-10-N1. GFP1-10 
expression cannot be detected using microscopy of live cells due to the lack of its 
green fluorescence, therefore, immunofluorescence was the proposed method to 
detect its expression. In order to perform immunofluorescent staining, HeLa cells 
were PFA fixed 16h after transfection and the plasma membrane was permeabilised. 
GFP-10 expression was detected using a primary anti-GFP antibody and stained with 
a fluorophore conjugated secondary antibody. Immunofluorescent staining against 
GFP was analysed using a widefield fluorescent microscope.  
Antibodies are highly specific to detect epitopes of proteins. Due to the lack of 
the 11th beta sheet in GFP1-10, the epitope of GFP1-10 was changed compared to 
full length GFP. For this reason two different anti GFP antibodies were tested to detect 
GFP1-10 (Table 2-6). It was shown that both antibodies can detect full length GFP 
but only one antibody (Vector Laboratories) that was manufactured to detect GFP 
and GFP variants did detect GFP1-10 expression (Appendix 9.3, Figure 9-2). Hence, 
further experiments were performed using the anti-GFP antibody that was able to 
detect GFP1-10 expression.  
When cytosolic GFP1-10 compared to EGFP expression was investigated using 
immunofluorescence it can be shown that control cells expressing full length GFP 
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showed green fluorescence in their cytosol (Figure 3-1 C). The fluorescent signal of 
the antibody co-localised with the GFP fluorescence indicating that the antibody 
specifically detects GFP (Figure 3-1 D). When the truncated version, GFP1-10, was 
expressed in HeLa cells, the green fluorescence of the protein was absent (Figure 
3-1 G) but the anti GFP antibody still detected its expression in the cytosol (Figure 
3-1 H). To exclude the possibility that the antibody detected non-specific cytosolic 
proteins, immunofluorescent staining was also performed on mock transfected cells. 
These cells were not green fluorescent (Figure 3-1 K) and the anti GFP antibody did 
not detect any proteins in the cytosol (Figure 3-1 L). 
 
 
 
Figure 3-1 Detection of GFP1-10 expression in HeLa cells using immunofluorescence.  
HeLa cells were transiently transfected with DNA constructs coding for GFP1-10 or full length 
EGFP. The transfection mix of mock transfected cells did not contain DNA. Cells were 
incubated in transfection mix overnight and PFA fixed the next day. The plasma membrane 
was permeabilised with 0.1 % Triton-X-100 and GFP or GFP1-10 expression was detected 
using a primary anti-GFP antibody raised in goat. A secondary anti-goat antibody conjugated 
to Alexa-647 was used to visualise GFP expression (Anti GFP). Nuclei were counterstained 
with DAPI. Representative images are shown for each condition. Scale bars: 30 µm. n=3.  
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 To further ensure that the detected fluorescence of the antibody was specifically 
due to the primary anti GFP antibody and not an artefact of a cross reaction of the 
Alexa-647 labelled secondary antibody, a second experiment was conducted. As 
control cells, cells transiently expressing EGFP were treated with the primary anti-
GFP antibody and the secondary Alexa-647 labelled antibody. As shown in the first 
experiment, cytosolic green fluorescence co-localised with the protein detected by the 
antibody (Figure 3-2 C, D). When the primary antibody was omitted and only the 
Alexa-647 conjugated secondary antibody was applied on cells expressing EGF, no 
antibody fluorescence could be detected (Figure 3-2 H). There was also no antibody 
fluorescence detected on cells expressing GFP1-10 or on Mock transfected cells 
(Figure 3-2 L, P).  These findings demonstrate that the staining of the antibody was 
specific to GFP. Furthermore, this experiment proves that the chosen primary anti 
GFP antibody (vectorlaboratories) not only detects expression of full length EGFP but 
can also be utilised to detect superfolder GFP derived GFP1-10.  
Taken together, these results show that HeLa cells can transiently express the 
GFP1-10 target protein and, importantly, GFP1-10 is non-fluorescent when excited 
with 488nm wavelength light (Figure 3-1 G). Moreover, its intracellular distribution 
was located in the cytosol (Figure 3-1 H).  
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Figure 3-2 Secondary antibody control for anti GFP detection in HeLa cells.  
HeLa cells were transiently transfected with DNA constructs coding for GFP1-10 or full length 
EGFP. The transfection mix of mock transfected cells did not contain DNA. Cells were 
incubated in transfection mix overnight. They were fixed the next day and the plasma 
membrane was permeabilised with 0.1 % Triton-X-100. Control cells expressing EGFP were 
incubated with the primary anti-GFP (goat) antibody followed by incubation with the secondary 
anti-goat-Alexa-647 antibody (1’+2’ Antibody). Other samples were incubated with the 
secondary anti-goat-Alexa-647 antibody only (2’ Antibody). Nuclei were counterstained with 
DAPI. Representative images shown for each condition. Scale bars 30 µm. n=3.  
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As a second method to confirm the expression of GFP1-10 in Hela cells, western 
blot analysis of cell lysates of cells transiently expressing EGFP and GFP1-10 was 
performed. To achieve this, cell lysates containing the cytosolic protein content of 
transfected cells were separated by their molecular weight using SDS gel 
electrophoresis and transferred onto a membrane. This membrane was probed with 
the same primary anti-GFP antibody that was previously used for 
immunofluorescence and detected with a secondary antibody conjugated to 
horseradish peroxidase.  
Analysis of the blot showed that one clear band was detected in each of the cell 
lysates. The molecular weight of the protein detected in the lysate of cells expressing 
EGFP was ~30 kDa (Figure 3-3). The expected molecular weight of EGFP is 27 kDa 
which is in the region of the weight detected on the western blot. The protein detected 
in the cells expressing GFP1-10 had a molecular weight of ~25kDa (Figure 3-3). As 
expected, the truncated protein carried a lower molecular weight compared to full 
length GFP and these results were a second indication that GFP1-10 can be 
expressed by HeLa cells.   
 
 
 
 
 
  
Figure 3-3 Western blot analysis of EGFP and GFP1-10 
expression.  
Cell lysates were obtained from cells transiently expressing 
EGFP (left) or GFP1-10 (right). Lysates were analysed using 
SDS gel electrophoresis and blotted onto a membrane. The 
membrane was probed against GFP using an anti-GFP (goat) 
antibody followed by a secondary anti-goat-HRP antibody. 
Sizes of proteins are shown in kDa. n=1.  
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3.2.2 Complementation of GFP1-10 with M3 in the cytosol – the ‘co-
transfection experiment’. 
Once it was ensured that the intracellular GFP1-10 target protein can be 
expressed in the cytosol of HeLa cells it was important to test that GFP1-10 can 
complement with M3 to form full length GFP in the cytosolic environment. A possibility 
to investigate this, was to co-transfect HeLa cells with the DNA constructs encoding 
for the single split GFP fragments, GFP1-10 and M3, so that the cell expresses both 
fragments in its cytosol and GFP complementation can occur. GFP complementation 
can then be observed using a widefield fluorescent microscope. To perform this 
experiment, mammalian DNA expression constructs for GFP1-10 and M3 had to be 
in place. As previously confirmed using immunofluorescence, the generated DNA 
construct for GFP1-10 expression can be used to express GFP1-10 in the cytosol of 
HeLa (3.2.1).  
To achieve the expression of the M3 fragment in Hela cells, a plasmid encoding 
for M3 needed to be generated. An existing plasmid for bacterial expression was 
utilised as a starting point for the generation of a mammalian expression plasmid and 
coded for the protein H6-Xa-R8-M3. This expression plasmid, pET3A-H6-Xa-R8-M3 
was generated within this project (2.11.3) to obtain the peptide R8-M3 as a result of 
bacterial expression. Hence, additionally to R8-M3, it contained the N-terminal H6, a 
Histidine tag and a Factor Xa protease cleavage site for purification steps. Due to 
time constraints, the plasmid pET3A-H6-Xa-R8-M3 was never utilised for bacterial 
expression to obtain R8-M3 and this peptide was chemically synthesised (2.2). 
Another reason why the plasmid pET3A-H6-Xa-R8-M3 was never utilised for bacterial 
expression to obtain R8-M3 was that the presence of bacterial factors present in the 
protein even after purification could affect cells in a live cell assay.  
 Nevertheless, pET3A-H6-Xa-R8-M3 served as a precursor to sub-clone an 
expression construct for mammalian expression coding for M3.  
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Ideally, this expression construct would have coded for M3 expression only. But 
due to the absence of restriction digest sites, the entire DNA encoding H6-Xa-R8-M3 
was sub-cloned from the bacterial expression vector pETA3a into the mammalian 
expression vector EGFP-N2 to obtain pH6-Xa-R8-M3-N2 (2.11.4). The successful 
generation of this expression construct was confirmed by sequencing but the cytosolic 
expression of H6-Xa-R8-M3 was not tested because of the lack of fluorescence of 
M3 and antibodies to detect the epitopes in the construct. Antibodies against a 
Histidine tag are available but results would have been difficult to interpret because 
no positive control was available (e.g. expression construct for mammalian protein 
expression fused to a Histidine tag). Hence, co-expression experiments were 
conducted with the confirmation of the sequencing results only, that a mammalian 
expression vector encoding for H6-Xa-R8-M3 had been generated.  
When H6-Xa-R8-M3 was co-expressed with GFP1-10, no GFP fluorescence 
could be detected indicating that no complementation of GFP had occurred (Figure 
3-4 C). Lack of GFP complementation could have been due to the failure of the GFP1-
10 and M3 fragment to complement to full length GFP. Another reason could have 
been failure of expression of one of the fragments and the resulting absence of one 
of the complementation partners. It was shown that GFP1-10 can be expressed in 
the cytosol of Hela cells, so that was highly likely that H6-Xa-R8-M3 was faulty. Thus, 
H6-Xa-R8-M3 expression was further investigated. 
 
An idea to be able to visualise H6-Xa-R8-M3 expression was to express it as a 
fusion protein to the fluorescent protein mCherry which can serve as a fluorescent 
expression partner. For this reason the plasmid pcDNA3.1.mCherry-H6-Xa-R8-M3 
was generated coding for the protein mCherry-H6-Xa-R8-M3 (0).  
When Hela cells were transfected with this construct, it enabled us to monitor if 
and where M3 is expressed inside the cell because it contained the fluorescent 
expression marker mCherry. The red fluorescence of mCherry-H6-Xa-R8-M3 
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fluorescence was accumulated in the nucleus, located at the nucleolus (Figure 3-5 
C). An explanation for the nucleolar staining could be that the highly positively 
charged cell penetrating peptide R8 targeted the whole protein to this location. R8 is 
known to localise to the nucleolus and can be used as a nucleolar marker in live cells 
(Martin et al. 2007). Hence, the presence of red fluorescence at the nucleolus was an 
indication that not only mCherry was expressed in the cytosol of HeLa cells but also 
the mCherry fusion protein coding for H6-Xa-R8-M3.  
It was further investigated if mCherry-H6-Xa-R8-M3 was exclusively located at 
the nucleolus. When the fluorescence of mCherry-H6-Xa-R8-M3 expression was 
oversaturated using ImageJ, it was visible that it was mainly located in the nucleus 
but was also located in the cytosol (Figure 3-5 F).  
 
 
 
 
Figure 3-4 Co-expression of GFP1-10 and H6-Xa-R8-M3.  
Cells were co-transfected with DNA encoding GFP1-10 and H6-Xa-R8-M3. Cells were left in 
transfection mix overnight and PFA fixed on the next day. Nuclei were counterstained with 
DAPI. Representative images show that no GFP fluorescence was detected (C). Scale bars: 
10 µm. n=1.  
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Figure 3-5 Expression pattern of mCherry-H6-Xa-R8-M3 in HeLa cells. 
HeLa cells were transfected with DNA encoding for mCherry-H6-Xa-R8-M3. Cells were left in 
transfection mix overnight and PFA fixed the next day. Nuclei were counterstained with DAPI. 
Localisation of mCherry-H6-Xa-M3 is found at the nucleolus (normal saturation). Cytosolic 
localisation can be seen when the same image is shown oversaturated. Representative 
images are shown. Scale bars: 10 µm. n=3.  
 
 
Having confirmed that GFP1-10 and mCherry-H6-Xa-R8-M3 can both be 
expressed in the cytosol, the co-expression experiment was repeated to investigate 
if GFP1-10 and mCherry-H6-Xa-R8-M3 can complement to form full length GFP. 
Cells were transfected with DNA constructs coding for GFP1-10 and mCherry-H6-Xa-
R8-M3 and incubated for 16 h with the transfection mix. According with previous 
results, GFP1-10 and mCherry-H6-Xa-R8-M3 did not fluoresce in green when single 
proteins were expressed (Figure 3-6 C, G).  When GFP1-10 and mCherry-H6-Xa-R8-
M3 were co-expressed in HeLa cells, cells did fluoresce in green indicating that GFP 
complementation had occurred (Figure 3-6 K). The green fluorescence was observed 
as concentrated spots at the nucleolus as well as in the nucleus and low amounts in 
the cytosol. This distribution correlated with the location where mCherry-H6-Xa-R8-
M3 was expressed (Figure 3-6 L) indicating that GFP complementation had only 
occurred where the M3 fragment was localised inside the cell.  
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The key role of M3 is to act as a proton acceptor in order for the GFP fluorophore 
to mature. To ensure that the GFP complementation with mCherry-H6-Xa-R8-M3 is 
specific to M3 and to rule out that the fluorophore mCherry is capable of acting as a 
proton acceptor and therefore replace the function of M3, cells were also co-
transfected with GFP1-10 and mCherry.  When mCherry was expressed alone, its 
fluorescence was distributed throughout the cells (Figure 3-6 P). Co-expression of 
GFP1-10 with mCherry did not result in GFP complementation because no green 
fluorescence was detected in those cells (Figure 3-6 S). This indicates that GFP 
complementation cannot occur through interaction of GFP1-10 with the fluorescent 
protein mCherry. Thus, GFP complementation is specific to the H6-Xa-R8-M3 
fragment and therefore complementation of GFP1-10 with M3 can be assumed.   
This experiment also indicated that detected GFP fluorescence is due to true 
GFP fluorescence and not an artefact of bleed through from the mCherry into the GFP 
channel on the microscope. When mCherry-H6-Xa-R8-M3 was expressed alone its 
red fluorescence was detected in the mCherry channel (Figure 3-6 H) but there was 
no bleed through into the GFP channel as there was no green fluorescence detected 
(Figure 3-6 G). When mCherry-H6-Xa-R8-M3 was co-expressed with GFP1-10, 
mCherry fluorescence, detected with the same microscope settings, was less than 
the fluorescence of mCherry-M3 alone (Figure 3-6 L, H) but green fluorescence was 
detected in the GFP channel (Figure 3-6 K). This confirmed that the green 
fluorescence was a true signal detected in the GFP channel and not an artefact of 
fluorescence that was collected from exciting mCherry.  
 
GFP complementation using co-transfection was further verified using a 
microplate reader to obtain quantitative information of complemented GFP 
fluorescence. HeLa cells were left to transfect with transfection mix for 16 h and the 
next day cells were trypsinised and green fluorescence of 1x105 cells was measured 
with a microplate reader. Green fluorescence of mock transfected cells where the 
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transfection mix did not contain DNA were used for background subtraction. No green 
fluorescence was measured when cells were transfected with GFP1-10 or mCherry-
H6-Xa-R8-M3 (Figure 3-7 A). Co-expression of GFP1-10 and mCherry-H6-Xa-R8-M3 
resulted in GFP complementation which resulted in detection of significant GFP 
fluorescence compared to when single fragments were expressed. There was no 
fluorescence from GFP complementation observed when GFP1-10 was co-
expressed with mCherry or when mCherry only was expressed. The fluorescence of 
complemented GFP1-10 and M3 was also compared to the green fluorescence when 
full length EGFP is expressed in HeLa cells. Interestingly, the brightness of 
complemented GFP was six fold lower than the green fluorescence that was 
measured when full length EGFP was expressed in HeLa cells (Figure 3-7 B).   
 
In all, the results obtained with the microplate reader (Figure 3-7) correlate with 
the co-expression results obtained by microscopy (Figure 3-6). These experiments 
demonstrate that GFP1-10 and mCherry-H6-Xa-R8-M3 can complement in the 
cellular environment of HeLa cells to form full length GFP that fluoresces upon 
illumination with 490nm wavelength light and this complementation is specific to the 
two fragments GFP1-10 and H6-Xa-R8-M3 where a complementation of GFP1-10 
and M3 can be assumed.   
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Figure 3-6 Co-transfection of GFP1-10 and mCherry-H6-Xa-R8-M3.  
Transfections or co-transfections of HeLa cells were performed with DNA encoding for GFP1-
10, mCherry-H6-Xa-R8-M3 and mCherry. The transfection mix of mock transfected cells did 
not contain DNA. Cells were left in transfection mix overnight and PFA fixed on the next day. 
Nuclei were counterstained with DAPI. Representative images are shown for each condition. 
Scale bars: 10 µm. n=3.  
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Figure 3-7 Detection of GFP complementation after co-tranfection using a microplate 
reader. 
Single transfections or co-transfections of HeLa cells were performed with DNA encoding for 
GFP1-10, mCherry-H6-Xa-R8-M3 and mCherry. The transfection mix of mock transfected 
cells did not contain DNA. Cells were left in transfection mix overnight. The next day, cells 
were detached from their dish using trypsin, washed and transferred into a clear bottom, black 
walled microwell plate. Green fluorescence was monitored using a microplate reader (A) 
Comparison of green fluorescence of single DNA fragments and co-transfection of GFP1-10 
and M3. For statistical analysis data was tested using a Kruskal-Wallis test. Significance of 
GFP1-10 + mCherry-H6-Xa-R8-M3 is shown compared to all other conditions. *: p<0.05, **: 
p<0.01, ***: p<0.001, n.s.: not significant. (B) Comparison of the green fluorescence of full 
length EGFP and complemented GFP. RFU=Relative Fluorescent Units. Error bars present 
Standard error of the mean. n=3.  
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3.2.3 The extracellular DDS-M3 peptide cargo  
In the split GFP assay to determine functional delivery of a peptide, GFP1-10 is 
expressed in the cytosol of cells and mimics the intracellular target and the M3 peptide 
acts as an extracellular cargo that requires delivery across the plasma membrane to 
complement with cytosolic GFP1-10 to form full length GFP. In preliminary 
experiments, it was shown that GFP1-10 can be expressed in the cytosol of target 
cells (3.2.1) and the cytosolic environment allows GFP complementation of GFP1-10 
and M3 (3.2.2).  
The next important step for the assay development was to acquire M3 cargo 
peptide that was conjugated to a drug delivery system that can facilitate its delivery 
across the plasma membrane. The aim of the assay to determine functional delivery 
of the M3 peptide, is to be able to evaluate the ability of its drug delivery system to 
deliver the peptide across the plasma membrane and thereby characterise novel 
DDSs. For the development stage of this assay, a model DDS candidate was chosen 
that was already well characterised and had previously been used for multiple uptake 
experiments by our lab, the cell penetrating peptide Octaarginine (R8) (Jones and 
Sayers 2012; Sayers et al. 2014).  This peptide was chemically synthesised by EZ 
Biolabs, USA.  
When peptides are synthesised, an important key factor to consider is the 
chirality of the amino acids used for synthesis as mentioned before (1.3.3.2). Hence, 
to achieve best uptake characteristics, all peptides in this study were synthesised 
using all L-amino acids which are displayed in Table 3-1.  
For the generation of a drug delivery system conjugated M3 peptide, R8 was 
conjugated to M3 using a flexible Serine-Glycine-linker (GSGGGSTS). This amino 
acid linker was used to provide a spacer between the high positive charge of R8 and 
M3. It was previously shown by Pineaud and his colleagues that GFP 
complementation can take place in presence of this N-terminal linker to M3 (Pinaud 
and Dahan 2011).  
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In addition to R8-M3, experimental control peptides were purchased. These 
included the DDS R8 alone without the M3 cargo peptide (R8) to serve as a control 
that GFP complementation is specific to the M3 peptide and R8 itself cannot 
complement GFP1-10; M3 alone without the cell penetrating peptide R8 (M3) to 
confirm that M3 itself cannot cross the plasma membrane; and a Linker-M3 peptide 
consisting of the flexible GSGGGSTS linker and the M3 peptide (L-M3) to exclude 
the possibility that the GSGGGSTS linker itself has a cell penetrating ability.  
 
When peptides are chemically synthesised they carry charged amino and 
carboxy termini. Hence, this charge can be removed using an acetylation or amidation 
of the N- or C-terminus, respectively. These modifications were also added to the 
purchased peptides. The C-terminus of R8 was amidated to remove its C-terminal 
charge to act as an appropriate control peptide for R8-M3 where the C-terminus of 
R8 lies within an amino acid sequence and therefore does not carry a charge. The 
M3 peptide is a fragment of full length GFP and the N-terminus of the amino acid in 
full length GFP that corresponds to the first amino acid in the M3 peptide is not 
charged. Hence, the N-terminus of the M3 peptide was modified with an acetylation 
to remove its charge. For the L-M3 peptide an N-terminal acetylation was added to 
remove the charge of the linker that is not charged within the R8-M3 peptide.
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Table 3-1 M3 Peptides and DDS-M3 peptides. 
 
Table displays sequences, modification and characteristics of M3 and CPP-M3 peptides and used in this study. All peptides use L-amino acids, blue letters 
denote the sequence of the cell penetrating peptide R8 (octaarginine) and M3 sequence is coloured in green. R8 is conjugated to M3 via a linker (grey).  
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3.2.4 In vitro testing of complementation of GFP1-10 with synthetic M3 
peptides – the ‘fix and stain experiment’. 
Before a live cell assay could be performed using the synthetic M3 peptides to 
test a DDS dependent delivery of M3 to GFP1-10, it was important to determine if the 
chemically synthesised M3 peptides are able to complement with cytosolic GFP1-10 
to form full length GFP in vitro. For this reason an ‘in vitro’ system was created where 
the plasma membrane barrier of cells expressing GFP1-10 was removed to allow 
direct access of the synthesised peptides to reassemble to full length GFP. Using this 
‘in vitro’ system, GFP complementation was not dependent on the delivery of M3 by 
a drug delivery system.  
In order to investigate GFP complementation of synthetic M3 peptides with 
cytosolic GFP1-10 an in vitro system was established where HeLa transiently 
expressing GFP1-10 were PFA fixed and the plasma membrane was permeabilised 
using 0.1% Triton-X-100. All M3 peptides shown in Table 3-1 were incubated at 20 
µM in PBS with the permeabilised cells for 1 hour at room temperature to allow GFP 
complementation. As a negative control in this experiment DMSO was chosen 
because it served as the diluent for the synthetic peptides. Cells were washed once 
after incubation and analysed with a widefield fluorescent microscope.  
Negative control cells incubated with DMSO did not show any green 
fluorescence in their cytosol (Figure 3-8 C). Cells incubated with R8 alone was also 
not able complement with GFP1-10 and rescue GFP fluorescence (Figure 3-8 F). 
Incubation with M3 or L-M3 did not result in GFP complementation showing no 
difference to the DMSO and R8 control sample (Figure 3-8 I, L). GFP 
complementation only occurred and was clearly detectable when cells were 
incubated with the R8-M3 peptide (Figure 3-8 O). These results indicated that 
complementation of synthetic R8-M3 peptide with cytosolic GFP1-10 results in 
functional GFP complementation. However, the complementation must have been 
specifically to the M3 peptide as incubation with R8 alone did not lead to GFP 
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complementation. For this reason, it was surprising the M3 and L-M3 did not 
complement with GFP1-10. One reason for this could have been that the plasma 
membrane was not sufficiently permeabilised and denied access to the non DDS 
conjugated M3 peptides. For this in vitro assay the same fixation and permeabilisation 
protocol as for the immunofluorescent staining was used where the plasma 
membrane had been permeabilised to allow access of the antibody to the cytosolic 
target. The molecular weight of an antibody is ~150 kDa which is considerably higher 
compared to M3 and L-M3 (1.8 kDa and 2.4 kDa respectively).  
Hence, sufficient permeabilisation can be assumed and it was next investigated 
if M3 peptides would complement with GFP1-10 when the incubation time was 
increased. To explore this, cells transiently expressing GFP1-10 were PFA fixed, 
0.1% Triton-X-100 permeabilised and peptides were incubated on cells for 36 hours 
at 20 µM M3 peptides in PBS. GFP complementation was observed with a 
microscope in the presence of peptides (Figure 3-9). After 36 hours of incubation 
there was clear GFP complementation observable for all the peptides containing M3. 
Cells incubated with M3 itself, L-M3 and R8-M3 did fluoresce in green (Figure 3-9 C, 
D, E) and there was no green fluorescence detectable in cells treated with DMSO or 
R8 (Figure 3-9 A, B).  Due to the transient transfection of GFP1-10 not every cell 
expressed the GFP1-10 target protein; hence not every cell was positive for GFP 
complementation. This experiment indicated that all synthetic peptides containing M3 
were able to complement with GFP1-10 in an in vitro situation where the plasma 
membrane barrier is removed and confirmed that R8 alone cannot complement with 
GFP.  
The finding that M3 and L-M3 will complement with GFP1-10 but not as efficient 
as R8-M3 raised the question if this is an effect of the applied method rather than 
inability of the peptide to complement with GFP1-10. PFA fixation and Triton-X-100 
permeabilisation can cause extraction of cytosolic proteins (Schnell et al. 2012). It 
was shown that the fluorescence of cytosolic EGFP is concentrated in the nucleus 
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after PFA fixation and Triton-X-100 permeabilisation which is an effect of the 
decrease of cytosolic EGFP fluorescence compared to the nucleus rather than 
relocation. When using this fixation and permeabilisation method to investigate 
complementation of GFP1-10 with a synthetic M3 peptide, the same effect was seen 
(Figure 3-9). The green fluorescence was mainly localised at the nucleus and less in 
the cytosol. Proteins can be better preserved during fixation and permeabilisation 
when they are located to organelles or associated with membranes (Stadler et al. 
2010).  
The assumption that GFP1-10 does not remain in the cytosol in high amounts in 
order to generate a sufficient GFP 1-10 with M3 and L-M3 leads to the question as to 
why R8-M3 did still complement with GFP1-10. R8 is highly positively charged and 
could interact with fixed and permeabilised cells through its charge. This interaction 
could favour a higher affinity for R8-M3 to the cells and gain access to the low levels 
of fixed GFP1-10.  
Due to the fact that M3 and L-M3 are not charged and these pure peptides had 
to be tested in an in vitro assay without alteration, the idea was further investigated, 
to achieve higher internal GFP1-10 levels after fixation by fusing GFP1-10 to an 
intracellular organelle. 
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Figure 3-8 Complementation of GFP1-10 and M3 peptides ‘in vitro’ after 1 hour.  
Hela cells transiently expressing GFP1-10 were PFA fixed and the plasma membrane was 
permeabilised using 0.1% Triton-X-100. Peptides were incubated at 20 µM in PBS for 1 hour 
at room temperature to allow complementation of GFP1-10 with M3 to form full length GFP. 
Cells were washed once in PBS and nuclei were counterstained with DAPI. Representative 
images are shown for each condition. Scale bars: 30 µm. n=3.  
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Figure 3-9 Complementation of GFP1-10 and M3 peptides ‘in vitro’ after 36 hours. 
Hela cells transiently expressing GFP1-10 were PFA fixed and the plasma membrane was 
permeabilised using 0.1% Triton-X-100. Peptides were incubated at 20 µM in PBS for 36 hours 
at room temperature to allow complementation of GFP1-10 with M3 to form full length GFP. 
Peptides were left on the cells and GFP complementation was investigated using a widefield 
fluorescent microscope. Representative images are shown for each condition. Scale bars: 30 
µm. n=2.  
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To test if the weak GFP complementation with M3 and L-M3 can be enhanced 
by using an organelle fused GFP1-10 that allows better preservation during the 
fixation and permeabilisation process, an expression construct was generated to 
express GFP1-10 as a C-terminal fusion of the Golgi stacking protein GRASP65 to 
obtain pGRASP65-EGFP-N2 (2.11.1). GRASP65 is a peripheral Golgi membrane 
protein on the cytoplasmic surface of the Golgi Apparatus which is retained at the 
plasma membrane through myristic acid at its N-terminus (Zhang and Wang 2015). 
The N-terminal domain is also the interaction surface to build a transoligomer with 
another GRASP65 molecule to form a Golgi stack (Wang et al. 2005). Hence, fusion 
of GFP1-10 to the C-terminus of GRASP65 ensured that GFP1-10 was localised to 
an organelle but was still accessible in the cytosol to complement with the M3 
peptides. 
To observe the expression pattern of GRASP65 it was first expressed as a fusion 
protein to EGFP. Cells were PFA fixed and triton-X100 permeabilised to investigate 
the remaining protein within the cell. In Figure 3-10 the phenotype of GRASP65-
EGFP can be seen. It varies from being solely localised to the Golgi apparatus to 
being overexpressed in the cytosol, but more importantly, the protein did remain 
present in the cell after fixation and permeabilisation. It was further tested if 
GRASP65-GFP1-10 could be expressed, and detected in the cell using 
immunofluorescence. When GRASP65-GFP1-10 was expressed in HeLa cells, it did 
not fluoresce in green but the antibody labelling showed expression of the protein at 
the Golgi apparatus as well as overexpressed in the cytosol (Appendix Figure 9-3). 
Complementation of GRASP65-GFP1-10 with mCherry-H6-Xa-R8-M3 was tested 
when both proteins were co-expressed in HeLa cells. Single fragments did not show 
green fluorescence, co-expression resulted in GFP complementation and detection 
of green fluorescence on the plate reader (Appendix Figure 9-4).  
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Having confirmed that GRASP65-GFP1-10 can be expressed in HeLa cells, it is 
localised to the Golgi apparatus and it can complement mCherry-H6-Xa-R8-M3 to 
form full length GFP, GRASP65-GFP1-10 was tested for complementation with 
synthetic peptides. For the GFP complementation experiment with synthetic M3 
peptides, cells transiently expressing GRASP65-GFP1-10 were PFA fixed and 
permeabilised using 0.1% Triton-X-100. Different peptides were incubated on cells at 
20 µM in PBS for 1 hour at room temperature to allow GFP complementation. Cells 
were washed in PBS, nuclei were stained with DAPI and the coverslips were mounted 
onto a glass slide to be analysed with a widefield fluorescent microscope. When R8 
itself was incubated with GRASP65-GFP1-10 expressing cells, no green 
fluorescence was observed (Figure 3-11 F) which correlated with cells incubated with 
DMSO (Figure 3-11 C). When L-M3 and M3 were incubated with the cells, weak GFP 
fluorescence was detected indicating that M3 had complemented with GRASP65-
GFP1-10 (Figure 3-11 I, L). When R8-M3 was incubated with the cells, bright green 
fluorescence was observed (Figure 3-11 O). The fluorescence of cells incubated with 
R8-M3 was much brighter compared to cells incubated with M3 or L-M3 peptides. 
Nevertheless, M3 and L-M3 did complement with GRASP65-GFP1-10 within 1 hour 
which can clearly be observed when the brightness levels of these samples are 
adjusted independently from the R8-M3 control (Figure 3-11 R, U). When the 
localisation of GFP fluorescence is examined, it correlates with the localisation when 
GRASP65-EGFP is expressed in the cell. Fluorescence is predominantly detected in 
overexpressing cells where GFP fluorescence is distributed throughout the cytosol 
but with a concentration of fluorescent signal in the perinuclear region where the Golgi 
apparatus is localised. 
 
Summing up the ‘in vitro’ complementation experiments of synthetic peptides 
with expressed GFP1-10 or GRASP65-GFP1-10, it was seen that R8-M3 can 
complement with cytosolic or Golgi localised GFP1-10 within one hour. M3 and L-M3 
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did complement with cytosolic GFP1-10 after a longer incubation time of 36 hours 
and as fast as 1 hour with GRASP65-GFP1-10. The GFP fluorescence detected in 
the experiments were generally weaker for M3 and L-M3 then when cells were 
incubated with R8-M3.  
Taken together, the experiments clearly show that GFP complementation with 
GFP1-10 or GRASP65-GFP1-10 occurs when peptides carry the M3 fragment. The 
complementation is specific to the M3 fragment, as neither the DMSO diluent nor R8 
by itself are able to replace the function of the proton acceptor which is located on the 
M3 peptide.  
The efficiency of M3 and L-M3 to complement with GFP1-10 seems to be 
dependent on where the intracellular GFP1-10 target is localised during the fixation 
and permeabilisation process, low success of complementation could therefore be 
due to the experimental design. It also has to be considered that the in vitro system 
is an artificial system and GFP complementation dynamics could vary significantly in 
live cells from this ‘in vitro’ system. Nonetheless, these experiments gave enough 
confidence that the synthetic M3 containing peptides will complement with expressed 
GFP1-10 which led to the next step to investigate M3 delivery in live cells. 
 
 
Figure 3-10 Phenotype of GRASP65-EGFP. 
HeLa cells were transiently transfected with GRASP65-EGFP. The next day the cells were 
PFA fixed and 0.1% Triton-X100 permeabilised. Scale bar: 30 µm. n=1. 
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Figure 3-11  Complementation of GRASP-65-GFP1-10 and M3 peptides ‘in vitro’. 
Hela cells transiently expressing GRASP65-GFP1-10 were PFA fixed and the plasma 
membrane was permeabilised using 0.1% Triton-X-100. Peptides were incubated at 20 µM in 
PBS for 1 hour at room temperature to allow complementation of GRASP65-GFP1-10 with M3 
peptides to form full length GFP. Cells were washed once in PBS and nuclei were 
counterstained with DAPI. Images A-O were processed using exactly the same GFP 
saturation. Images P-U display images shown in G-L but the brightness of the GFP channel 
is increased. Scale bars: 30 µm. n>3. The data displayed is taken from an experiment that 
was performed by Alexander Dudziak under my supervision.  
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3.3 Investigation of real time functional delivery of M3 by the DDS R8 
using the split GFP system. 
Previous experiments have ensured that the intracellular target GFP1-10 can be 
expressed in the cytosol of Hela cells (3.2.10) and that GFP1-10 complements with 
M3 when co-expressed in HeLa cells (3.2.2) as well as with synthetic M3 peptides in 
an in vitro assay (3.2.4). These are important results that lead up to the successful 
development of a live cell assay to investigate if M3 can be functionally delivered 
across the plasma membrane using the DDS R8.   
 
3.3.1 Delivery of M3 by the DDS R8 
To test if functional delivery of the M3 peptide by R8 can be detected using a 
widefield fluorescent microscope in live cells, HeLa cells were transiently transfected 
in MatTek glass bottom dishes  with pGFP1-10-N1 to express cytosolic GFP1-10. On 
the day of the experiment the transfected cells were washed once in serum free 
medium and peptides were incubated with cells at 20 µM in serum free medium. 
Serum free medium was chosen as a diluent to avoid peptide degradation by 
proteases that are contained in FBS. In previous experiments within our lab, uptake 
of labelled R8 containing peptides was monitored after 1 hour and found in endocytic 
compartments when incubated at 2 µm or 5 µm (Sayers et al. 2014). For the live 
experiments an incubation time of 2 h was used to allow R8-M3 to be taken up by the 
cell, reach the cytosol and for GFP complementation to take place. After 2 hours cells 
were washed in phenol red free RPMI, nuclei were counterstained with Hoechst and 
cells were imaged in phenol red free RPMI on a widefield fluorescent microscope at 
37°C and 5% CO2.  
Control cells that were incubated with DMSO in serum free media only showed 
background levels of green fluorescence in the GFP channel (Figure 3-12 C). When 
cells were incubated with the L-M3 peptide the same background levels as in the 
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DMSO control were detected indicating that GFP complementation had not occurred 
(Figure 3-12 F). Incubation with R8-M3 resulted in the occurrence of green fluorescent 
cells (Figure 3-12 I), indicating that M3 had been functionally delivered to its 
intracellular GFP1-10 to form full length GFP. Here, the L-M3 peptide was tested as 
due to the presence of the N-terminal linker it represents a better control to R8-M3, 
where R8 is connected to M3 via the same linker.  
 
To further verify this outcome, green fluorescent intensities of the cytosol of 
single cells where quantified from microscopy images that were randomly taken 
during the experiment (Figure 3-13 A). The corrected total cell fluorescence (CTCF) 
of the green fluorescence was calculated for 25-30 cells per condition. DMSO control 
cells show a distribution of a cytosolic CTCF between 0-8 (Figure 3-13 A) with a mean 
value of 2.5 between experiments (Figure 3-13 B). When cells were incubated with 
L-M3, fluorescent CTCF of single cells ranged from 0-6 (Figure 3-13 A) with an overall 
average CTCF of 2.5 between experiments (Figure 3-13 B). This data correlates with 
the images displayed in Figure 3-12, that cells incubated with DMSO or L-M3 have 
the same level of green background fluorescence in their cytosol indicating that L-M3 
did not functionally reach the cytosol to complement with GFP1-10. Analysis of green 
fluorescent intensity of cells that were incubated with 20 µM R8-M3 revealed that 
there was a large distribution of CTCF ranging from zero to the highest value of 17 
(Figure 3-13 A). The average fluorescent intensity was 3.9 (Figure 3-13 B). This is a 
1.5 increase in mean fluorescence compared to the DMSO negative control. 
These important results prove the principle of this assay: L-M3 cannot pass the 
plasma membrane by itself and the flexible linker connecting it to its drug delivery 
system has no ability to facilitate delivery of the peptide. When the M3 peptide is 
attached to the DDS R8, the cell penetrating peptide facilitates delivery of M3 to the 
cytosol where it complements with GFP1-10 resulting in green fluorescence. Hence, 
functional M3 delivery to its intracellular target is dependent on R8 and this data set 
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supports the hypothesis that the split GFP assay can be utilized to investigate 
functional delivery of the M3 peptide by a drug delivery system such as R8. 
 
When cells were incubated with 20 µM R8-M3 for 2h, the green fluorescence had 
not increased in every single cell indicating that GFP complementation had not 
occurred in every cell that was exposed to R8-M3. This could either be due to 
transient expression of GFP1-10 and that cells were not expressing the intracellular 
GFP1-10 target or lack of the delivery of M3 to a GFP1-10 expressing cell. Figure 
3-13 C shows an example image that was obtained when cells were incubated with 
20 µM R8-M3 and their corresponding green fluorescent values can be seen in Figure 
3-13 D. Delivery of M3 and GFP complementation had clearly occurred in cell 1 and 
its fluorescence corresponds to 17 which is highly increased compared to the average 
fluorescent intensity obtained from DMSO control cells (2.5). The fluorescence seen 
in cell 2 and 3 corresponds to 6.4 and 4.5, respectively. This amount of fluorescence 
lies within the range of fluorescence that was detected for DMSO control samples 
and leads to the suggestion that those cells were negative for GFP complementation.  
Because cells were transiently expressing GFP1-10, expression in single cells 
varies between high expression levels of GFP1-10 to not expressing the protein at 
all. Hence, only cells will complement with M3 that express GFP1-10 in their cytosol 
and the degree of complementation will be dependent on the amount of GFP1-10 that 
is expressed. It could be possible that cells 2 and 3 (Figure 3-13 C) do contain 
functionally delivered M3 but do not express GFP1-10 and therefore were not positive 
for GFP complementation.  
Another possibility is that cells 2 and 3 are expressing GFP1-10 in their cytosol 
but R8-M3 has not been taken up by the cells or M3 was not functionally delivered 
and therefore GFP complementation had not occurred. R8-M3 is a non-fluorescent 
peptide, hence uptake of this peptide into cells cannot be monitored live. In order to 
investigate if the R8-M3 peptide is taken up evenly across the cell population and to 
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confirm that GFP1-10 expression is the limiting factor for lacking GFP 
complementation, a fluorescently labelled version of R8-M3 was synthesised: 
Rhodamine-R8-M3 (Rh-R8-M3).  
 
 
 
 
 
Figure 3-12 Delivery of M3 and GFP complementation in live cells.  
Cells transiently expressing GFP1-10 were washed once in serum free media and incubated 
with DMSO, L-M3 or R8-M3 at 20µM in serum free media for 2 hours at 37˚C. Cells were 
washed with phenol red free RPMI and counterstained with Hoechst nuclear dye. Live cells 
were images at 37˚C and 5% CO2 in phenol red free RPMI. Scale bar: 10µm.  
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Figure 3-13 Quantification of R8 dependent delivery of M3 peptide into cells transiently 
expessing GFP1-10.  
Quantification of random images taken on the microscope of cells transiently expressing 
GFP1-10 that were incubated with 20µM  DMSO, L-M3 or R8-M3  in serum free media for 2 
hours at 37˚C. CTCF=Corrected Total Cell Fluorescence. (A) Every data point represents a 
single cell treated with DMSO, L-M3 or R8-M3. (B) Mean fluorescence intensity represents 
the average CTCF from three individual experiments of cells treated with DMSO, L-M3 or 
R8M3. N=3, 25-30 cells were analysed per sample per experiment. Error bars display 
standard error of the mean between three experiments. For statistical analysis data was tested 
using a Kruskal-Wallis test. Significance is shown compared to M3 and DMSO. *: p<0.05, **: 
p<0.01, ***: p<0.001, n.s.: not significant. (C) Representative image of cells incubated with 
20µM R8-M3. Scale bar represents 10µm. (D) Quantification of corrected total cell 
fluorescence (CTCF) of the cells three cells shown in image C.  
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3.3.2 Labelled peptide to monitor R8-M3 uptake: Rhodamine-R8-M3. 
Rhodamine is a small fluorescent dye with an excitation and emission maximum 
of 555 nm and 580 nm, respectively. With these fluorescent properties, a minimal 
amount of bleed through into the green channel was expected which made it a 
suitable fluorophore to study the uptake of R8-M3 with little interference with the 
signal obtained from GFP complementation in the green channel (excitation and 
emission spectrum see Appendix Figure 9-5). To be able to conjugate Rhodamine to 
the N-terminus of R8-M3, an additional Glycine had to be added to the N-terminus of 
the amino acid sequence. Conjugation of Rhodamine to the R8-M3 peptide changed 
the molecular weight of the cargo complex from 3.64 kDa for R8-M3 (Table 3-1) to 
4.14 KDa for Rh-R8-M3 (Table 3-2) which is a small change in the molecular weight 
of the peptide, which led to the expectation that uptake and delivery of M3 would not 
be altered significantly compared to unlabelled R8-M3.  
 
 
 
Table 3-2 RhodamineR8-M3 peptide 
 
Table displays sequences, modification and characteristics of RhR8-M3. Blue letters denote 
the sequence of the cell penetrating peptide R8 (octaarginine) and M3 sequence is coloured 
in green. R8 is conjugated to M3 via a linker (grey) Rhodamine is conjugated to a Glycine (G) 
that was added N-terminally to the amino acid sequence (black). 
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In order to investigate the uptake of the Rhodamine labelled R8-M3 peptide 
(RhR8-M3), the live assay was performed with cells transiently expressing GFP1-10 
that were incubated with 20 µM DMSO, L-M3, R8-M3 or RhR8-M3. After two hours 
cells were imaged using a widefield fluorescent microscope. No green fluorescence 
was detected in the cytosol of cells incubated with the DMSO and L-M3 control 
peptides, (Figure 3-14 C, H). For cells incubated with R8-M3, green fluorescence can 
be displayed in the GFP channel in this image (Figure 3-14 M). Cells incubated with 
RhR8-M3 showed that the peptide was taken up evenly across the cell population 
(Figure 3-14 S) and a high amount of GFP complementation could be detected in 
these cells, (Figure 3-14 R). Interestingly, the green fluorescence was mainly 
localised to the nucleolus.  
When images were processed for Figure 3-14, all grey levels of the GFP channel 
were adjusted so that GFP fluorescence was clearly visible for cells incubated with 
RhR8-M3 and no sample was shown overexposed. Due to the large difference of 
green fluorescence that occurred in cells incubated with R8-M3 compared to RhR8-
M3, only low green fluorescence could be shown for cells incubated with R8-M3 in 
Figure 3-14 M. 
To emphasize low fluorescent GFP levels that were actually detected in cells 
over the black background of the image, all images of the GFP channel were 
converted to be displayed on a sepia lookup table (Figure 3-14 E, J, O, T). Images 
shown on a sepia scale reveal that no GFP complementation was detected on cells 
incubated with DMSO and L-M3 (Figure 3-14 E, J) whereas low levels of GFP 
fluorescence was detected in cells incubated with R8-M3 (Figure 3-14 O).  This 
fluorescence was very low compared to GFP fluorescence detected in cells incubated 
with RhR8-M3 where the brightest GFP fluorescence was observed at the nucleolus 
(Figure 3-14 T).  These results suggest that a DDS dependent functional delivery of 
the M3 peptide had occurred in cells incubated with R8-M3 and RhR8-M3.  
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As shown before, only one cell in the field of view was positive for GFP 
complementation when cells were incubated with R8-M3 (Figure 3-14 O). When the 
uptake of R8-M3 was monitored using the Rhodamine labelled peptide (RhR8-M3), it 
was clearly visible that the fluorescence of the peptide was associated with every cell.  
(Figure 3-14 S). GFP complementation was visible in most cells of the field of view 
confirming that the peptide had been taken up by the cell and the M3 peptide was 
delivered to cytosolic GFP1-10.  Despite this even uptake of RhR8-M3 across the cell 
population, the degree of GFP complementation was decreased in one cell (Figure 
3-14 R, marked with a star) compared to others. This could have been an effect of 
cells expressing a different amount of GFP1-10 in their cytosol and therefore GFP 
complementation was limited by intracellular GFP1-10 levels.  
Surprisingly, the number of cells where GFP complementation had occurred was 
increased when cells were incubated with RhR8-M3 compared to R8-M3. A reason 
for this could be a different transfection efficiency between samples. However, cells 
that were incubated with R8-M3 and RhR8-M3 were transfected with the same DNA 
transfection mix to express GFP1-10 which means distribution of GFP1-10 
expression levels should remain the same between these samples. Thus, it seems 
more likely that the observed effect is dependent on the incubation of the cells with 
Rh-R8-M3 and that this peptide delivers M3 more efficiently into the cells than R8-
M3.  
  
In summary, the above findings show that the number of cells where GFP 
complementation had occurred as well as the degree of GFP complementation is 
increased when cells are incubated with RhR8-M3 compared to R8-M3 meaning that 
the rhodamine label could have an increasing effect on functional delivery of the M3 
peptide.  However, red fluorescence of the rhodamine labelled R8-M3 peptide was 
extremely bright under the microscope, so that bleed through of rhodamine signal into 
the GFP channel is a concern. Originally the RhR8-M3 peptide was purchased 
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because it was thought that there was a low amount of bleed through signal between 
the red and the green channel. However the rhodamine labelled peptides showed 
extremely bright fluorescence. The capture settings on the microscope were set to 
11% light power and 10 ms exposure time (Alexa 568 filter setting) compared to 100% 
light power and 500 ms exposure time to capture GFP fluorescence. This bright red 
fluorescence could be the source of more bleed through into the green channel than 
it was expected when this peptide was purchased.  
Hence, to prove the that GFP complementation is increased with RhR8-M3 
compared to R8-M3, it needs to be investigated if the GFP fluorescence seen in cells 
transiently expressing GFP1-10 is a true signal resulting from GFP complementation 
or an artefact of microscopy bleed through.  
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Figure 3-14 Monitoring peptide 
uptake using Rhodamine-R8-
M3.  
Cells transiently expressing GFP1-
10 were washed once in serum 
free media and incubated with 
DMSO, L-M3, R8-M3 or 
Rhodamine labelled R8-M3 
(RhR8-M3) at 20µM in serum free 
media for 2 hours at 37˚C. Cells 
were washed with phenol red free 
RPMI and counterstained with 
Hoechst nuclear dye. Live cells 
were imaged at 37˚C and 5% CO2 
in phenol red free RPMI. Images 
from the GFP channel are 
additionally shown with a sepia 
filter to enhance weak 
fluorescence of cells. Sepia lookup 
table calibration bar displays a 
range from 689 to 34627 grey 
levels. (P-T) Cell marked with a 
star shows a cell that has taken up 
the same amount of RhR8-M3 as 
other cells but shows lower levels 
of GFP. Scale bar: 10µm. n=3. 
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To investigate the amount of bleed through of the Rhodamine labelled peptide, 
cells incubated with RhR8-M3 on transiently expressing GFP1-10 were compared to 
untreated HeLa cells incubated with RhR8-M3 (Figure 3-15). Incubation of RhR8M3 
on HeLa cells that are not expressing GFP1-10 cannot lead to GFP complementation 
because the cytosolic GFP1-10 target protein is not expressed in these cells. Thus, 
the fluorescence detected in the GFP channel will only be a result of “false” green 
fluorescence where Rhodamine was excited with 488 nm wavelength and the 
emission was collected as a bleed through signal that passed through the GFP 
emission filter.  
Microscopy images suggest that there is little difference of RhR8-M3 uptake 
between cells transiently expressing GFP1-10 and untreated HeLa cells (Figure 3-15 
A- IV, IX). Quantification of the corrected total cell fluorescence (CTCF) of single cells 
in three independent experiments confirms that the distribution of CTCF values of 
rhodamine fluorescence in single cells is similar between cells transiently expressing 
GFP1-10 and untreated HeLa cells (Figure 3-15 B). Surprisingly there is a high 
variation in the amount of rhodamine fluorescence in these cells, ranging from 0-2000. 
This high range of fluorescent intensities between cells suggests that cells do take up 
varying amounts of the peptide and uptake is not even across the cell population as 
expected. The mean fluorescent intensities of the CTCF of rhodamine between three 
experiments appeared to be slightly increased in HeLa cells compared to cells 
expressing GFP1-10 with values of 517 and a SEM of 77 compared to 448 and a 
SEM of 60, respectively (Figure 3-15 C). This difference is not significant, confirming 
that the overall uptake is not altered between GFP1-10 transfected cells and 
untransfected HeLa cells.  
 
Investigation of the GFP fluorescence between GFP expressing cells and 
untreated HeLa cells that were incubated with RhR8-M3 using microscopy clearly 
shows that GFP fluorescence was only detected when cells were expressing GFP1-
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10 (Figure 3-15 A- III, VIII). Moreover, this can be confirmed by quantification of the 
microscopy images. CTCF of GFP in single cells expressing GFP1-10 ranged from 8 
to >1000 on a logarithmic scale compared to HeLa cells with values between 8 and 
80 (Figure 3-15 D). Mean values of the CTCF of GFP between three experiments 
were 121 with and 16 for cells expressing GFP1-10 and untreated HeLa cells, 
respectively. This difference in green fluorescence is significant (p<0.001) confirming 
that green fluorescence detected in cells transiently expressing GFP1-10 is derived 
from GFP fluorescence that resulted from GFP complementation of GFP1-10 and M3. 
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Figure 3-15 Comparison of RhR8-M3 
uptake on GFP1-10 expressing cells and 
untransfectd HeLa cells. 
Cells transiently expressing GFP1-10 
(GFP1-10) or untransfected HeLa cells 
(HeLa) were washed once in serum free 
media and incubated with Rhodamine 
labelled R8-M3 (RhR8-M3) at 20µM in 
serum free media for 2 hours at 37˚C. Cells 
were washed with phenol red free RPMI, 
counterstained with Hoechst nuclear dye 
and imaged live. (A) Representative images 
of cells shown. Images from the GFP 
channel is additionally shown with a sepia 
filter. Sepia calibration bar displays a range 
from 689 to 34627 grey levels. Scale bar: 
10µm. (B-E) Quantification of fluorescence 
of microscopy images shown, 25-29 cells 
were analysed per sample per experiment. 
(B) CTCF of Rhodamine in the cytosol of 
single cells. Every data point represents 
CTCF of rhodamine of one cell. (C) Mean 
fluorescent intensity represents the average 
CTCF of Rhodamine fluorescence of cells. 
Error bars display SEM. (D) CTCF of GFP in 
the cytosol of single cells. Every data point 
represents CTCF of rhodamine of one cell. 
(E) Mean fluorescent intensity represents 
the average CTCF of Rhodamine 
fluorescence of cells. Error bars display 
SEM. For statistical analysis data was tested 
using a Shapiro-Wilk normality test followed 
by a Mann-Whitney Wilcoxon test. *: p<0.05, 
**: p<0.01, ***: p<0.001, n.s.: not significant. 
n=3. 
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3.3.3 Comparison of delivery efficiency of R8-M3 and Rh-R8-M3 
Finally, the ability to functionally deliver M3 into cells expressing GFP1-10 was 
compared between L-M3, R8-M3 and RhR8-M3 (Figure 3-16).  As experimental 
controls were cells expressing GFP1-10 incubated with DMSO and untransfected 
HeLa cells incubated with RhR8-M3. Both of these samples cannot be positive for 
GFP complementation as Hela cells incubated with Rh-R8-M3 lack the intracellular 
GFP1-10 cargo and GFP1-10 expressing cells incubated with DMSO lack M3 cargo 
peptide. Nevertheless, it was visible that untransfected HeLa cells incubated with 
RhR8-M3 (RhR8-M3 HeLa) show a higher GFP fluorescence compared to GFP1-10 
expressing cells incubated with DMSO (Figure 3-16 A). As untransfected HeLa cells 
will not be able to complement with M3 to form full length GFP, this increase in GFP 
fluorescence shows the amount of “false” GFP signal that is derived from the 
rhodamine fluorophore that is collected as GFP signal. 
In order to be able to show the fold change of GFP fluorescence as a result of 
GFP complementation, this value was subtracted as the background from cells 
expressing GFP1-10 that were incubated with RhR8-M3 (green bar). For L-M3 
(orange bar) and R8-M3 (purple bar), the value obtained from cells treated with 
DMSO was subtracted as the background.  
The comparison of delivery of M3 between L-M3, R8-M3 and RhR8-M3 after 
background subtraction is shown in Figure 3-16 B.  The fold change of GFP 
fluorescence as a result of GFP complementation is shown on a logarithmic scale. L-
M3 shows very little change in GFP fluorescence indicating that this peptide was not 
able to cross the plasma membrane and M3 did not complement with cytosolic GFP1-
10. Incubation of 20 µM R8-M3 led to GFP fluorescence suggesting that R8 facilitated 
the delivery of M3 to the cytosol of GFP 1-10 transfected cells. The Rhodamine 
labelled R8-M3 peptide that was originally purchased to enable to track the uptake of 
R8-M3 using a microscope, however when cells transiently expressing GFP1-10 were 
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incubated with this peptide, green fluorescence increased meaning that GFP 
complementation had occurred. Compared to R8-M3 the delivery efficiency of RhR8-
M3 was increased. These results are based on the assumption that the transfection 
efficiency between the different samples were consistent because the same 
transfection mix was used between the samples.  
 
In summary, these findings strongly suggest that Rhodamine can enhance the 
efficiency of R8 to deliver M3 across the plasma membrane to complement with 
cytosolic GFP1-10. The reason for enhancement of the delivery is further discussed 
at the end of this chapter.  
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Figure 3-16 Comparison of M3 delivery into cells transiently expressing GFP1-10 using 
20 µM L-M3, R8-M3 or RhR8-M3.  
Cells transiently expressing GFP1-10 were washed once in serum free media and incubated 
with DMSO, L-M3, R8-M3 or Rhodamine labelled R8-M3 (RhR8-M3) at 20µM in serum free 
media for 2 hours at 37˚C. Non transfected HeLa control cells were incubated with RhR8-M3 
at 20 µM (RhR8-M3 HeLa). This figure combines data derived from three individual 
experiments shown in Figure 3-13 and Figure 3-15. (A) Fold change of GFP fluorescence of 
all samples shown. (B) DMSO background was then subtracted to obtain L-M3 and R8-M3 
values. Background of RhR8-M3 HeLa was subtracted to obtain the fold change of GFP 
fluorescence of Rh-R8-M3 incubated with cells transiently expressing GFP1-10. n=3. 
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3.3.4 Localisation of complemented GFP at the nucleolus 
When live uptake and delivery of the M3 peptide was investigated, it was striking 
that complemented GFP was strongly localised to the nucleolus when GFP1-10 
expressing cells were incubated with 20 µM RhR8-M3 (Figure 3-14 K). This nucleolar 
localisation of complemented GFP was also investigated in previous experiments 
when mCherry-H6-Xa-R8-M3 was co-expressed with GFP1-10 (Figure 3-6). When 
R8-M3 was incubated with cell expressing GFP1-10, complemented GFP appeared 
to be mainly localised in the cytosol (Figure 3-12 I, Figure 3-13 C). Detailed analysis 
of HeLa cells expressing GFP1-10 incubated with 20 µM R8-M3, M3 or DMSO reveals 
that complemented GFP also localised to the nucleolar region when R8-M3 is used 
to deliver M3 into the cytosol of cells (Figure 3-17).  After 2 hours of incubation with 
20 µM R8-M3, the green fluorescence increases in the cytosol and concentration of 
green fluorescence can be detected in the nucleus, localised to the nucleolar region 
(Figure 3-17 L arrowheads). These structures cannot be seen in the nuclei of cells 
that were incubated with 20 µM DMSO or M3 (Figure 3-17 D, H). In DMSO and M3 
control cells, green fluorescence is mainly localised around the nucleus or the whole 
nucleus appears to be fluorescent. This green fluorescence is weaker compared to 
cells were GFP complementation has occurred and it can be detected when cells 
were treated with M3 as well as with DMSO. As DMSO treated cells are not able to 
complement GFP1-10 with M3, this green fluorescence was assumed to be 
autofluorescence of the cell. When the concentration of R8-M3 is increased to 40 µM, 
the nucleolar structures can be seen more clearly (Figure 3-17 P arrowheads).  
This data suggests that nucleolar localisation of complemented GFP can serve 
as an indication of functional delivery of M3 by R8 or Rh-R8. In addition to increasing 
levels of GFP fluorescence when M3 is delivered to GFP1-10, this fluorescence 
appearing at this defined localisation inside the cell can additionally be used to identify 
cells in which M3 has been delivered by R8 or RhR8-M3. This feature can be 
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especially advantageous when fluorescent levels of GFP complementation have little 
increase compared to DMSO control cells.  
This data is a great example that a drug delivery system can have an influence 
on the intracellular localisation of its target and this will further be investigated in 
Chapter 6.  
 
 
Figure 3-17 Localisation of complemented GFP in live cells.  
Cells transiently expressing GFP1-10 were incubated with DMSO, L-M3 or R8-M3 at 20µM 
(A-K) or with 40µM R8-M3 (M-O) in serum free media for 2 hours at 37˚C. Cells were 
counterstained with Hoechst nuclear dye. Green fluorescence of cells in panel O was adjusted 
independently of other samples to show localisation of complemented GFP. Image would have 
been overexposed and nucleolar structures not visible if adjusted to the grey levels of other 
images. Red arrowheads point out nucleolar location of GFP. Scale bar: 10µm. 
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3.3.5 Visualisation of functional delivery of M3 in live cells. 
One aim to utilise split GFP to show functional delivery of a peptide, is that it will 
enable us to detect GFP complementation in live cells as the peptide is delivered 
inside the cell with a microscope. Previous results demonstrated that M3 delivery and 
GFP complementation can be detected 2 hours after R8-M3 has been incubated on 
cells expressing GFP1-10.  
It was next examined if functional delivery of the M3 peptide cargo to its 
intracellular GFP1-10 target, resulting in GFP complementation and an increase of 
GFP fluorescence can be shown in real time in live cells using a widefield fluorescent 
microscope. To investigate this, media of HeLa cells transiently expressing GFP1-10 
was removed and replaced with serum free media containing 20 µM R8-M3. GFP 
complementation was then monitored every minute for 67 min (Movie Figure 3-18, 
Figure 3-19A). The movie shows increasing GFP fluorescence over time suggesting 
delivery of M3 and GFP complementation.  Detailed examination of the single time 
points reveals that when the cell was first imaged on the microscope, green 
fluorescence was detected in the cytosol with increased green fluorescence located 
in the nucleus (Figure 3-19, 0 min). This green fluorescence decreased in the first 10 
minutes of the experiment (Figure 3-19, 10 min). The nuclear green fluorescence was 
similar to the fluorescence detected in earlier experiments in DMSO control cells 
(Figure 3-17) which could mean that this is green auto fluorescence of the cell that 
photobleaches within the first 10 frames of the movie.  
It was hypothesised earlier that complemented GFP mainly localises in the 
cytosol where GFP1-10 is expressed or to the nucleolus where R8 could target it to, 
thus, it was of interest to analyse how the GFP fluorescence in different compartments 
of the cell changes over time. Detailed analysis was performed to monitor the change 
in green fluorescence in the cytosol, nucleolus and the nucleus (Figure 3-19 B). To 
do so, a region of interest (ROI) was drawn in those localisations as well as the 
background. Measurements of the mean green fluorescence in the ROI were taken 
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between 0 and 66 minutes. The mean fluorescence displayed in Figure 3-19 B equals 
the mean fluorescence in that ROI after background subtraction. The mean 
fluorescent intensity measured in each ROI decreased slightly in the first 10 minutes, 
which is in alignment with what was seen on the microscopy images. In the cytosol 
GFP fluorescence changed linear with time and increased by 8 fold over 66 minutes 
(from 225 to 1873) indicating that GFP complementation had taken place in the 
cytosol. The fluorescence in the nucleus and the nucleolus increased by 2.8 fold and 
4.7 fold, respectively in 66 minutes.  
 
This data shows that complemented GFP is present at all three localizations of 
the cell, with the highest amount being localised in the cytosol where GFP1-10 is 
expressed and which is the first location where M3 is present after it has overcome 
the plasma membrane barrier. The change in green fluorescence at the nucleolus 
was higher than in the nucleus suggesting that this complemented GFP could be 
targeted to this position rather than being a result of passive diffusion into the nucleus.  
Importantly, this movie proves that the developed split GFP assay can be utilised 
to investigate M3 peptide delivery by the drug delivery system R8 in real time using a 
microscope. 
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Figure 3-18 Movie of GFP complementation in live cells over time.  
HeLa cells transiently expressing GFP1-10 were washed once in serum free media which was 
replaced with serum free and phenol red free RPMI containing R8-M3 peptide at 20 µM. GFP 
complementation was monitored every minute for 67 min. Sclae bar: 20 µm 
Movie is available at https://youtu.be/pm969otSftA  
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Figure 3-19 GFP complementation in live cells over time.  
HeLa cells transiently expressing GFP1-10 were washed once in serum free media which was 
replaced with serum free media containing R8-M3 peptide at 20 µM. GFP complementation 
was monitored every minute for 67 min. (A) Single images from movie shown, captured at 0 
min, 10 min, 20 min, 30 min, 40 min, 50 min and 67 min. Scale bar: 20µm. (B, right) Regions 
of interest (ROI) were placed in the nucleolus (dark blue), the nucleus (red) and the cytosol 
(light blue). (B, left) Mean fluorescent intensity shown for ROIs between 0 and 66 minutes. 
Data from a single cell from one experiment shown.  
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3.4 Discussion 
Despite the great potential of peptides to act as therapeutic cargos, it is a 
challenge to facilitate their delivery to the cytosol of cells where they can carry out 
their function at their intracellular target. Drug delivery vectors such as cell penetrating 
peptides hold great potential to act as DDSs and facilitate their uptake (Copolovici et 
al. 2014). A major hurdle to evaluate the efficiency of these DDS to deliver their 
peptide cargo is to assess delivery into the cytosol and to asses if the peptide is intact 
to carry out its biological function.  
 In this chapter an assay was introduced that can serve as a solution to 
investigate delivery of a peptide to the cytosol facilitated by drug delivery systems and 
importantly also allows a direct correlation with its function. This assay allows the 
evaluation of DDS and their ability to functionally deliver peptides. This assay is based 
on split GFP (Cabantous et al. 2005) where GFP1-10 is expressed in the cytosol of a 
target cell and the M3 peptide serves as the model peptide cargo that is delivered by 
a DDS. 
 
It was described previously that short amphipathic peptide carrier, Pep-1 can be 
used deliver M3 across the membrane by co-incubation to complement with its 
intracellular target (Pinaud and Dahan 2011). However, the intracellular GFP1-10 
target protein was fused to Caveolin-1. Caveolin-1 is a protein involved in various 
processes within the cell. It is expressed at the cytoplasmic face of the plasma 
membrane and involved in endocytic uptake of cargo, membrane recycling back to 
the plasma membrane as well as trafficking to the Golgi apparatus (Rothberg et al. 
1992; Conrad et al. 1995). These are mechanisms that can be involved in uptake and 
trafficking of a cargo molecule and overexpression of proteins can lead to mis-
localisation to other cellular compartments. Hence, we excluded this protein as an 
intracellular GFP1-10 target to avoid the possibility of GFP complementation prior to 
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the M3 peptide reaching the cytosol. For this reason, the split GFP method in this 
project was developed to ensure cytosolic expression of the GFP1-10 target protein.  
 
In this chapter it was shown that methods have been developed to prove that 
HeLa cells can express the intracellular GFP1-10 target when its green fluorescence 
is lost. GFP1-10 is missing the 11th beta sheet in its structure, nevertheless, it was 
possible to prove its presence in the cytosol using immunofluorescent staining as well 
as western blot analysis of cell lysate using an anti-GFP antibody.  
 
An important finding that led towards the development of the split GFP assay 
was that GFP1-10 and M3 are able to complement in the cytosol to form full length 
GFP and GFP fluorescence is rescued. This was demonstrated using a co-
transfection assay where GFP1-10 and mCherry-H6-Xa-R8-M3 were expressed in 
cells which served as a reliable method to test GFP complementation in the cytosol.  
Importantly, it was possible to detect the GFP signal arising from complemented GFP 
on a microscope which was crucial in order to develop the split GFP assay as a live 
cell imaging technique.  
The M3 expression construct included various modifications resulting in 
expression of mCherry-H6-Xa-R8-M3. It was ruled out that mCherry can serve as a 
proton acceptor for GFP1-10 to rescue GFP expression. Thus, fusion of mCherry had 
the great advantage of being able to investigate H6-Xa-R8-M3 expression in live cells. 
Complementation of GFP1-10 with mCherry-H6-Xa-R8-M3 also confirmed that the 
drug delivery system R8 did not inhibit the complementation. This is an important 
finding leading towards a live assay where R8 is covalently conjugated to M3 to 
facilitate its delivery into the cytosol.  
Proof of complementation of the split GFP fragments was not possible when cells 
were co-transfected with GFP1-10 and H6-Xa-R8-M3. This could have been due to 
expression and subsequent rapid degradation of the short peptide. It is important that 
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expressed proteins fold correctly inside the cell since there are pathways to degrade 
misfolded or damaged proteins to protect the cell. This mechanism, targeting proteins 
to the proteasome for degradation ensures quality of proteins and protects the cell 
from non-functional and potentially toxic proteins (reviewed in (Goldberg 2003)). H6-
Xa-R8-M3 is a short peptide and with multiple repetitive, charged amino acids, 
consisting of mainly Histidine and Arginine, it is possible that it does not exhibit an 
ordered three dimensional structure. Hence, the cell could have detected it as a 
misfolded protein and targeted it for proteasomal degradation. One way to confirm 
this hypothesis would be to investigate GFP complementation when both fragments 
are co-expressed and cells are treated with a proteasome inhibitor to maintain H6-
Xa-R8-M3 in the cell. Another possibility to prove H6-Xa-R8-M3 expression inside the 
cell could have been to detect the N-terminal His tag of the peptide using 
immunofluorescent staining with a His-tag antibody.  
 
The development of an in vitro assay to assess complementation of GFP1-10 
with pure synthetic peptides that will be evaluated and compared regarding their 
delivery efficiency of M3 is crucial. The proposed ‘fix and stain experiment’ was able 
to give information as to if the M3 peptide will complement with GFP1-10 but 
suggested that R8-M3 complements to a higher degree with GFP1-10 then M3 or L-
M3. However, the success of GFP complementation with M3 and L-M3 was 
dependent on intracellular localisation of GFP1-10 in the cytosol or the Golgi 
apparatus. Due to the influence of PFA fixation and Triton-X100 permeabilisation on 
subcellular localisation of a cytosolic protein (Schnell et al. 2012) it is suggested that 
the lack of GFP complementation of M3 and L-M3 with cytosolic GFP1-10 was an 
artefact of the fixation method rather than inability of the two fragments to 
complement.  
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Hence, investigation of in vitro split GFP complementation should not involve 
fixation and permeabilisation protocols where protein could relocate to a different 
localisation inside the cell.  
A better system to investigate GFP complementation of GFP1-10 with M3 
peptides without the need for the peptides to cross the plasma membrane barrier is 
microinjection of M3 into the cytosol of cells expressing GFP1-10. This method would 
give a detailed insight of complementation dynamics of GFP1-10 with M3 peptides in 
the cytosol of live cells. However, microinjection is a time consuming process. 
Moreover, transient expression of GFP1-10 will introduce varying levels of expressed 
GFP1-10 which will require microinjection of a high amount of cells in order to gain 
information about complementation dynamics across a transient transfected cell 
population.  
For this reason a true in vitro system would be beneficial where pure GFP1-10 
protein can be mixed with M3 containing peptides. An even better estimation of 
complementation dynamics would be if M3 peptides are mixed with GFP1-10 
originated from expression by HeLa cells. Thus, a cell lysate from HeLa cells 
expressing GFP1-10 could be obtained and used to investigate complementation with 
M3 containing peptides. This improvement of the split GFP in vitro assay will further 
be explored in Chapter 4.   
 
When the live cell assay was performed to investigate M3 delivery by the drug 
delivery system R8 it was seen that GFP complementation took place and green 
fluorescence was increased when cells expressing GFP1-10 were incubated with 20 
µM R8-M3 for 2 hours compared to L-M3 or DMSO. This data clearly showed that the 
split GFP assay can be used to investigate delivery of the M3 cargo peptide across 
the plasma membrane. Incubation of 20 µM L-M3 resulted in the same green 
fluorescent levels as detected in the DMSO control. No penetration ability of the M3 
peptide or the flexible Serine-Glycine linker has been reported and Glycine rich linkers 
136 
 
are common in the CPP field to connect protein domains without interfering with the 
function of each domain (Sayers et al. 2014; Reddy Chichili et al. 2017). Hence, it is 
suggested that L-M3 cannot pass the plasma membrane. However, due to the lack 
of in vitro data about the L-M3 peptide to complement with cytosolic GFP1-10 it is 
also possible that L-M3 might have crossed the plasma membrane but was not able 
to complement with GFP1-10 in the live cell assay. Hence it is of high importance to 
assess complementation of GFP1-10 and L-M3 with the improved in vitro system to 
be able to correlate this data with the information gained from the live cell assay.  
It was demonstrated that incubation time of 2 hours was sufficient in order to 
allow M3 delivery to the cytosol by R8 and complementation with GFP1-10. When 
delivering peptide cargo to the cytosol it is critical to consider uptake dynamics into 
the cytosol. The proposed uptake mechanism for R8 at low concentrations (< 10 µM) 
is endocytosis and labelled R8 was shown to be found in endocytic vesicles after 1 
hour of incubation of Alex-488 labelled R8 with acute myeloid leukemic KG1a cells 
and HeLa cells (Jones and Sayers 2012; Sayers et al. 2014). Furthermore it was 
shown that defined endocytic labelling is lost in HeLa cells when incubated with 
increasing concentration of the fluorescein labelled Polyarginine peptide 
nonargginine (R9). From 10 µM, labelled peptide was found distributed in the cytosol 
with clear cytosolic labelling at 20 µM after 30 min which was suggested to be direct 
transcytosis across the plasma membrane (Duchardt et al. 2007; Jones and Sayers 
2012). Based on that knowledge is was suggested that R8-M3 when applied at 20 
µM crosses the plasma membrane through direct transcytosis in 30 min-1h. The 
movie of live delivery of M3 by R8 at 20 µM revealed that GFP complementation starts 
as fast as 20 min after R8-M3 has been applied onto the cells. This supports that 
hypothesis that R8-M3 crosses the plasma membrane through direct transcytosis.  
 
Utilising the split GFP system to evaluate different drug delivery systems and 
their ability to deliver M3 has shown that differences in deliver efficiency can be 
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detected when R8-M3 is compared to RhR8-M3 at 20 µM. The Rhodamine peptide 
was originally purchased to be able to track the uptake of R8-M3 into the cell using a 
microscope. In order to explore the uptake mechanism of cell penetrating peptides 
using a microscope the attachment of a fluorophore is required. However, it has been 
reported that the attachment of fluorophores can lead be the reason of changed 
uptake dynamics into the cell (Jones and Sayers 2012). Rhodamine was shown to 
interact with arginine rich peptides like TAT and R9 which can enhance photo-induced 
release through endosomolytic activity and it can also be used as a photosensitiser. 
This was demonstrated when it was attached to the CPP Tat. Tetramethylrhodamine 
produced reactive oxygen species upon irradiation that can cause membrane 
damage when in close proximity to the plasma membrane through attachment to a 
CPP, thereby facilitating uptake (Meerovich et al. 2014). However, its photo-induced 
release through endosomolytic activity was also accompanied with phototoxicity and 
loss of plasma membrane integrity (Srinivasan et al. 2011). Furthermore, when it was 
conjugated to the CPP Penetratin an increase of the hydrodynamic radius of the CPP 
as well as a significant cellular uptake into cells was observed (Hyrup Moller et al. 
2015). For these reasons Rhodamine might have not been the best choice to label 
R8-M3.  
 
Nevertheless, it was an important finding that the uptake of 20 µM RhR8-M3 in 
GFP1-10 transfected cells was not significantly different compared to untransfected 
HeLa cells. This shows that Fugene6 transfection of cells did not alter plasma 
membrane characteristics and did not affect M3 delivery by Rh-R8-M3. Another 
important finding was that it was possible to show that RhR8-M3 increases delivery 
of M3 into the cytosol of cells compared to R8-M3. This outcome is a great example 
that differences of delivery efficiency can be evaluated using this split GFP assay 
when two different DDSs are used to deliver M3.   
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Detailed investigation of M3 delivery using a microscope revealed that 
complemented GFP was strongly localised to the nucleolus when GFP1-10 
expressing cells were incubated with 20 µM RhR8-M3 and R8-M3.  When GFP1-10 
expression was investigated using immunofluorescence, GFP1-10 was expressed 
throughout the cytosol and was not concentrated in the nucleus. Hence, when 
complemented GFP can be found concentrated at the nucleolar region it was likely to 
be an effect of re-association with RhR8-M3 or R8-M3. This nucleolar localisation was 
shown before in co-expression experiments when GFP1-10 had complemented with 
mCherry-H6-Xa-R8-M3. R8 and other arginine rich peptides are well known to 
localise at the RNA in the nucleolus of cells (Vives et al. 1997; Gustafson et al. 1998; 
Martin et al. 2007) which could explain that complemented GFP was found at that 
location when GFP1-10 was expressed with R8 containing mCherry-H6-Xa-R8-M3 or 
in the live experiments when incubated with R8-M3 or RhR8-M3. This suggests that 
R8 was able to target M3 peptides (3.6 – 4 kDa) or even the whole fusion protein 
mCherry-H6-Xa-R8-M3 (~35kDa) through the nuclear pore to the nucleolus resulting 
in the nucleolar labelling once complemented with GFP1-10, if GFP1-10 was present 
in the nucleus through passive diffusion through the nuclear pore. Another scenario 
could have involved GFP complementation of GFP1-10 and mCherry-H6-Xa-R8-
M3/R8-M3/RhR8-M3 in the cytosol and relocalisation of a complex of ~ 50kDa (for 
mCherry-H6-Xa-R8-M3) by R8 post complementation. With a size of ~ 50kDa it is a 
very large complex but it was found that proteins as large as 60 kDa are able to pass 
through the nuclear pore (Wang and Brattain 2007). It was also striking in the movie 
of live R8-M3 delivery that GFP complementation mainly took place in the cytosol and 
GFP fluorescence increased more at the nucleolar region compared to the 
surrounding nuclear region.  
 
This is an important finding when characterising drug delivery systems because 
it shows what influence a DDS can have on the subcellular localisation of its cargo. 
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The movie of real time delivery as well as visualisation of the localisation of M3 
delivery was only possible by detection of GFP complementation using a microscope. 
Results of previous studies using the split GFP complementation assay have only 
shown concentration depnendent peptide delivery by flow cytometry (Milech et al. 
2015; Schmidt et al. 2015b). Further, more detailed microscopic analysis of the 
localisation of comoplemented GFP will be shown in Chapter 6.  
 
In order to develop a method to evaluate drug delivery systems and their ability 
to functionally deliver the M3 peptide, it is of importance that this method is robust 
and reproducible. However, most importantly, the seen effect (e.g. increasing GFP 
fluorescence through GFP complementation) has to be solely dependent on the 
delivery efficacy of the drug delivery system itself. 
A result of transient transfection of cells is that the expression levels of the protein 
vary hugely between single cells. This high variation in expression levels can be seen 
when GFP1-10 is expressed in HeLa cells. M3 will only complement to form full length 
GFP when GFP1-10 is available in the cytosol of the target cell. When cells express 
GFP1-10, it is non-fluorescent and it is not possible to determine if and how much 
GFP1-10 is expressed in a live cell experiment. For this reason it is not possible to 
differentiate between cells where the M3 peptide has been delivered to the cytosol 
but the cells were not expressing GFP1-10, and cells that were expressing GFP1-10 
but delivery of M3 was not successful. The amount of expressed GFP1-10 will also 
determine the maximal degree of GFP complementation, regardless if more M3 was 
delivered into that cell. Hence, GFP1-10 is a limiting factor in this assay and 
represents a variable in this assay.  
 
Furthermore, the uptake of RhR8-M3 into cells largely varied between single 
cells. This finding suggests that another mechanism is involved that determines how 
much peptide is taken up into cells. This variation of uptake was only possible to 
140 
 
determine by adding rhodamine as a fluorescent tag to the drug delivery system. 
Hence, if this is a Rhodamine specific effect or holds true for R8-M3 is unknown. 
However, the aim of this assay is to determine DDS specific delivery of the M3 peptide 
to be able to characterise the DDS. An assay with a cell population that expresses 
varying amounts of GFP1-10 and drug delivery systems that might enter the single 
cells unevenly across a cell population does not supply sufficient information to be 
able to determine a DDS specific effect on delivery. Hence, as novel DDSs will be 
characterised using this system they have to be the only variable in the assay. For 
this reason levels of GFP1-10 expression across the cell population have to be 
known.  
There are two models proposed to achieve this. Firstly, generating a clonal stable 
cell line that expresses even amounts of GFP1-10 across the cell population. 
Secondly, a fluorescent expression marker of GFP1-10 can be introduced which 
would allow to track which cells express GFP1-10 and how much protein is expressed 
inside the cell. Generation of a stable cell line that expresses mCherry-GFP1-10 
would even be more beneficial for the assay development because it would eliminate 
the chances of a cell not expressing the intracellular GFP1-10 at all, therefore making 
the assay even more robust. This system would then allow us to investigate 
concentration dependent functional M3 delivery by DDSs, and make a direct 
comparison of DDSs.  
The improvement of the split GFP system by generating stable cell lines as well 
as an improved in vitro assay are further shown in Chapter 4.  
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4 Generation of stable cell lines for the 
improvement of the split GFP assay.  
4.1 Introduction 
In chapter 3 it was demonstrated that the split GFP system can be utilised to 
show that drug delivery systems are able to functionally deliver M3 peptide cargo to 
the cytosol when GFP1-10 is expressed transiently. Transient transfection, however, 
introduces high variability in GFP1-10 expression levels and makes it difficult to prove 
that a seen effect can solely be attributed to the delivery efficiency of the drug delivery 
system. In order to improve the split GFP system and be able to specifically evaluate 
the delivery efficiency of DDSs to deliver M3 peptide, two solutions are hypothesised. 
Firstly, to decrease the variation levels of GFP1-10 expression and ensure even 
GFP1-10 expression levels across the cell population. This will allow the full 
characterisation of M3 delivery systems because the degree of GFP 
complementation is only dependent on M3 delivery and not influenced by GFP1-10 
expression. This can be achieved by the generation of a stable cell line that expresses 
GFP1-10 in its cytosol.  
A second solution is to create a system where the variation of GFP1-10 expression 
levels can be quantified. This can be achieved by introducing a fluorescent expression 
partner that labels GFP1-10 expression. Previously it was shown that the fluorescent 
protein mCherry did not interfere with GFP complementation when GFP1-10 was 
expressed with mCherry-H6-Xa-R8-M3. Hence, mCherry is used in this Chapter to 
act as a fluorescent expression partner for GFP1-10 and its fluorescence can be 
correlated with the amount of expressed GFP1-10.  
 
The aim of this chapter is to improve the split GFP system as hypothesised 
above, and the characterisation of these systems. The first focus of this chapter lies 
on the generation of the stable cell line that expresses GFP1-10. The second part of 
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this chapter will describe the full characterisation of the split GFP system when 
mCherry-GFP1-10 is utilised to obtain an expression marker for GFP1-10 expression.   
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4.2 Generation of a stable cell line that expresses GFP1-10: Stable 
Cell Line 1 (SCL1) 
In order to generate a stable cell line that evenly expresses GFP1-10 across its 
cell population, HeLa cells were transfected with DNA coding for GFP1-10. GFP1-10 
is cloned into the background vector EGFP-N1 which also carries the neomycin 
resistance gene (For vector map see Figure 9-1). Thus, cells that had stably 
integrated this expression construct into their genome were selected using selection 
media containing 400 mg/mL Geneticin (G418). To obtain a clonal cell line, limiting 
dilution was performed (for detailed stable cell line generation see (2.8.2). Because 
cells expressing GFP1-10 are not fluorescent, cells could not be sorted by fluorescent 
activated cell sorting (FACS). For this reason colonies that were obtained from limiting 
dilution were screened by immunofluorescence using an anti GFP antibody to detect 
cytosolic expression levels of GFP1-10. From over 1000 microwells that were 
screened, 56 wells contained cell colonies that expressed GFP1-10. The other wells 
did either not contain cells at all or cells did not express GFP1-10. From 56 cell 
colonies, the two most promising colonies were selected. The main criteria for 
selection was to identify a population in which every single cell was expressing GFP1-
10, levels of GFP1-10 expression were equal between cells. From those two colonies 
the one expressing the highest amount of GFP1-10 in the cytosol was chosen. This 
cell line was named Split Cell Line 1 (SCL1) and underwent detailed characterisation 
using techniques developed previously to ensure a stable expression of GFP-10 while 
retaining compatibility of reassembly with M3.  
 
4.2.1 Proof of even GFP1-10 expression levels in SCL1 cells 
In order to confirm that SCL1 cells express even levels of GFP1-10 across the 
cell population compared to cells transiently transfected with GP1-10, 
immunofluorescent staining against GFP was performed (Figure 4-1). Microscopy 
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images demonstrate that there was a high variation in GFP1-10 expression levels in 
the cytosol of cells that were transiently expressing GFP1-10 (Figure 4-1 A IV). The 
GFP antibody detected very high expression levels in the cytosol of some cells and 
no expression at all in other cells. In comparison, GFP1-10 expression in SCL1 cells 
can be detected evenly across the cell population (Figure 4-1 A IX). The amount of 
expressed GFP1-10 appears to be considerably lower than when the protein is 
expressed transiently, hence, the staining detected for the anti-GFP stain is also 
displayed as a fire table which enhances low signals over the black background 
(Figure 4-1 A X). Importantly, Mock transfected cells did not show any staining against 
GFP (Figure 4-1 A XIV, XV) confirming that the low anti-GFP signal detected in SCL1 
cells is a result of GFP1-10 detection rather than non-specific antibody staining that 
would also be visible in mock transfected cells. The microscopy images also reveal 
that GFP1-10 is not green fluorescent when transiently expressed in the cytosol 
(Figure 4-1 A III) as shown before when this system was characterised (see chapter 
3 xy). This absence of green fluorescence is maintained when GFP1-10 is stably 
expressed in SCL1 cells (Figure 4-1 A VIII).  This is of high importance for the assay 
in order to obtain a green fluorescent signal when M3 peptide is delivered to cytosolic 
GFP1-10 by a DDS.  
Quantification of the corrected total cell fluorescence (CTCF) of anti GFP staining 
in the cytosol of these cells confirms what can be seen on the images. Because of 
the very high range of expression levels that is seen in transient transfections, this 
data is displayed on a logarithmic scale (Figure 4-1 B). Mock transfected cells show 
fluorescence in a range between 0.08 and 0.6 with a mean CTCF of 0.27. In 
comparison, SCL1 cells display a CTCF n a range between 1.1 and 21.2. When HeLa 
cells transiently express GFP1-10, expression levels range from 0.1 to 75.9 which is 
a 759 fold difference across the cell population. These data points include cells not 
expressing GFP1-10 as well as cells highly overexpressing GFP1-10 in their cytosol. 
Cells transiently expressing GFP1-10 and SCL1 cells show a mean CTCF of 7.7 and 
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5.1, respectively. Furthermore, the coefficient of variation is shown (Figure 4-1 C) that 
describes the variability of the data points to the mean and is was calculated by 
dividing the standard deviation of all data points by the mean value of all the data 
points. This means that if the mean value equals the standard deviation a value of 1 
is obtained. The smaller the standard deviation is compared to the mean, the smaller 
the number appears with a minimum value of zero if a standard deviation of the value 
zero had been obtained.  
The coefficient of variation was found to be 0.4 for mock transfected cells, 
showing the natural variation of fluorescence of the antibody stain, 0.7 for SCL1 cells 
and 1.4 for cell transiently expressing GFP1-10. Hence, even though the mean 
fluorescent intensity between cells transiently expressing GFP1-10 and SCL1 cells 
was found to be similar, the variation of fluorescence between the cells was 
decreased in SCL1 cells.  
This data demonstrates that the stable cell line SCL1 expresses even amounts 
of GFP1-10 across the cell population. More importantly, every single cell is 
expressing GFP1-10, with the data of CTCF of anti GFP staining clearly separating 
from the fluorescent levels obtained from mock transfected cells (Figure 4-1 B). The 
amount of expressed protein is low (mean value of 5.1) compared to the maximum 
expression that can be achieved when cells are transiently transfected with GFP1-10 
(maximum value > 60). In summary, SCL1 cells express even but low levels of GFP1-
10.  
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Figure 4-1 Comparison of GFP1-10 expression levels of SCL1 cells and cells transiently expressing GFP1-10 using immunofluorescence.  
HeLa cells transiently expressing GFP1-10, SCL1 cells stably expressing GFP1-10 or mock transfected cells were PFA fixed and the plasma membrane was 
permeabilised with 0.1 % Triton-X-100. GFP1-10 expression was detected using a primary anti-GFP antibody raised in goat. A secondary anti-goat antibody 
conjugated to Alexa-647 was used to be able to visualise GFP expression. Nuclei were counterstained with DAPI. (A) Representative images of the 
immunofluorescent stain shown. Grey levels displayed on fire table range between 110-9487. Scale bars represent 30 µm. (B) Quantification of the CTCF of 
the anti GFP staining. Single data points represent the fluorescence in the cytosol of single cells. Bar displays the average CTCF of three experiments. Error 
bars show standard error of the mean between experiments. 46 to 68 cells were analysed per condition per experiment.(C) Coefficient of variation was calculated 
by dividing the standard deviation of the CTCF of all data points by the value of the mean CTCF. n=3.   
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4.2.2 GFP complementation in SCL1 cells using transfection  
Next, it was tested if the expressed GFP1-10 in SCL1 cells is able to complement 
to full length GFP when DNA coding for the M3 fragment is transiently expressed in 
this cell line. It was found that GFP fluorescence can be detected with a microscope 
when mCherry-H6-Xa-R8-M3 is expressed in SCL1 cells (Figure 4-2 A III). No GFP 
fluorescence could be seen in mock transfected SCL1 cells (Figure 4-2 A VII). 
Transfection of a DNA construct coding for mCherry-H6-Xa-R8-M3 has the 
advantage that it is possible to identify which cells express the M3 fragment by its 
mCherry fluorescence (Figure 4-2 A IV). Every single cell that was transfected with 
mCherry-H6-Xa-R8-M3 was positive for GFP complementation which confirms that 
each of those cells was also expressing GFP1-10. The GFP fluorescence was 
detected in the nucleus or the cytosol consistent with what was found in transient co-
expression experiments (3.2.2). GFP complementation through co-expression was 
also compared between SCL1 cells and HeLa cells transiently expressing GFP1-10 
and mCherry-H6-Xa-R8-M3 (Figure 4-2 B) which was detected on a microplate reader 
(2.4.3.2).  When HeLa cells were transfected with single DNA constructs coding for 
GFP1-10 and mCherry-M3 only very low signal of 1000 – 1500 RFU was detected 
when GFP fluorescence was measured. When these DNA constructs were co-
expressed, GFP complementation occurred in transfected cells and high levels of 
12,000 RFU were detected. GFP complementation was also detected when mCherry-
H6-Xa-R8-M3 in SCL1 cells which confirmed what was seen before when co-
expression was analysed using microscopy. GFP fluorescence was detected at 6400 
RFU, hence, the brightness of GFP fluorescence when GFP complemented in SCL1 
cells was half as bright as when both fragments were expressed in HeLa cells. This 
drop in fluorescence can be explained by the lower expression levels of GFP1-10 in 
SCL1 cells. The degree of GFP complementation is limited by the amount of GFP1-
10 that is express in the cytosol and in previous studies it was shown that higher 
GFP1-10 expression can be achieved when cells transiently express this protein, 
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compared to the stable cell line (Figure 4-1). In previous experiments it was also 
shown that the fluorescent protein mCherry has no ability to complement GFP1-10 
that is transiently expressed in HeLa cells (3.2.2). This also held true when mCherry 
alone was expressed in SCL1 cells. Levels of GFP fluorescence were not higher than 
in mock transfected SCL1 cells (Figure 4-2 B).  
This data shows that M3 can complement with GFP1-10 expressed in the stable 
cell line SCL1 but to a lower degree as it can be achieved with transient transfection 
of GFP1-10 and mCherry-M3.  
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Figure 4-2 GFP complementation in SCL1 cells using transfection of mCherry-H6-Xa-
R8-M3. 
(A) Representative images of SCL1 cells transfected with mCherry-H6-Xa-R8-M3 or mock 
transfected. Cells were PFA fixed and imaged on a widefield microscope. Scale bar represent 
30 µm. n=3 (B) Hela cells (solid grey) or SCL1 cells (grey pattern) were transfected with the 
indicated DNA constructs coding for GFP1-10, mCherry-H6-Xa-R8-M3, mCherry or no DNA 
(Mock). Green fluorescence of ~ 0.8 x 105 live cells was detected in triplicates on a microplate 
reader. Background subtraction of mock transfected HeLa cells was performed. n=2. Error 
bars show SEM.  
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4.2.4 In vitro GFP complementation of M3 peptides with SCL1 cells 
Before a live cell assay could be performed on SCL1 cells, it was of importance 
to ensure that GFP1-10 expressed in the stable cell line is able to complement with 
the M3 and DDS-M3 peptides in vitro. The developed method in order to test this 
involved PFA fixation and Triton-X100 permeabilisation of the cells transiently 
expressing GFP1-10 followed by an incubation with 20 µM of the different peptides 
(3.2.4). However, it was shown in previous experiments that this method was not 
suitable when GFP1-10 was expressed in the cytosol (3.2.4). Hence, this method had 
to be improved in order to determine if GFP1-10, stably expressed in the cytosol of 
SCL1 cells can complement with the synthetic M3 peptides in vitro.  
An undergraduate student in our lab had investigated the improvement of this 
assay under my supervision and had found that M3 peptides will complement with 
GFP1-10 in the presence of 0.1 % Triton-X-100 leading to the development of an 
improved in vitro assay including cell lysates obtained by Triton-X-100 
permeabilisation of the plasma membrane. For the new in vitro assay, SCL1 cells 
stably expressing GFP1-10 were detached from the cell culture dish, cells were 
pelleted and resuspended in PBS containing 0.1% Triton-X-100 and left at room 
temperature for 4 min to allow permeabilisation of the plasma membrane. The 
obtained cell lysate containing GFP1-10 was then mixed in a 1:1 ratio with 80 µM or 
20 µM of M3 containing peptides in PBS (Table 3-1). Thus, the final mixture contained 
40 µM or 10 µM M3 containing peptide in a 0.05% Triton-X-100 in PBS solution and 
the GFP1-10 content of 0.8 X105 SCL1 cells. The SCL1 cell lysate and M3 peptide 
mix was transferred into a 96 well plate which was kept under constant agitation at 
4ºC and GFP complementation was monitored over time. The incubation temperature 
of 4ºC was chosen to avoid degradation of the proteins by proteases. 
When the SCL1 cell lysate was incubated with the different peptides, no GFP 
complementation was detected with 10 µM (Figure 4-3 A) or 40 µM (Figure 4-3 B) R8 
showing that the drug delivery system R8 by itself cannot replace the proton acceptor 
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located within the M3 peptide and rescue GFP fluorescence. A time dependent GFP 
complementation was seen when GFP1-10 lysate contained 10 µM or 40 µM M3, L-
M3 or R8-M3. When GFP1-10 lysate was incubated with 10 µM peptides, first 
appearance of green fluorescence can be seen after 60 minutes for M3 and R8-M3. 
In comparison, GFP complementation was detected as fast as 5 min after the start of 
incubation of GFP1-10 with 40 µM M3 containing peptides. The fluorescent intensity 
of GFP is similar between M3 and R8-M3 throughout the experiment at 10 µM and 
40 µM which suggest that M3 and R8-M3 complement with GFP1-10 at the same rate 
and they have the same ability for complementation in vitro. This is an important 
finding and an improvement to the ‘fix-and stain’ in vitro assay where GFP 
complementation of M3 could not be detected at the same rate and degree as it was 
seen for R8-M3 (Table 3-1).  Importantly, the detected fluorescence was lower 
throughout the time course of the experiment when 10 µM peptides were mixed with 
the cell lysate compared to 40 µM. This confirms that utilising this in vitro assay a 
dose response of GFP complementation with varying amounts of M3 peptide can be 
seen.   
Interestingly, when the cell lysate was incubated with the L-M3 peptide, 
fluorescence of GFP was increased at both concentrations and throughout the time 
course of the experiment compared to M3 and R8-M3. If fluorescence of 
complemented GFP was significantly different was tested at two time points; at the 
beginning of incubation after 2 hours and at the end of the incubation after 7 hours. It 
was found that there was no significant difference of GFP complementation between 
the M3 and the R8-M3 peptide. The fluorescence of L-M3 was found to be significantly 
different compared to either sample after 2 h (p<0.001) and 7 h (p<0.01). The 
significance was only determined between M3 containing peptides.  
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Figure 4-3 In vitro GFP complementation of SCL1 cell lysate with peptides. 
SCL1 cells expressing GFP1-10 were trypsinised and lysed using 0.1% Triton-X100 in PBS. Cell lysate of 0.8X105 cells was mixed with (A) 20 µM M3 and 
CPP-M3 peptides to obtain a final concentration of 10 µM in 0.05% Triton-X-100/PBS or (B) 80 µM M3 and CPP-M3 peptides to obtain a final concentration of 
40 µM in 0.05% Triton-X-100/PBS. Lysate mixture was left under constant agitation at 4 ºC. The fluorescent signal resulting from GFP complementation was 
minored over 24 h using a microplate reader. DMSO only control was subtracted as sample background. n=3. Error bars present standard error of the mean. 
For statistical analysis data was tested using a One way Annova followed by multiple comparison using a Turkey HSD (honest significant difference) test. 
Data was tested at two time points, 120min and 7h. Significance is shown compared M3 and R8-M3. *: p<0.05, **: p<0.01, ***: p<0.001, n.s.: not significant. 
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This increased fluorescence seen for the L-M3 peptide could be due to enhanced 
complementation of M3 with GFP1-10 achieved by the linker or an increased 
fluorescence of the peptide itself compared to other peptides.  
 
The autofluorescence of the L-M3 peptide was also noticed during microscopy 
experiments compared to DMSO or R8-M3 when peptides were applied to the cells 
at a concentration of 30 µM. Increased green fluorescence was mainly localised to 
between the cells, indicating that it was not green fluorescence derived from GFP 
complementation and suggesting that this fluorescence is an effect caused by the 
peptide itself (Figure 4-4 A I, IV). Quantification of the background fluorescence 
detected in the GFP channel in this experiment also suggested that the green 
background fluorescence could be increased when L-M3 was incubated on cells 
compared to DMSO or R8-M3 (Figure 4-4 B).  
Furthermore fluorescence derived from pure M3 containing peptides was 
investigated on a microplate reader. To compare the green autofluorescence of M3 
containing peptides utilised in the in vitro assay, peptides at a final concentration of 
40 µM and 10 µM diluted in 0.05% Triton-X-100/PBS were measured (Figure 4-4 C). 
Fluorescence of 10 µM peptide detected on the microplate reader did not show a 
difference between the fluorescence of the peptides themselves. When 40 µM of 
peptides were measured, fluorescence of the L-M3 peptide showed a low increased 
compared to other peptides. This data could indicate that the increased fluorescence 
of the L-M3 peptide could be due to the autofluorescence of the peptide itself rather 
than a different ability to complement with GFP in the in vitro assay, however this 
would need to be confirmed in further experiments.  
 
In summary, the in vitro system using cell lysate is a major improvement to the 
characterisation of the split GFP assay. GFP complementation can be measured in a 
time and concentration dependent manner and this method also allows direct 
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comparison of the ability to complement with GFP between M3 and DDS-M3 
peptides. It was shown that M3 and R8-M3 have the same complementation 
dynamics with GFP1-10 in vitro. Hence, addition of the DDS R8 does not interfere 
with GFP complementation. Moreover, R8 by itself cannot rescue GFP fluorescence.   
 
 
Figure 4-4 Autofluorescent background of the L-M3 peptide.  
SCL1 cells were incubated with 30 µM L-M3, R8-M3 or DMSO for 2h at 37ºC. (A) 
Representative images of fluorescent background in the different conditions. GFP channel 
was converted into a Fire table. Scale bar: 10 µm. (B) Quantification of green fluorescent 
intensity of background located between single cells. N=1, 3 images analysed per condition 
with 4 background measurements each. Error bar shows standard deviation of the mean 
between 3 images of the same condition. (C) M3 and CPP-M3 peptides were diluted in 0.05% 
Triton-X-100/PBS to a final concentration of 40 µM and 10µM. Green fluorescence of the 
peptides was monitored using a microplate reader. n=2. Error bars present standard deviation 
of the mean.  
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4.2.5 Live cell assay investigating functional delivery of M3 into SCL1 
Next, it was tested if SCL1 cells can be used to show the delivery of M3 peptide 
into the cytosol. To investigate this, a live cell assay was performed where 30 µM L-
M3, R8-M3 or DMSO was incubated with SCL1 cells for 2 hours, and cells were then 
analysed with a widefield microscope. No GFP complementation was detected when 
SCL1 cells were incubated with DMSO cells at 30 µM (Figure 4-5 C) or L-M3 (Figure 
4-5 G). For cells incubated with 30 µM R8-M3, the M3 peptide was functionally 
delivered into the cytosol and complemented with GFP1-10 to form full length GFP 
(Figure 4-5K). Complemented GFP was again mainly localised in the cytosol and 
excluded from the nucleus (Figure 4-5K).  
Interestingly, even though it was shown that cells of the SCL1 cell line expresses 
similar amounts of GFP1-10 in their cytosol, GFP fluorescence was not detected in 
every cell (Figure 4-5K). This means that M3 was delivered functionally in some cells 
but not in every cell, indicating there might be another cellular mechanism involved 
that determines functional delivery into cells.  
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Figure 4-5 Live split GFP assay using SCL1 cells. 
SCL1 cells were washed once in serum free media and incubated with L-M3, R8-M3 or DMSO 
at 30 µM for 2h at 37ºC. Cells were washed with phenol red free RPMI and counterstained 
with Hoechst nuclear dye. Live cells were images at 37˚C and 5% CO2 in phenol red free 
RPMI. Representative images are shown for each condition. n=3. Scale bar: 10 µm.  
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4.2.6 Visualisation of real time delivery of M3 into SCL1 cells  
In order to confirm that SCL1 cells can be utilised to explore real time delivery of 
the M3 peptide into the cytosol, GFP complementation was investigated over time 
when 40 µM R8-M3 peptide was applied on the cells in serum free and phenol red 
free RPMI. GFP complementation was investigated every two minutes using a 
fluorescent widefield microscope.  Cells were first imaged 10 minutes after R8-M3 
was incubated with the cells which when, surprisingly, GFP complementation had 
already taken place (Movie Figure 4-6). Increasing GFP fluorescence was clearly 
observed over 128 min and can be seen in single images extracted from the movie 
at time point 2 – 128 min (Figure 4-7 A). To investigate the increase in GFP 
fluorescence in one area of the cell, a region of interest (ROI) was selected (Figure 
4-7 A white square). The increase of GFP fluorescence within this ROI over time is 
shown in Figure 4-7 B. M3 delivery and GFP complementation in this ROI mainly 
occurred within the first 20 min when the curve shows a rapid increase in 
fluorescence. This is followed by a decrease in fluorescence because the RIO was 
located closely to the nucleus and due to cell movement the fluorescence within the 
nucleus was detected which was lower compared to the cytosol. Overall, the 
fluorescence in the cytosol only increased slightly after 20 min and maintained this 
fluorescence until the end of the movie.  
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Figure 4-6 Movie of real time delivery of M3 using SCL1 cells 
SCL1 cells were washed once in serum free media which was replaced with serum free and 
phenol red free RPMI containing R8-M3 peptide at 40 µM. GFP complementation was 
monitored every two minutes for 128 min. Scale bar: 20µm. 
Video is available at https://youtu.be/YDNJjmhePIE   
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Figure 4-7 Real time delivery of M3 using SCL1 cells 
SCL1 cells were washed once in serum free media which was replaced with serum free and 
phenol red free RPMI containing R8-M3 peptide at 40 µM. GFP complementation was 
monitored every two minutes for 128 min. (A) Single images from movie shown, captured at 
2 min, 14 min, 28 min, 46 min, 92 min and 128 min. White square is RIO. Scale bar: 20µm. 
(B) RFU of GFP fluorescence shown over time at ROI.  Black lines indicate time points of 
images shown in (A). Data from a single cell from one experiment shown.  
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4.2.7 Autofluorescence of SCL1 cells 
During microscopy experiments it was noticed that untreated SCL1 cells exhibit 
green fluorescence above that of control cells when excited with 488 nm wavelength 
light. In order to fully characterise the SCL1 cell line, this fluorescence was 
investigated further. Figure 4-8 shows a comparison of green fluorescence found in 
mock transfected Hela cells, cells transiently expressing GFP1-10 and SCL1 cells. 
Mock transfected HeLa cells show a faint green fluorescence localised around the 
nucleus in the cell (Figure 4-8 A I). SCL1 cells show increased green fluorescence in 
the cytosol and the nucleus (Figure 4-8 A V). The population of cells transiently 
expressing GFP1-10 is mixed with cells that have a faint fluorescence around the 
nucleus which is similar to the fluorescence detected in mock transfected HeLa cells 
(marked with a star) and cells where green fluorescence is increased like in SCL1 
cells (marked with an arrow) (Figure 4-8 A III). When microscopy images of three 
independent experiments are quantified it can be clearly seen that the green 
fluorescence in mock transfected HeLa cells is consistently low in HeLa cells (Figure 
4-8 B). SCL1 cells have an increased fluorescence but fluorescence can vary by 5 
fold within the cell population. Cells transiently expressing GFP1-10 have single cells 
with fluorescence as low as mock transfected HeLa cells as well as cells with a high 
range of green fluorescent levels like SCL1 cells. Resulting from that, the mean green 
fluorescent intensity across the cell population is the highest in SCL1 cells, decreased 
for cells transiently expressing GFP1-10 and the lowest for mock transfected HeLa 
cells (Figure 4-8 C). Furthermore, the green fluorescence was significantly different 
(p<0.001) in cells transiently expressing GFP1-10 as well as SCL1 cells compared to 
HeLa cells. HeLa cells are known to contain natural components that exhibit green 
autofluorescence. However, because the increased green fluorescence in live cells 
appears in addition to the expression of GFP1-10 in SCL1 or cells transiently 
expressing GFP1-10, it was hypothesised that this fluorescence might not be 
increased autofluorescence of the cell but actual GFP fluorescence.  
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Figure 4-8 Green fluorescence in untreated cells. 
Green fluorescence was detected in Mock transfected Hela cells, HeLa cells transiently 
expressing GFP1-10 and SCL1 cells. To ensure sufficient signal from the faint fluorescence, 
exposure time was set to 5.0 sec. (A) Representative images for each condition. Cells with 
high green fluorescence marked with arrow, cells with low green fluorescence marked with 
star. Scale bar: 10 µm. (B) Quantification of the corrected total cell fluorescence in single cells. 
(C) Mean fluorescent intensity of green fluorescence. 10-16 cells quantified per condition per 
experiment. For statistical analysis data was tested using a Kruskal-Wallis test. Significance 
of is shown compared to HeLa Mock. *: p<0.05, **: p<0.01, ***: p<0.001, n.s.: not significant. 
Error bar: standard error of the mean. n=3.  Two of three experiments performed by Alexander 
Dudziak under my supervision.  
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In order to explore if the green fluorescence detected is originated from GFP 
fluorescence or autofluorescence, mock transfected cells, cells transiently expressing 
GFP1-10 and SCL1 cells were further analysed using spectral detection on a confocal 
microscope in a single experiment. This technique allows the detailed analysis of 
emission spectra that were collected from a sample excited with a 488 nm wavelength 
laser. The emission spectrum is divided regarding its wavelength between 496 nm 
and 682 nm wavelength light and collected on different detectors. This spectrum can 
then be analysed regarding the intensity of fluorescence collected on each detector. 
Figure 4-9 A shows examples images of each condition and the ROI selected in those 
cells. To obtain a positive control of the emission spectrum of EGFP, data from cells 
expressing EGFP was collected (no image shown). When the EGFP spectrum was 
analysed a peak was detected at 513 nm wavelength light (Figure 4-9 B black curve). 
In comparison, the green autofluorescence in mock transfected HeLa cells peaked at 
539 nm wavelength light. This peak can be shown clearer when data is normalised 
so that the peak value of each spectrum is set to the value 1 (Figure 4-9 C grey curve).  
This result suggests that the green fluorescence derived from EGFP expression or 
autofluorescence of HeLa cells could be differentiated by the peak of their emission 
spectrum at 513 nm and 539 nm wavelength light, respectively when using the 
spectral detection method.  
In comparison to these emission spectra, cells transiently expressing GFP1-10 
were analysed. It was shown before that cells transiently expressing GFP1-10 consist 
of a divided cell population with cells showing low fluorescence like mock transfected 
HeLa cells and cells with higher fluorescence. When the emission spectrum of cells 
with low fluorescence was analysed, it peaked at 539 nm wavelength light (Figure 4-9 
B, C orange curve). This aligns with the wavelength of light which was suggested to 
describe the autofluorescence in HeLa cells and could therefore be derived from the 
autofluorescence of these cells. 
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The emission spectrum of cells with high green fluorescence peaked at 513 nm 
wavelength light (Figure 4-9 B, C purple curve) which was suggested describe the 
wavelength of the emission peak for cells expressing EGFP. This could imply that the 
fluorescence of cells found with high green fluorescence is derived from GFP1-10 
expression. 
The same is suggested for the green fluorescence detected in SCL1 cells as the 
emission spectrum showed a peak at 513 nm aligning with the suggested EGFP 
emission spectrum (Figure 4-9 B, C blue curve). The fluorescent spectrum of cells 
transiently expressing GFP1-10 containing high green fluorescence as well as SCL1 
could be a superposition of the spectra obtained when cells are expressing EGFP or 
autofluorescent control cells. This can be seen in more detail in Figure 4-9 B where 
the peaks of the emission spectra align with the emission spectrum of EGFP at 513 
nm and an addition small peak can be seen at 539 nm and the shape of the emission 
spectrum curve is more similar to shape of the spectrum obtained for mock 
transfected control cells.  
This data suggests that the green fluorescence seen in live SCL1 cells or cells 
transiently expressing GFP1-10 is derived from both, autofluorescence as well as 
GFP fluorescence derived from GFP1-10 expression.   
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Figure 4-9 Spectral analysis of 
green fluorescence in SCL1 
cells.  
HeLa cells or SCL1 cells were 
grown on coverslips. HeLa cells 
were mock transfected or 
transfected with the plasmid 
coding for GFP1-10 or EGFP 
expression. (A) Example images 
of green fluorescence found in 
HeLa cells (I), GFP1-10 
expressing HeLa cells (II) or 
SCL1 cells (III) no image for 
EGFP expression shown. ROI 
marked with coloured square. 
Scale bar: 10 µM. Images taken 
on a widefield microscope. (B) 
Spectral analysis of ROI on a 
confocal microscope. 
Untransfected HeLa cells (grey), 
HeLa cells expressing EGFP 
(black), HeLa cells expressing 
GFP1-10 with low fluorescence 
(orange), HeLa cells expressing 
GFP1-10 with high fluorescence 
(purple) and SCL1 cells (blue). 
Colours correspond to ROIs 
shown in (A). The data displayed 
is was collected and analysed by 
Alexander Dudziak under my 
supervision. n=1  
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4.3 Characterisation of mCherry-GFP1-10 expression 
The main concern of a split GFP system where cells transiently express GFP1-
10 was that expression levels between single cells vary.  Hence it is difficult to 
determine if lack of GFP complementation is due to failure to deliver the M3 peptide 
or cells were not expressing the GFP1-10 target protein.  
A first improvement was to create a stable cell line that expresses even amounts 
of GFP1-10 across the cell population (see 4.2). It was hypothesised that a second 
method to improve the split GFP assay is to introduce the fluorescent expression 
partner mCherry to express mCherry-GFP1-10. This fluorescently labels the 
presence of GFP1-10 expression and allows correlation of mCherry fluorescence with 
GFP1-10 expression levels in a live experiment.  In order to pursue this strategy, two 
new expression constructs were generated: pcDNA3.1mCherry-GFP1-10 which 
codes for cytosolic mCherry-GFP1-10 expression and pcDNA3.1mCherry-GFP which 
served as a control construct coding for cytosolic mCherry-EGFP expression (see 
2.11.6, 2.11.7). The generated mCherry-GFP1-10 expression construct was first 
tested regarding its expression in HeLa cells as well as its ability to complement with 
M3 using DNA co-expression and in vitro complementation with synthetic M3 
peptides.  
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4.3.1 Immunofluorescent staining of cells expressing mCherry-GFP1-10  
Immunofluorescent staining using an anti GFP antibody revealed that mCherry-
GFP1-10 can be expressed in the cytosol of HeLa cells. GFP1-10 is non-fluorescent 
(Figure 4-10 H) while mCherry fluorescence serves as a marker of its expression and 
co-localises with the anti GFP staining detected by the antibody (Figure 4-10 I, J). 
Expression of full length mCherry-EGFP showed that the pattern of EGFP expression 
colocalised with mCherry expression and the anti-GFP staining.  
Due to the structural similarity of the fluorescent proteins mCherry and GFP it 
was further tested that the anti GFP antibody would not cross react to detect mCherry 
expression. It was seen that fluorescence was detected in the Alexa647 channel on 
the microscope (Anti GFP) only when cells expressed high amounts of mCherry 
(Figure 4-10 O). This fluorescence could be due to cross reaction of the antibody or 
an effect of bleed through from mCherry which was excited with the excitation 
wavelength used in the Alexa647 channel. In order to fully investigate this, the bleed 
through into the Alexa647 channel of cells expressing mCherry but not treated with 
antibodies has to be investigated.  
However the fluorescence seen in the Alexa647 channel for cells expressing 
mCherry is weak compared to the fluorescence seen when mCherry-EGFP and 
mCherry-GFP1-10 were expressed in the cytosol (Figure 4-10 E, J). Thus, the 
majority of the anti GFP antibody staining was still specific to EGFP or GFP1-10 
expression.  
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Figure 4-10 Detection of mCherry-GFP1-10 expression in HeLa cells using 
immunofluorescence.  
HeLa cells were transiently transfected with DNA constructs coding for mCherry-GFP1-10 or 
full length mCherry-EGFP. The transfection mix of mock transfected cells did not contain DNA. 
Cells were incubated in transfection mix overnight and PFA fixed the next day. The plasma 
membrane was permeabilised with 0.1 % Triton-X-100 and GFP or GFP1-10 expression was 
detected using a primary anti-GFP antibody raised in goat. A secondary anti-goat antibody 
conjugated to Alexa-647 was used to visualise GFP expression. Nuclei were counterstained 
with DAPI.  Representative images shown for each condition. Scale bars: 30 µm. n=3, 
mCherry n=2.  
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4.3.2 GFP complementation using co-expression of GFP fragments 
Next, GFP complementation of M3 with mCherry-GFP1-10 was investigated 
using co-transfection of DNA coding for mCherry-H6-Xa-R8-M3 and mCherry-GFP1-
10. GFP complementation was detected using a microscope (Figure 4-11 A).  
Complementation only occurred when both split GFP fragments were co-expressed 
inside the cell (Figure 4-11 XII); no GFP fluorescence was detected when the single 
fragments were expressed alone (Figure 4-11 III, VII). Furthermore, the localisation 
of complemented GFP was found in the cytosol and localised at the nucleolus (Figure 
4-11 XII).   
Detection of GFP complementation was also confirmed using detection of green 
fluorescence in trypsinsed cells on the microplate reader (Figure 4-11 B). Single split 
GFP fragments did not fluoresce in green; when both fragments were co-expressed, 
GFP complementation occurred and was detected as GFP fluorescence that was 
significantly different (p<0.001) from when single GFP fragments were expressed in 
in HeLa cells. 
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Figure 4-11 Co-transfection of GFP1-10 and mCherry-H6-Xa-R8-M3.  
Transfections or co-transfections of HeLa cells were performed with DNA encoding for split 
GFP fragments. The transfection mix of mock transfected cells did not contain DNA. (A) Cells 
were left in transfection mix overnight and PFA fixed on the next day. Nuclei were 
counterstained with DAPI. Representative images for each condition shown. Scale bars: 10 
µm. N=1. (B) Detection of co-expression on a microplate reader. RFU=Relative Fluorescent 
Units. Fluorescent background of mock transfected cells was subtracted from sample values. 
For statistical analysis data was tested using a One way Annova followed by multiple 
comparison using a Turkey HSD (honest significant difference) test. Significance is shown 
compared to mCherry-GFP1-10 and mCherry-H6-Xa-R8-M3. *: p<0.05, **: p<0.01, ***: 
p<0.001, n.s.: not significant. Error bars present standard error of the mean. n=3.  
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4.3.3 In vitro complementation of M3 peptides with transient mCherry-GFP1-
10  
It was also investigated in a single experiment if cell lysate containing mCherry-
GFP1-10 was able to complement with synthetic M3 peptides in vitro at 40 µM (Figure 
4-12 A) using the improved in vitro assay. In vitro complementation of cell lysate 
derived from cells transiently expressing mCherry-GFP1-10 with M3 containing 
peptides was monitored for 2 hours. The data suggests that lysate of mCherry-GFP1-
10 complemented with M3, L-M3 and R8-M3 resulting in GFP fluorescence that 
increased 2-3 fold between 15 min to 2 hours. The green fluorescence of L-M3 was 
slightly increased as it was shown in previous experiments. Interestingly, R8 itself 
shows a slight increase in GFP fluorescence over 2 hours. However, it was shown 
before that R8 itself cannot complement with GFP1-10 which suggests that this 
increase could be due to fluctuations of the measurements on the plate reader.   
It is further shown on microscopy images that cell lysate incubated with R8 did 
not fluoresce in green (Figure 4-12 B) which could support the suggestion that the 
measured fluorescence on the microplate reader is due to plate reader variability. 
Microscopy images further show that all samples contained cell lysate of 
mCherry-GFP1-10 indicated by its red fluorescence (Figure 4-12 B II, V, VIII, XII, XIV). 
However, GFP complementation only occurred when the cell lysate was incubated 
with M3 containing peptides L-M3, M3 and R8-M3 (Figure 4-12 B XI, XII, XV). No 
complementation was detected with the microscope when DMSO or R8 were 
incubated with the lysate (Figure 4-12 B III, VI). Interestingly, the cell lysate mixture 
looked like a homogenous solution when incubated with M3 and L-M3 but contained 
particles when incubated with R8-M3 (Figure 4-12 XV).  
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Figure 4-12 In vitro GFP complementation of transient mCherry-GFP1-10 cell lysate 
with peptides. 
HeLa cells expressing mCherry-GFP1-10 were trypsinised and lysed using 0.1% Triton-X100 
in PBS. Cell lysate of 0.8X105 cells was mixed with 80 µM M3 and CPP-M3 peptides to obtain 
a final concentration of 40 µM in 0.05% Triton-X-100/PBS. Lysate mixture was left under 
constant agitation at 4 ºC. (A) The fluorescent signal resulting from GFP complementation 
was monitored over 2 h using a microplate reader. DMSO only control was subtracted as 
sample background. (B) Microscopy images of cell lysates after two hours of incubation. Left 
edge of well was taken as a reference point in each well to image the same focal plane 
between conditions. Scale bar: 150 µM. n=1.  
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4.3.4 Live delivery of M3 by R8 to the cytosol of cells transiently expressing 
mCherry-GFP1-10  
Next M3 delivery by R8 was tested in cells transiently expressing mCherry-
GFP1-10. When DMSO and M3 at 20 µM were incubated with the cells, no GFP 
complementation was detectable after 2h (Figure 4-13 C, G). However, weak green 
fluorescence in cells was seen in both samples, the DMSO control as well in the cells 
incubated with M3. This weak fluorescence has been detected before when GFP1-
10 was expressed in cells which could suggest that the weak fluorescence is derived 
from mCherry-GFP1-10 expression. An observation that could confirm this 
hypothesis is that only cells that were expressing mCherry-GFP1-10 (Figure 4-13 D, 
H) showed this weak fluorescence in the green channel.  
Because this fluorescence was found in DMSO control cells it is suggested that 
it cannot derive from GFP complementation with the M3 peptide. Green fluorescence 
was also found previously in cells expressing GFP1-10, hence it is possible that this 
GFP fluorescence is also present when cells transiently express mCherry-GFP1-10. 
When 20 µM R8-M3 were incubated with cells transiently expressing mCherry-GFP1-
10 for 2 h, GFP fluorescence is detectable in one cell and suggests that R8 mediated 
M3 delivery may have occurred in that cell (Figure 4-13 K). It can also be seen that 
GFP complementation occurred in cells expressing mCherry-GFP1-10 (Figure 4-13 
L, K).  
 
Taken together, this data presented suggests that cells transiently expressing 
mCherry-GFP1-10 could also be utilised to investigate M3 delivery by the DDS R8. 
mCherry can serve as an expression marker for GFP1-10 expression that enables us 
to track which cell expresses GFP1-10 and how much is expressed. This is an 
improvement to the assay and allows transient expression of mCherry-GFP1-10. 
However, it was seen that R8-M3 does not deliver M3 evenly across the cell 
population when it was incubated with the stable cell line SCL1 and another 
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mechanism was proposed to determine in which cells M3 cargo delivery is successful.  
Thus, utilising an assay where mCherry-GFP1-10 is expressed transiently will result 
in a diverse cell population where some cells do not express the protein at all. In order 
to be able to investigate the underlying mechanism of heterogeneous delivery across 
a cell population in the future, it is necessary to have a homogenous population of 
cells. Thus, a stable cell line was generated to express mCherry-GFP1-10. Another 
advantage to create a stable cell line was that experimental conditions are constant 
between experiments and not affected by transfection efficiency.  
 
 
 
 
Figure 4-13 Delivery of M3 by R8 and GFP complementation in live cells transiently 
expressing mCherry-GFP1-10.  
Cells transiently expressing mCherry-GFP1-10 were washed once in serum free media and 
incubated with DMSO, M3 or R8-M3 at 20µM in serum free media for 2 hours at 37˚C. Cells 
were washed with phenol red free RPMI and counterstained with Hoechst nuclear dye. Live 
cells were images at 37˚C and 5% CO2 in phenol red free RPMI. Representative images 
shown for each condition. n=1. Scale bar: 10µm.  
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4.4 Generation of mCherry-SCL51 
In order to generate a stable cell line that expresses mCherry-GFP1-10, HeLa 
cells were transfected with one DNA plasmid coding for mCherry-GFP1-10 and 
neomycin resistance. Thus, cells that had stably integrated this expression construct 
into their genome were selected using selection media containing 400 mg/mL 
Geneticin (G418). To obtain a clonal cell line, limiting dilution was performed (for 
detailed stable cell line generation see 2.8). mCherry as an expression marker for 
GFP1-10 had the great advantage that colonies could be screen by live microscopy. 
Single colonies were screened to obtain colonies with high and even fluorescent 
expression levels of mCherry-GFP1-10 throughout the cell population. In the first 
round of screening, mCherry-GFP1-10 expression was determined by mCherry 
fluorescence of live cells. In total 864 wells were screened using limiting dilution, 38 
wells contained cells that showed mCherry fluorescence. From these cells the most 
promising cell colony with highest mCherry-GFP1-10 expression levels was mCherry 
Split Cell Line 34 (mCherry-SCL34). However, mCherry-SCL34 was a polyclonal cell 
line with a high number of cells not expressing mCherry-GFP1-10 at all (Appendix 
9.4, Figure 9-6). For this reason, this cell line was expanded and another round of 
limiting dilution was performed. 96 cell colonies were screened in the second round 
of limiting dilution and 17 more colonies of cells were obtained. Of these cell lines the 
cell line which expressed highest amounts of mCherry-GFP1-10 and showed most 
even expression levels across the cell population was named mCherry Split Cell Line 
51 (mCherrySCL51) and underwent detailed characterisation using techniques 
developed previously to ensure stable expression of mCherryGFP-10 while retaining 
compatibility of reassembly with M3.  
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4.4.1 Immunofluorescent staining of mCherry-SCL51 
Immunofluorescent staining against GFP was performed to confirm that not only 
mcherry is expressed evenly across the cell population but also GFP1-10 as a fusion 
to mCherry. Staining against GFP revealed that the obtained cell line mCherry-SCL51 
expressed even levels of mCherry-GFP1-10 compared to cells transiently expressing 
mCherry-GFP1-10 where expression levels vary highly between cells (Figure 4-14 A 
VI, XII). However, despite two rounds of limiting dilution in order to obtain a clonal cell 
line where every cell expresses mCherry-GFP1-10, the cell population of mCherry-
SCL51 was not clonal and cells either expressed the same amount of mCherry-GFP1-
10 or did not express the protein at all (Figure 4-14 A, XII).  This finding was confirmed 
by quantification of the anti GFP stain of microscopy images (Figure 4-14 B). Mock 
transfected cells displayed a very low anti GFP staining. When mCherry-GFP1-10 
was transiently expressed in HeLa cells, anti GFP staining ranged by 100 fold 
between the cells with cells not expressing the protein at all or cells highly expressing 
the protein. The quantification of the anti GFP staining for the mCherry-SCL51 cell 
line confirms that this cell line is split into two populations: cells not expressing 
mCherry-GFP1-10 showing the same fluorescent values as mock transfected cells 
and cells expressing mCherry-GFP1-10 in their cytosol with values located in the 
medium expression range of cells transiently expressing the protein. Calculation of 
the coefficient of variation confirmed that the variation of expression levels of GFP1-
10 in single cells is reduced in the stable cell line mCherry-SCL51 (0.64) compared 
to cell transiently expressing mCherry-GFP1-10 (1.45) (Figure 4-14 C). Even though 
mCherry-SCL51 was found to be a polyclonal cell line containing cells not expressing 
mCherry-GFP1-10 at all, there was little difference of the coefficient of variation 
between mock transfected cells (0.56) and the stable cell line (0.64).       
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Figure 4-14  Comparison of mCherry-GFP1-10 expression levels of mCherry-SCL51 
cells and cells transiently expressing mCherry-GFP1-10 using immunofluorescence.  
HeLa cells transiently expressing mCherry-GFP1-10, mCherry-SCL51 cells or mock 
transfected cells were PFA fixed and the plasma membrane was permeabilised with 0.1 % 
Triton-X-100. GFP1-10 expression was detected using a primary anti-GFP antibody raised in 
goat. A secondary anti-goat antibody conjugated to Alexa-647 was used to be able to visualise 
GFP expression. Nuclei were counterstained with DAPI. (A) Representative images of the 
immunofluorescent stain. Grey levels displayed on fire table range from 38 to 4368. Scale 
bars represent 30 µm. (B) Quantification of the CTCF of the anti GFP staining. (C) Coefficient 
of variation was calculated by dividing the standard deviation of the CTCF of all data points 
by the value of the mean CTCF. Error bars show SEM between experiments. 72 to 85 cells 
were analysed per condition per experiment. n=3.   
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4.4.2 Correlation of mCherry fluorescence and GFP1-10 expression 
In order to use mCherry as a fluorescent expression marker for GFP1-10 
expression it was next observed if there if the mCherry fluorescence can be correlated 
with the fluorescence obtained from the immunofluorescent staining against GFP1-
10. For this reason the corrected total cell fluorescence (CTCF) of mCherry was 
determined in the same cells where the CTCF of the anti GFP stain was detected 
(Figure 4-15 A, B). When comparing the fluorescence of the antibody stain (Figure 
4-15 A) with the mCherry fluorescence (Figure 4-15 B), it can be seen that the 
distribution of the single data points correlate. There is a high variation of mCherry 
and anti GFP fluorescence for cells transiently expressing mCherry-GFP1-10 and a 
divided cell population of mCherry-SCL51 cells, expressing even amounts of 
mCherryGFP1-10 or non-expressing cells with low values as low as mock transfected 
cells.  These observations confirm that mCherry-SCL51 is a polyclonal cell line but 
cells expressing mCherry-GFP1-10 express similar amounts that are in the medium 
range of the expression that can be achieved using transient transfection. 
Furthermore, it is shown that the fluorescence of the antibody stain detecting GFP1-
10 expression and mCherry fluorescence comparable when the same cells are 
measured suggesting that mCherry fluorescence can be correlated with GFP1-10 
expression.  
Next it was tested if mCherry fluorescence can be correlated with GFP1-10 
expression in mCherry-SCL51 cells. Figure 4-15 C shows a graph correlation the 
mean fluorescence of mCherry of a single cell with the mean fluorescence of the anti 
GFP stain measured in the same cell representing GFP1-10 expression. A correlation 
coefficient of 0.79 was found which presents a correlation between mCherry 
fluorescence and anti GFP staining. The variation of data leading to a 0.79 correlation 
could have been due to the antibody detection of the GFP1-10 expression and the 
variability of antibody staining of GFP1-10 between single cells.   
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Figure 4-15 Correlation of GFP1-10 and mCherry expression 
(A) Quantification of the CTCF of the anti GFP staining (B) Quantification of the CTCF of 
mCherry fluorescence. Single data point represent the fluorescence in the cytosol of single 
cells. Fluorescent intensities were measured within the same cells. Error bars show standard 
error of the mean between experiments. (C) Correlation of mean fluorescence of mCherry and 
anti-GFP staining in Mcherry-SCL51 cells. Fluorescence was measured within the same cell. 
72 to 85 cells were analysed per condition per experiment. n=3.   
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4.4.3 Co-expression of mCherry-H6-Xa-R8-M3 in mCherry-SCL51  
Next GFP complementation was tested using expression of the small split GFP 
fragment, mCherry-H6-Xa-R8-M3 in the stable cell line. When fluorescence of 
transfected cells was investigated using a microplate reader, it was seen that GFP 
complementation occured when mCherry-GFP1-10 and mCherry-H6-Xa-R8-M3 are 
co-expressed in the cytosol of HeLa cells (Figure 4-16). This fluorescence was 
significantly defferent compared to the fluorescence that was detected when single 
GFP fragments were expressed alone. When mCherry-H6-Xa-R8-M3 was expressed 
in the stable cell line mCherry-SCL51, GFP complementation occurred showing that 
the stable cell line expressing mCherry-GFP1-10 is abe to complement with the M3 
fragment encoded in mCherry-H6-Xa-R8-M3. Importantly, this fluorescence was 
significantly different compared to fluorescence detected when mCherry was 
expressed in the stable cell line or when cell were mock transfected. This means 
expression of mCherry alone did not rescue GFP fluorescence confirming that 
mCherry does not have the ability to complement with GFP1-10 to form full length 
GFP. Fluorescence seen when mCherry was transfected into mCheryy-SCL51 was 
equal to the fluorescence on mock transfected cells.  
It can also be seen that GFP fluorescence resulting from complementation with 
mCherry-H6-Xa-R8-M3 was five times lower in the stable cell line then in cells 
transiently expressing both split GFP fragements. This could have been due to one 
part of the cell population not expressing mCherry-GFP1-10 at all as well as lower 
expression levels of mCherry-GFP1-10 of the remaining cells compared to cells 
transiently expressing mCherry GFP1-10.  
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Figure 4-16 GFP complementation in mCherry-SCL51 cells using transfection of 
mCherry-H6-Xa-R8-M3. 
HeLa cells (solid grey) or mCherry-SCL51 cells (striped) were transfected with DNA coding 
for with single or both split GFP fragments. Green fluorescence derived from GFP 
complementation was detected on a microplate reader. Value of mock transfected HeLa was 
subtracted to correct for background fluorescence. For statistical analysis data was tested 
using a One way Annova followed by multiple comparison using a Turkey HSD (honest 
significant difference) test. *: p<0.05, **: p<0.01, ***: p<0.001, n.s.: not significant. Error bars 
present standard error of the mean. n=3.  
 
 
4.4.4 In vitro GFP complementation of M3 peptides with mCherry-SCL51 
Next mCherry-SCL51 was tested regarding its ability to complement with 
synthetic M3 peptides in vitro. It was also of interest if the in vitro assay using cell 
lysate could be further improved by allowing GFP complementation at room 
temperature compared to 4°C. For this reason cell lysate of mCherry-SCL51 was 
incubated with M3 containing peptides in 0.05%Triton-X-100/PBS at a final 
concentration of 40 µM. Then the same cell lysate-peptide mix was incubated at either 
4°C (Figure 4-17 A) or room temperature (Figure 4-17  B) under constant agitation, 
and GFP fluorescence was monitored on a microplate reader over 7h. In both 
samples R8 itself did not rescue GFP fluorescence. Moreover, the green fluorescence 
of lysate incubated with L-M3 was increased in samples incubated at 4°C as well as 
at room temperature throughout the experiment, as found earlier. Furthermore, the 
data from this single experiment suggested that GFP complementation was faster at 
room temperature compared to 4°C. This could be due to the increased motion of the 
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GFP fragments in solution which results in an increased rate of fragments 
complementing. When incubated at 4°C (Figure 4-17 A) green fluorescent levels 
reached 2100 and 1600 RFU after 5 min of incubation with M3 and R-M3, 
respectively. Green fluorescence peaked after 5 hours when GFP levels had reached 
8600 RFU for M3 and 6900 RFU for R8-M3. Over the next two hours there was a 
slight decrease detected which resulted in 5800 RFU for M3 and 5700 RFU for R8-
M3 after 7 h. Compared to that, GFP complementation constantly increased over time 
when the cell lysate was incubated with the peptides at room temperature (Figure 
4-17 B). After 5 min green fluorescence was comparable with samples that were 
incubated at 4°C with 2500 RFU of M3 of and 1200 RFU for R8-M3. However, due to 
preparation of the samples at room temperature, samples had not been incubated at 
4°C at that time. GFP fluorescence increase to 28,000 RFU for R8-M3 and M3 after 
7 h which is a 10 fold increase compared to the fluorescence measured after 5 min. 
The increase of fluorescence of samples incubated at 4°C was only 3 fold. The data 
from this single experiment suggested that GFP complementation occurs faster, and 
time dependent complementation was more consistent at room temperature. Hence, 
in vitro complementation of peptides was continued to be investigated at room 
temperature in further experiments (Figure 4-17 C). The data from three independent 
in vitro experiments performed at room temperature confirmed that GFP 
complementation increased constantly over time and complementation only occurred 
when the M3 peptide was present.  
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Figure 4-17 In vitro GFP 
complementation of mCherry-
SCL51 cell lysate with M3 
peptides. 
mCherry-SCL51 cells were 
trypsinised and lysed using 0.1% 
Triton-X100 in PBS. Cell lysate of 
0.8X105 cells was mixed with 80 µM 
M3 and CPP-M3 peptides to obtain 
a final concentration of 40 µM in 
0.05% Triton-X-100/PBS. GFP 
complementation was monitored 
over 7 h using microplate reader. 
(A) GFP complementation at 4ºC. 
(B) The same samples were 
incubated at room temperature. 
n=1. (C) GFP complementation at 
room temperature. DMSO only 
control was subtracted as sample 
background. n=3. Error bars 
present standard error of the mean. 
For statistical analysis data was 
tested using a One way Annova 
followed by multiple comparison 
using a Turkey HSD (honest 
significant difference) test. Data 
was tested at two time points, 
120min and 7h. No significant 
differences were detected between 
M3 containing peptides at time 
points 2h and 7h. n.s.: not 
significant.  
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4.4.5 Live cell assay mCherry-SCL51 
Finally, it was investigated if M3 delivery by the DDS R8 can be monitored using 
the mCherry-SCL51 cell line. When DMSO and M3 were incubated with the cells at 
40 µM, a high green fluorescent background in all cells was detected in the cytosol 
with a higher fluorescence in the nucleus (Figure 4-18 C, G). Incubation of 40 µM R8-
M3 with mCherry-SCL51 resulted in clear GFP complementation in the cytosol of one 
cell in the field of view, other cells showed the same amount of fluorescent 
background like cells incubated with DMSO and M3 (Figure 4-18 K). This experiment 
suggests R8 dependent delivery at 40 µM as well as a heterogeneous M3 delivery 
across the cell population where every cell was expressing the mCherry-GFP1-10 
target but GFP complementation was only successful in one cell. Furthermore, 
complemented GFP was localised in the cytosol, no GFP fluorescence was detected 
in the nucleus (Figure 4-18 K).  
 
Figure 4-18 Live delivery of M3 into mCherry-SCL51 cells. 
mCherry-SCL51 cells were washed once in serum free media and incubated with DMSO, L-
M3 or R8-M3 at 40µM in serum free media for 2 hours at 37˚C. Cells were washed with phenol 
red free RPMI and counterstained with Hoechst nuclear dye. Live cells were images at 37˚C 
and 5% CO2 in phenol red free RPMI. Representative images shown for each condition. n=1. 
Scale bar: 10µm.  
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4.4.6 Autofluorescence of mCherry-GFP1-10 
The high green fluorescence that was seen in the stable cell line during live cell 
experiments, was further investigated to examine if this fluorescence can be attributed 
to the expression of GFP1-10 within the mCherry-GFP1-10 expression construct. It 
was found that green fluorescence located in the nucleus and the cytosol of cells is 
present when mCherry-GFP1-10 is expressed transiently in HeLa cells (Figure 4-19 
C) as well as in the stable cell line mCherry-SCL51 (Figure 4-19 G). Mock transfected 
HeLa cells had a decreased green fluorescence and if fluorescence was found, it was 
localised in the perinuclear region (Figure 4-19 O). Cell transiently expressing 
mCherry also showed a decreased green fluorescence compare to the stable cell line 
or cells transiently expressing mCherry-GFP1-10 (Figure 4-19 K). For cells transiently 
expressing mCherry-GFP1-10 it was clearly visible that increased green fluorescence 
is only present in cells that express mCherry-GFP1-10, indicated by mCherry 
fluorescence (Figure 4-19 D). Compared to this no increase in green fluorescence 
can be seen in cells expressing mCherry transiently. The cell population of cells 
transiently expressing mCherry showed similar green fluorescence in the cytosol of 
cells (Figure 4-19 K) independent if they were expressing mCherry (Figure 4-19 L). 
Hence, the increased green fluorescence is not source of the mCherry fluorophore. 
This data suggests that increased green fluorescence is derived from GFP1-10 that 
is expressed as a fusion protein to mCherry. This green fluorescence was seen before 
when GFP1-10 was expressed in HeLa cells and spectral analysis suggested that 
this fluorescence is low GFP fluorescence. Hence, it is possible that this phenomenon 
is also present in cells expressing mCherry-GFP1-10 and this could be confirmed by 
spectral analysis of the emitted GFP fluorescence.  
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Figure 4-19 Autofluorescence in mCherry-SCL51 
Green fluorescence in live cells was detected in Mock transfected Hela cells, HeLa cells 
transiently expressing mCherry-GFP1-10 or mCherry, and mCherry-SCL51 cells. 
Representative images for each condition. Nuclei of live cells were counterstained with 
Hoechst nuclear dye. Scale bar: 10 µm. n=1. 
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4.5 Discussion  
In this Chapter it was shown that a stable cell line was successfully generated 
that expresses the large fragment of split GFP, GFP1-10, in the cytosol. The stably 
expressed protein was able to complement with the small fragment of GFP, M3, using 
co-expression and in vitro with chemically synthesised M3 peptides. Furthermore, an 
R8 dependent M3 delivery could be shown using this cell line.  
The second stable cell line that was generated is mCherry-SCL51 expressing 
mCherry-GFP1-10 in its cytosol. mCherry as an expression marker of GFP1-10 had 
the advantage of marking cells that express GFP1-10. In a transient transfection 
model, as well as in the stable cell line it was shown that mCherry can serve as a 
fluorescent expression marker of GFP1-10 without interfering with its ability to 
complement with M3 using co-expression, in vitro complementation or in a live cells 
assay to show R8 dependent, functional M3 delivery.  
While SCL1 expresses GFP1-10 evenly across its cell population, the generation 
of a clonal cell line that expresses even amounts of mCherry-GFP1-10 was not 
successful. The technique utilised to generate both cell lines was chosen to be limiting 
dilution where a cell line is aimed to be grown up from a single clone. This method 
was chosen to guarantee sterile culture conditions throughout the selection process. 
In order to further improve this cell line in the future to obtain a clonal cell line where 
cells express even amounts of mCherry, fluorescent activated cell sorting could be 
utilised where single cells can be separated according to their fluorescence.  
 
Up until this stage, the split GFP system to investigate functional delivery of the 
M3 peptide by DDSs was extensively characterised in transient as well as stable cell 
models. Moreover it was shown that these models allow a DDS dependent evaluation 
of M3 delivery.  
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In studies by other groups, split GFP systems were utilised with transient 
transfection of mCherry-GFP1-10 into HEK293T cells as well as stable cell lines 
expressing GFP1-10 (HeLa, CHO-K1 and HCC827). (Schmidt et al and Kim et al) or 
S11 ((Milech et al. 2015)). The amino acid sequence of GFP11 is consistent with the 
M3 sequence used in this study and as it was first designed by Cabantous et al. 
(Cabantous et al. 2005). The S11 sequence utilised by Milech et al consists of an 
additional Glycine residue at its N-terminus.   
The validation of split GFP complementation prior to live cell experiments in other 
studies was performed using co-transfection of the DNA of split GFP fragments (Kim 
et al. 2015; Milech et al. 2015). The split GFP assay of Milech et al included delivery 
of a cargo in addition to S11  (Milech et al. 2015).  
The same group used a flexible GSSG linker to connect the cargo with S11. They 
validated the optimal linker size between the cargo and S11 for complementation with 
GFP1-10 and found that the linker [GSSG]x4 showed best results. In comparison, in 
this study a linker is used consisting of the amino acid sequence GSGGGSTS which 
is half the length of [GSSG]x4. It would be interesting to investigate if GFP 
complementation can be increased when this linker size is increased in size. 
Compared to this, Schmidt et al., used a very short linker (GSTS) to connect R9 to 
the M3 sequence and Kim et al connected GFP11 via a linker consisting of [GGGS]x3 
to their cell penetrating antibody.   
 
Techniques to investigate GFP complementation of DDS-GFP11 peptides 
without the plasma membrane as a barrier included electroporation of live cells 
expressing GFP1-10 to induce M3 or DDS-GFP11 peptides followed by flow 
cytometry analysis of GFP complementation (Schmidt et al. 2015a). Using this 
technique, Schmidt et al were able to show a concentration dependent increase of 
GFP complementation with M3 after 2 h. In this chapter an improved in vitro method 
was introduced where M3 peptides can be mixed with cell lysate of cells expressing 
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GFP1-10 and GFP complementation can be monitored using a microplate reader. 
Comparing these two methods, electroporation of live cells is advantageous because 
it assesses GFP complementation in the cellular environment of a live cell. However, 
when cells are electroporated, the total amount of GFP11 that enters the cell is 
unknown.  
Milech et al. have developed an in vitro system where GFP1-10 and 
CPP_TRX_S11 peptides can be investigated when both fragments are sourced from 
bacterial expression and purification (Milech et al. 2015).  A dose response was 
shown when 12.5 µM GFP1-10 was mixed with 0.375 – 3.0 µM CPP_TRX_S11 
peptides at a single time point which is stated as overnight incubation and GFP 
fluorescence was measured on a microplate reader. This in vitro assay can be 
compared to the in vitro assay developed in this chapter. Milech et al. incubate split 
GFP fragments at room temperature. When GFP complementation was investigated 
here, incubation of split GFP fragments at room temperature and 4°C was compared 
and it was found that more GFP complementation had occurred when incubated at 
room temperature. However, Milech et al. utilises purified proteins for this assay 
compared to cell lysate containing GFP1-10 in the assay introduced in this chapter. 
With increasing temperature, cellular proteases can be more active. Hence, it would 
be interesting to investigate if the in vitro assay introduced in this chapter can be 
further improved by adding protease inhibitor to the cell lysate mix.   
 
With help of the improved in vitro assay it was shown in this chapter that in vitro 
GFP complementation is time and concentration dependent. Furthermore, R8-M3 
and M3 had a comparable amount of complemented GFP at each time point. L-M3 
consistently showed a slight increase in GFP fluorescence. This was attributed to the 
increased green fluorescence of the peptide itself that was noticed during microscopy 
experiments and which also could be detected on the plate reader when green 
fluorescence of pure peptides was measured. Importantly, in this study it was shown 
189 
 
that the DDS R8 did not have an effect on GFP complementation compared to the 
pure M3 peptide.  
In contrast, Milech et al., showed very different GFP complementation between 
the pure M3 peptide (S11) or CPP conjugated S11. In their study, pure TXR_S11 
complementation with GFP1-10 was set to 100%. When the fluorescence achieved 
with the same concentration of R9_TXR_S11 was compared to this, it only reached 
approximately 30%. Moreover, other CPP_TXR_S11 fusions also showed decreased 
GFP complementation compared to the pure TXR_S11 peptide control. However, it 
was not further explored what the source of this difference is which could be due to 
difference in autofluorescence of the peptides or difference of the actual 
concentrations of the peptides even though they were believed to be used at the same 
concentrations. Nevertheless, their in vitro assay clearly shows that CPP_TXR_S11 
peptides were able to achieve >100% GFP complementation compared to the 
TXR_S11 control meaning they are functional for GFP complementation in vitro but 
they did not deliver  TXR_S11 in the live assay and no GFP complementation was 
detected. 
This is also key to the improvement that was made to the in vitro assay here. In 
the fix and stain method in chapter 3 it was not possible to show that M3, L-M3 and 
R8-M3 have the same ability to complement with GFP1-10 when cells were fixed and 
permeabilised, therefore missing complementation for the M3 or L-M3 peptide in the 
live cell assay could not certainly be attributed to the inability for those peptides to 
cross the plasma membrane. Knowing that L-M3 and M3 complement with GFP1-10 
and complementation is not significantly different to R8-M3 complementation with 
GFP1-10 in vitro, allows us to state that the absence of GFP fluorescence in the live 
assay when cells are incubated with 30 µM L-M3 means that L-M3 had not been 
delivered functionally into the cytosol of these cells. This also confirms that M3 
delivery in the split GFP system is R8 dependent.   
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The in vitro GFP complementation system showed time dependent increase of 
GFP fluorescence over 24h. This can only be seen as an approximation of GFP 
complementation dynamics as they could occur in the cytosol of a living cell at 37°C. 
Nevertheless, the in vitro system shows a big increase between GFP fluorescence 
measured after 2 h and 24h. This raises the question if assessment of M3 delivery 
after 2h in live cells is too early and longer incubation time could achieve higher GFP 
complementation signals.  
The live cell assay of Milech et al., is performed when peptides were incubated 
with cells for 24 hours. It is not stated if peptides are added in serum free or serum 
containing media (Milech et al. 2015). In the paper of Schmidt et al, a comparative 
study is shown when GFP complementation is assessed after 2h and 24h of 
incubation with CPP-GFP11 peptides (Schmidt et al. 2015a). They identified 2h 
incubation as the better time point to assess GFP complementation because there 
was no increase in fluorescence detected after 24h incubation. However it is also 
important to mention that 10% FCS was added to the cell culture media when 
peptides were incubated for 24h which could affect peptide stability (Kosuge et al. 
2008). Peptide stability is not only a factor to consider when peptides are incubated 
with cells but also once they have entered the cells. In this study presented here, L-
amino acids were used to synthesize DDS-M3 peptides. It was demonstrated CPPs 
composed of the D-isoform were more stable in HeLa cells than CPPs composed of 
L-amino acids (Derek S. Youngblood et al. 2006) but this is also associated with 
decreased uptake compared to L-CPPs (Verdurmen et al. 2011). For this reason it is 
preferred use L-CPPs compared to D-CPPs even though the stability is decreased.  
Strategies to prevent peptide degradation in the cytosol were shown to be 
through C-terminal attachment of a polyethylene glycol (PEG) moiety or amino acid 
substitution in order to prevent proteolytic degradation (Schmidt et al. 2015a).  
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Live assessment of M3 peptide delivery by DDSs was developed to be a 
microscopy technique in this study. Using a widefield fluorescent microscope it was 
possible to show delivery of M3 by R8 at concentrations ranging from 20-40 µM in 
single experiments. Due to the faint green fluorescence of complemented GFP, 
imaging had to be performed in glass bottom microscopy dishes on the highest 
magnification (100x, oil). This was associated with low throughput.  
In other studies using GFP complementation to assess concertation dependent 
delivery of M3 peptide by DDSs, success of delivery was measured using flow 
cytometry (Milech et al. 2015; Schmidt et al. 2015a). This allowed the measurement 
of multiple peptides at a range of concentrations within one experiment. Nevertheless, 
it does not allow investigation of peptide uptake in real time. 
 
Another important information when investigating drug delivery into cells is to 
determine how much cargo has been delivered to its intracellular target. Utilising 
mCherry as an expression marker for GFP1-10 expression could help us to 
investigate this. In this chapter it has been shown that mCherry-GFP1-10 can be 
expressed transiently or stably in cells and that GFP complementation upon M3 
delivery can be determined. However, direct correlation between the amount of 
expressed mCherry and complemented GFP fluorescence has not been investigated 
further. For future experiments it would be beneficial to investigate if mCherry 
fluorescence and complemented GFP fluorescence can be correlated so that it will 
allow us to gain information about the amount of delivered M3 peptide. Quantitative 
assessment of delivered cargo using the split GFP system has been investigated by 
(Kim et al. 2015) where the complemented GFP fluorescence was compared to the 
fluorescence obtained from a standard curve obtained from intact GFP.  
 
In summary, comparison of the split GFP systems utilised by other groups and 
the system presented in this study has shown that the similar techniques have been 
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utilised in order to characterise the split GFP system such as co-transfection of the 
split GFP fragments as well as in vitro complementation using pure split GFP 
fragments. The main difference is that the split GFP assay to determine functional 
delivery of a peptide presented here was characterised using microscopy. Already 
during the characterisation phase of the split GFP system in Chapter 3 it was 
emphasised that microscopy can add valuable information compared to techniques 
where only green fluorescent intensity is measured. One example is the co-
expression experiment. Utilising the expression plasmid mCherry-H6-R8-M3 to 
express the small M3 fragment of GFP led to accumulation of complemented GFP to 
the nucleolus due to the presence of R8. Hence, using a microscope to assess the 
success of GFP complementation not only determined if the two fragments 
complement but also where they localise inside the cell.  
This localisation change was also noticed in live experiments when M3 delivery 
by R8 across the plasma membrane was assessed using microscopy. When peptide 
delivery by a DDS was assessed in live cells by Milech et al. and Schmidt el al., GFP 
fluorescence was only detected by flow cytometry measurement. Localisation 
changes of complemented GFP inside the cell remained due to conjugation to CPPs 
remains unknown in their experiments.  
Split GFP to determine functional peptide delivery by DDSs is a powerful 
technique that should be utilised to its full potential. This includes to determine if a 
peptide is delivered by detection of green fluorescence but also when the peptide is 
delivered and where it is delivered to inside the cell. When and where the M3 peptide 
is delivered inside the cell is clearly shown in study during the extensive 
characterisation of the split GFP system using a microscope presented in Chapter 3 
and 4. This demonstrates that data generated in this study help to characterise DDSs 
more detailed than it has been shown by Milech et al. and Schmidt el al.. 
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Another finding when characterising the stable cell lines live on a microscope 
was the increased green fluorescence in cells that expressed GFP1-10 or mCherry-
GFP1-10 transiently as well as in stable cell lines. When compared to mock 
transfected HeLa cells this fluorescence differed in brightness as well as localisation. 
While autofluorescence in HeLa cells was mostly localised in the cytosol in the 
perinuclear region, increased fluorescence upon expression of GFP1-10 or mCherry-
GFP1-10 was found throughout the cytosol as well as in the nucleus. This increased 
green fluorescence was also noticed in single cells during previous experiments when 
cells transiently expressed GFP1-10.  
This fluorescence was also described by other groups working with split GFP. In 
a study by Kent and his colleagues it was mentioned that once GFP fragments had 
reassembled and the chromophore maturated, they can be separated by denaturation 
and GFP1-10 contains a mature chromophore (GFP1-10mat). They stated that only 
weak fluorescence is observed for GFP1-10mat (Kent et al. 2008). That statement 
could be indicative that the GFP fluorescence seen in cells expressing GFP1-10 and 
mCherry-GFP1-10 is due to the matured chromophore that is located on the central 
alpha helix of the GFP1-10 fragment. Furthermore, when stable cell lines expressing 
GFP1-10 were generated in other studies, low fluorescent background signal from 
the marginal fluorescent capability of GFP1-10 was observed (Milech et al. 2015).  
 
NADH and FAD are autofluorescent cofactors in the 500 – 600 nm spectral 
region located in the mitochondrial electron transport chain (Aubin 1979; Benson et 
al. 1979).  FAD with its emission spectrum of 535 nm lies within the spectral range 
that is collected when GFP emission is measured (GFP emission filter setting: 525/36 
nm). For this reason it is likely that the autofluorescence seen in Hela cells, located 
in the perinuclear region is derived from FAD. Its localisation within the mitochondria 
also correlates with the phenotype of the autofluorescence in located around the 
nucleus. The change of the localisation of green fluorescence to the cytosol and the 
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nucleus, seen when GFP1-10 or mCherry-GFP1-10 were expressed was a first 
indication that this is a different phenomenon than simple autofluorescence.   
Using spectral detection it was suggested that the green fluorescence seen when 
GFP1-10 is expressed is a combination of real GFP fluorescence as well as 
autofluorescence of the cell. The emission spectra of full length GFP and the 
spectrum detected in cells expressing GFP1-10 aligned and peaked at 513 nm 
wavelength light. Two scenarios could explain the emission of GFP fluorescence GFP 
fluorescence. The function of the M3 peptide to rescue GFP fluorescence is 
dependent in the proton acceptor Glutamic acid 222. It could be possible that GFP1-
10 may have found another proton acceptor in the cytosol and GFP fluorescence in 
partly rescued. Another possibility is that the chromophore that is contained in GFP1-
10 emits GFP fluorescence. Kent et al. 2008 have stated that weak fluorescence is 
observed for GFP1-10 when complemented GFP is denatured into two fragments and 
GFP1-10 contains a matured chromophore (Kent et al. 2008). 
 
In summary, in this chapter it was shown that two stable cell lines were generated 
and functional M3 delivery can be assessed using these cell lines. The methods to 
validate GFP complementation in these cell lines were also used by other groups in 
the field utilizing the same assay. Furthermore, it was demonstrated that the 
developed split GFP assay can be utilised using a microscope to show real time 
delivery of the M3 peptide as well as its localisation adding valuable information 
beyond what has been published by other groups.  
It is now of interest if the delivery efficiency of different DDSs can be evaluated 
in a concentration dependent manner using this system as well as the detailed 
analysis of subcellular localisation of the delivered M3 peptide.  
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5 Evaluation of the delivery efficiency of different 
DDSs using the split GFP assay 
5.1 Introduction   
In previous chapters, it was demonstrated that the split GFP assay can be utilised 
to investigate the delivery of the M3 peptide by the CPP R8 to the cytosol of cells 
expressing GFP1-10 or mCherry-GFP1-10. The same method has been utilised by 
other research groups in order to evaluate concentration dependent delivery of the 
M3 peptide by DDSs (Milech et al. 2015; Schmidt et al. 2015b).  
In order to fully characterise the split GFP assay developed in this study, it was 
of interest to investigate if delivery efficiency can also be detected in a concentration 
dependent manner. Until now, functional delivery of M3 was only investigated using 
fluorescent widefield microscopy. The faint fluorescence of complemented GFP does 
not allow high throughput analysis of cells in a 96 well format at low magnification, 
yet.  Due to this reason, data collection is a time consuming process and imaging can 
only be performed in single microscopy dishes at high magnification. Hence, analysis 
of multiple conditions within the same experiment is challenging. Moreover high 
magnification imaging only allows us to analyse a small subset of cell that might not 
represent the whole cell population.  
Other research groups have used flow cytometry to determine M3 delivery by 
DDSs (Milech et al. 2015; Schmidt et al. 2015a). Flow cytometry can determine the 
fluorescence of 10,000 cells in only 1 minute which allows us to gain information on 
the fluorescence of multiple cell populations treated with different concentrations and 
different peptide formulations in a short amount of time.  Importantly this data can be 
collected within the same experiment which allows accurate comparison of different 
conditions. For this reason, it was of interest to examine if the split GFP 
complementation assay developed utilising stable cell line SCL1 and mcherry-SCL51 
can be performed, and GFP complementation detected using flow cytometry.  
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Hence, the primary focus of this chapter is to characterise stable cell lines by 
flow cytometry and then investigate if concentration dependent delivery of M3 by R8 
into the cytosol of the stable cell lines SCL1 or mCherry-SCL51 can be detected.  
 
Furthermore it is of interest to examine if the delivery efficiency of different DDSs 
can be investigated to allow the evaluation of DDSs to act as a peptide delivery vector. 
Other research groups have already investigated a wide range of well-known CPPs 
to deliver peptides using the split GFP assay (Milech et al. 2015; Schmidt et al. 
2015a).  
For this reason the peptide delivery performance of R8 based peptides with 
single amino acid additions will be examined here. It has been shown by our group 
that a single residue change from Glycine to Phenylalanine in the linker sequence 
GSGSGSGSG, N-terminally attached to cell penetrating peptides had a striking effect 
on the uptake of fluorophores into HeLa cells (Sayers et al. 2014). Two of the CPPs 
that were investigated in this study were R8 and TP10. N-terminal exchange of 
Glycine to Phenylalanine in the linker sequence attached to TP10 had the most 
enhancing effect on its uptake into HeLa cells at 2 µM and 5 µM. Single amino acid 
exchange of the linker attached to R8 showed a significant increase of its uptake in 
KG1a cells at 2 µM and 5 µM. In HeLa cells a significant increase was only observed 
at 5 µM and not at 2 µM. In this previous study, uptake of CPPs and enhancement of 
their uptake was investigated using fluorophore conjugated CPPs.  
However, uptake does not equal cytosolic delivery and using fluorophores to 
track the uptake into cells did not assess cytosolic delivery which is of high interest 
when using CPPs as drug delivery systems. Furthermore fluorophores can change 
the uptake of CPPs into cells  (Jones and Sayers 2012). For this reason it was of 
interest to utilise the split GFP system to elucidate if N-terminal phenylalanine can not 
only enhance cellular uptake, but also enhance functional delivery of a peptide cargo 
into the cytosol.  
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Thus, as a second focus of this chapter, delivery efficiency of R8 will be 
compared to R8 with N-terminal addition of Glycine or Phenylalanine residues. This 
will shed light on the influence of Phenylalanine substitution on R8 to enhance 
functional delivery of a peptide as well as further explore the potential of the split GFP 
assay to evaluate and compare different DDSs for peptide delivery.  
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5.2 Characterisation of stable cell lines using Flow cytometry 
5.2.1 Cell morphology and viability 
Before performing a split GFP complementation assay and measurement of 
green fluorescence by flow cytometry, the characteristics of the different cell lines and 
appropriate filter settings of the flow cytometer were examined. Schmidt et al., have 
published the split GFP complementation assay based on flow cytometry where GFP 
signal was measured from morphological intact cells based on forward scatter (FSC) 
and sideward scatter (SSC) measurements (Schmidt et al. 2015a). FSC and SSC 
measure cell size and cellular granularity (e.g. number and size of vesicles and 
mitochondria or the nucleus structure), respectively. In order to explore which FSC 
and SSC measurements correlate with morphological intact cells, HeLa, SCL1 and 
mCherry-SCL51 cells were analysed regarding their viability and morphology. 
Untreated cells were detached from the cell culture dish using trypsination and 
prepared for flow cytometry. After washing the cells with PBS twice, cells were treated 
with LIVE/DEAD™ Violet Stain and left on ice for 30min. Cells were washed again, 
resuspdended in PBS, transferred into a FACS tube and left on ice until flow 
cytometry measurements.  
First, the cell morphology was explored using FSC and SSC measurements 
(Figure 5-1). On the dot plots obtained from the measurement it can be clearly seen 
that the variety of cell morphology was very similar between HeLa cells (Figure 5-1 I) 
and the stable cell line mCherry-SCL51 (Figure 5-1 III). The cells of the cell line SCL1 
were bigger in size as well as more granular and the whole cell population was shifted 
towards the centre of the FACS plot (Figure 5-1 II).  This difference in granularity 
could be due to the different shape of the nucleus between SCL1 cell and HeLa cells 
that was observed by Alexander Dudziak during his placement in our lab (Appendix 
9.5, Figure 9-7). He further performed morphological analysis of SCL1 cells compared 
to HeLa cells and demonstrated that the morphology of the cell membrane of SCL1 
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stained with Concanavalin-A did not differ from HeLa cells (Appendix 9.5, Figure 9-8). 
Furthermore, he analysed the actin (Appendix 9.5, Figure 9-9) and tubulin (Appendix 
9.5, Figure 9-10) cytoskeleton in HeLa and SCL1 cells using immunofluorescence 
and found that the morphology was not different between then.  
 
To investigate the viability of these cells, the fluorescence of the LIVE/DEAD™ 
Violet Stain (excitation/emission: 405/451) was measured using the violet laser (407 
nm excitation) Pacific Blue filter setting (collection of 425 - 475 nm wavelength light) 
(Figure 5-2). The stain reacts with free amines and when cells are intact it is restricted 
to the cell surface which results in weak fluorescent staining. When the plasma 
membrane is compromised the dye has access to amines on the cell surface and the 
interior of the cell which results in more intense staining. The cells were gated into 
two populations to describe morphologically intact cells (live cell gate) and cells where 
the plasma membrane was not intact (dead cells). The live cell gate was drawn 
around the centre in which cells where highly concentrated which included 92.5% 
cells, 86.5% cells and 93.8% cells of the population for the cell lines HeLa, SCL1 and 
mCherry-SCL51, respectively (Figure 5-2 I, IV, VII) . Detection of the live/dead cell 
staining within this gate showed one clear peak for each cell line with the same 
fluorescent intensity between the cell lines (Figure 5-2 II, V, VIII). The dead cell gate 
was located around cells that were smaller and less granular than intact cells and 
only included 2.31%, 4.16% and 1.08% cells of the population for the cell lines HeLa, 
SCL1 and mCherry-SCL51, respectively (Figure 5-2 I, IV, VII). When measuring the 
live/dead cell stain within this gate all cell lines showed one peak in the same position 
as the live cell gate and another peak shifted to the right indicating more intense 
staining of the dye (Figure 5-2 III, VI, IX).  
 
This data suggests that the cells measured in the live cell gate were 
morphologically intact and the dye did not enter the cells because only one clear peak 
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with weak fluorescence of the dye was seen. The cells within the dead cell gate 
consisted of cells that were morphologically intact as well as cells with a compromised 
plasma membrane. This was visible by the separation of cells into two peaks, one 
that was positive for the live/dead cell dye and one with only weak fluorescence of 
the dye.  
A clearer result could have been obtained with an experimental control that 
contained cells with a compromised plasma membrane (e.g. Triton-X-100 treatment). 
However this control was absent in this experiment but measurements should be 
confirmed in the future.  
For further experiments morphologically intact cells were gated according to the 
position of the live cell population dependent on FCS and SSC measurements shown 
in this experiment.   
 
 
 
 
Figure 5-1 Morphology of HeLa cells and stable cell lines  
Hela cells, SCL1 cells or mCherry-SCL51 cells were detached from a cell culture dish using 
trypsinisation and prepared for flow cytometry measurement including LIVE/DEAD™ Violet 
Stain treatment. Cell morphology was assessed using forward scatter (FSC-A) and sideward 
scatter (SSC-A) measurement. Assessment of morphology of 50,000 cells. Samples were 
measured in duplicates. n=1. 
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Figure 5-2 Gating for morphologically intact cells. 
Hela cells, SCL1 cells or mCherry-SCL51 cells were detached from a cell culture dish using 
trypsinisation and prepared for flow cytometry measurement including LIVE/DEAD™ Violet 
Stain treatment. Cell morphology was assessed using forward scatter (FSC-A) and sideward 
scatter (SSC-A) measurement. Assessment of morphology of 50,000 cells. (I, IV, VII). 
LIVE/DEAD™ Violet Stain (excitation/emission: 405/451) was excited using the violet laser 
(405 nm) and collected using the Pacific blue filter setting (425 - 475 nm). Live cell gate was 
drawn around cells that were assumed to be morphologically intact. Dead cell gate was drawn 
around smaller and less granular cells that were assumed to be dead. LIVE/DEAD™ cell stain 
signal is shown for cells included in the live cell gate (II, V, VIII) and the dead cell gate (III, VI, 
XI). Samples were measured in duplicates. n=1. 
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5.2.2 Cell fluorescence 
Next, green fluorescence was measured in morphologically intact cells shown in 
Figure 5-2. HeLa, SCL1 and mCherry-SCL51 cells were excited using the 488 nm 
wavelength light laser and green fluorescence was collected using the FITC filter (515 
- 545 nm) (Figure 5-3). The geometric mean of FITC fluorescence was measured in 
duplicates for the different cell types. Figure 5-3 A demonstrates that the stable cell 
lines had increased green fluorescence compared to HeLa cells. HeLa cells showed 
a fluorescence of 274 RFU; For SCL1 cells and mCherry-SCL51 cells a value of 1395 
RFU and 1226 RFU was measured, respectively. This shows that the green 
fluorescence in SCL1 cells is 5 times higher compared to HeLa cells and 4.5 times 
increased in mCherry-SCL51 cells. 
Comparison of the histograms shows that the cell population of HeLa cells 
(Figure 5-3 B I, IV) and SCL1 (Figure 5-3 B II) cells had a single peak and even 
distribution of green fluorescence across the cell population. When comparing this 
green fluorescence between HeLa cells and SCL1 cells (Figure 5-3 B II), it is visible 
that the green fluorescence of SCL1 cells is shifted to the right which means that 
these cells are more fluorescent than HeLa cells.  
mCherry-SCL51 cells showed 2 peaks when green fluorescence was measured 
in this cell line (Figure 5-3 B V). When this fluorescence is compared to HeLa cells 
(Figure 5-3 B VI) the smaller peak did align with the fluorescence measured in HeLa 
cells and the larger peak was shifted to the right indicating higher green fluorescence 
similar to that observed for the SCL1 cell line.  
 
These findings are consistent with the observation made using fluorescent 
microscopy, that stable cell lines were found to be more fluorescent in the GFP 
channel compared to HeLa cells. mCherry-SCL51 was characterised to be a 
polyclonal cell line. Hence, the two cell populations when green florescence was 
measured could represent this separation of the cell population.  
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Figure 5-3 Green fluorescence of stable cell lines measured by flow cytometry. 
Hela cells, SCL1 cells or mCherry-SCL51 cells were detached from a cell culture dish using 
trypsinisation and prepared for flow cytometry measurement including LIVE/DEAD™ Violet 
Stain treatment. Green fluorescence of morphologically intact cells was measured using the 
488 nm excitation laser and the FITC filter (515 - 545 nm). (A) Geometric mean of cell 
fluorescence is shown. Cell types were measured in duplicates. Error bar shows standard 
deviation. (B) Histograms of green fluorescence of single cell populations shown in I,II,IV and 
V. Green fluorescence of stable cell lines with respect to the fluorescence of HeLa cells shown 
in III, VI. 50,000 cells were measured in total. n=1. 
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Due to the fact that mCherry-SCL51 is a polyclonal cell line it is necessary that 
GFP complementation in live cells is only measured in mCherry positive cells (e.g. 
only cells that express mCherry-GFP1-10). For this reason it is important that 
mCherry fluorescence can be measured with the flow cytometer in order to allow 
appropriate gating for a mCherry positive cell population. The excitation maximum of 
mCherry is at 587 nm wavelength light, which would require a yellow laser (560 nm 
excitation wavelength) to excite the fluorescent protein mCherry at its excitation 
maximum. The flow cytometer that was used in this study was not equipped with a 
yellow laser. Due to the absence of this laser it was tested if mCherry fluorescence in 
these cells can be determined using excitation of the fluorescent protein with the 
488nm wavelength light laser. This wavelength does not correspond with the 
excitation optimum of mCherry, but it lies within the wavelength range which can 
excite mCherry (Figure 5-4). However, excitation with 488nm wavelength light will 
also excite GFP which has its excitation maximum at 488nm wavelength light. Thus, 
to clearly separate the emission of the fluorophores and to only collect signal that is 
emitted following mCherry excitation, it was important to choose an emission filter 
that lies outside the emission range of GFP. The chosen filter for that measurement 
was the PerCP-Cy5-5 filter collecting 670 – 753nm wavelength light.  
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Figure 5-4 Excitation and emission spectrum of mCherry and GFP with regard to flow 
cytometer laser excitation and emission filter setting. 
The graph shows GFP excitation (light green) and emission (dark green) spectrum and 
mCherry excitation (light orange) ad emission (dark orange) spectrum. Spectra were obtained 
from the Chroma website. Black dotted line indicates excitation wavelength 488 nm. Solid 
black box indicates wavelengths 670-753 nm collected by the PerCP-Cy5-5 emission filter.  
 
 
 
When mCherry fluorescence was measured using the described filter settings, it 
was seen that it was possible to measure the emission of mCherry fluorescence in 
the stable cell line mCherry-SCL51. The stable cell line showed high red fluorescence 
(2757 RFU) compared to HeLa cells (246 RFU) (Figure 5-5 A). Furthermore, the 
percentage of mCherry positive cells was analysed in duplicate samples. It revealed 
that 86% of the cell population of mCherry-SCL51 is positive for mCherry 
fluorescence, therefore expressing mCherry-GFP1-10 (Figure 5-5 B).  
When the histograms of these samples were analysed, a single emission peak 
was seen in HeLa cells (Figure 5-5 C I). mCherry-SCL51 cells showed two peaks 
indicating varying mCherry fluorescence across the cell population (Figure 5-5 C II). 
When both histograms where superimposed, the two peaks of mCherry-SCL51 cells 
were clearly separate from each other and the lower peak aligned with the mCherry 
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fluorescence detected in untreated HeLa cells(Figure 5-5 C II). The second peak was 
shifted to the right indicating higher fluorescent signal.  
This data is another conformation that mCherry-SCL51 is a polyclonal cell line 
and that there are cells within the cell population that do not express mCherry-GFP1-
10, aligning with the emission spectrum obtained from HeLa cells. Furthermore, it 
confirmed that mCherry fluorescence can be measured on the flow cytometer which 
will allow the investigation M3 delivery and GFP complementation in mCherry-GFP1-
10 positive cells.  
 
 
 
Figure 5-5 Detection of mCherry fluorescence using flow cytometry. 
Hela cells or mCherry-SCL51 cells were detached from a cell culture dish using trypsinisation 
and prepared for flow cytometry measurement including LIVE/DEAD™ Violet Stain treatment. 
mCherry fluorescence of morphologically intact cells was measured using the 488 nm 
excitation laser and the PerCP-Cy5-5 emission filter (670 – 753 nm). (A) Geometric mean of 
cell fluorescence is shown. Cell types were measured in duplicates. Error bar shows standard 
deviation. (B) Percentage of mCherry positive cells within the cell population of mCherry-
SCL51. (C) Histograms of red fluorescence of single cell populations shown in I and II. Green 
fluorescence of stable cell line mCherry-SCL51 with respect to the fluorescence of HeLa cells 
shown in III. Samples were measured in duplicates. 50,000 cells were measured in total. n=1. 
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5.3 Design of different R8 based peptides 
In order to investigate if the split GFP assay allows us to evaluate the delivery 
efficiency of different DDSs, new R8 based peptides were designed. Based on 
previous studies that showed that a switch from a N-terminal Glycine to Phenylalanine  
attached to CPPs can enhance their uptake into cells (Sayers et al. 2014), it was of 
interest to examine if this exchange of amino acids can also facilitate enhancement 
of the functional delivery of M3 cargo peptide. The enhancing effect on uptake due to 
a Glycine to Phenylalanine exchange was investigated when the Glycine (G) or 
Phenylalanine (F) residue were attached N-terminally via an 8 amino acid linker 
(SGSGSGSG). Enhancement of uptake using this amino acid change was less 
effective for R8 than other CPPs tested in this study. Hence, for the design of new R8 
based peptides to deliver M3, the linker sequence was removed and Phenylalanine 
or Glycine were directly attached to the N-terminus of R8 to obtain the new peptides 
FR8-M3 and GR8-M3 (Table 5-1). Direct attachment of the amino acid addition to R8 
was hoped to achieve enhanced delivery characteristics. Along with these peptides, 
two more R8 based peptides were purchased with the addition of two N-terminal 
Phenylalanine (FFR8-M3) or Glycine (GGR8-M3) residues to investigate if delivery 
can be further enhanced when two Phenylalanine residues are attached to R8.   
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Table 5-1 R8 based peptides with Glycine or Phenylalanine modifications  
 
Table displays sequences, modification and characteristics of DDS-M3 peptides used in this chapter. All peptides use L-amino acids, blue letters denote the 
sequence of the cell penetrating peptide R8 (octaarginine) containing Glycine (G) or Phenylalanine (F) modifications; M3 sequence is coloured in green. R8 is 
conjugated to M3 via a linker (grey).  
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5.4 Delivery of M3 by different R8 based peptides in SCL1 cells 
5.4.1 Concentration dependent delivery of M3 by R8 
Using flow cytometry measurement it was first explored if a concentration 
dependent increase of functional M3 delivery by R8 can be detected using the stable 
cell line SCL1. To test this, SCL1 cells were washed once in serum free media and 
incubated with DMSO, M3, L-M3 or R8-M3 at a concentration range of 10-40 µM for 
2h at 37ºC. Then cells were washed in 0.5 mg/ml Heparin 3 times in order to remove 
membrane bound CPP-M3 peptide. Cells were detached from the cell culture dish 
using trypsin and washed with PBS twice. Cells were then transferred into a FACS 
tube in a volume of 500 µl of PBS and kept on ice until flow cytometry measurements. 
GFP fluorescence of 20,000 cells were detected using flow cytometry and cells were 
gated for morphologically intact cells using FSC and SSC measurements. Green 
fluorescence was measured and the geometric mean of samples was taken to 
compare GFP complementation. The geometric mean of all samples was normalised 
to the DMSO control that was set to a value of 1 to display a fold change in GFP 
fluorescence. The results are shown in Figure 5-6.  
Incubation of the cells with M3 or L-M3 at a concentration range of 10-40 µM did 
not result in functional delivery of M3. This is shown by green fluorescence levels that 
were lower or the same as the DMSO control. M3 delivery using R8 did result in M3 
delivery and green fluorescence of cells increased in a concentration dependent 
manner. Even at a low concentration of 10 µM, M3 was successfully delivered to the 
cytosol of GFP1-10 expressing cells and resulted in a 1.06 fold change of GFP 
fluorescence. Delivery was linear to the concentration for 10 µM (1.06 fold), 20 µM 
(1.11 fold) and 30 µM (1.18 fold) and increased to 1.36 fold when cells were incubated 
with 40 µM R8-M3. This was significantly different compared to the fluorescence 
detected when 40 µM M3, L-M3 or DMSO were incubated with the cells. 
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This experiment shows a concentration dependent increase of M3 delivery and 
GFP complementation when R8-M3 was applied on SCL1 cells. Importantly, M3 as 
well as L-M3 were not able to cross the plasma membrane at concentrations of 10-
40 µM. This data also reveals that SCL1 cells can be utilised to determine a DDS 
dependent M3 delivery into cells. Furthermore, flow cytometry can be utilised as a 
method to detect concentration dependent delivery of M3 by a DDS.  
 
 
Figure 5-6 Concentration dependent delivery of M3 by R8 using SCL1 cells. 
SCL1 cells were washed once in serum free media and incubated with DMSO, M3, L-M3 or 
R8-M3 at 10-40 µM for 2h at 37ºC. Cells were washed in 0.5 mg/ml Heparin 3 times and 
detached from the cell culture dish using trypsin. Cells were washed with PBS twice, 
transferred into a FACS tube in a volume of 500 µl of PBS and kept on ice until flow cytometry 
measurements. In total 20,000 cells were measured. Cells were gated for morphologically 
intact cells using SSC and FSC measurements and green fluorescence within this cell 
population was measured using the 488 nm excitation laser and the FITC emission filter. Fold 
change is shown compared to the DMSO control which was set to the value 1. Error bars 
show standard error of the mean. For statistical analysis data was tested using a One way 
Annova followed by multiple comparison using a Turkey HSD (honest significant difference) 
test. Significance is shown compared to treatment with 40 µM M3, L-M3 or DMSO. *: p<0.05, 
**: p<0.01, ***: p<0.001, n.s.: not significant. n=3. 
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5.4.2 Effect of Phenylalanine or Glycine substitution to R8 on the efficiency 
to deliver M3 to the cytosol of SCL1 cells 
Next it was tested if an N-terminal addition of one or two Phenylalanine (FR8-
M3/FFR8-M3) or Glycine (GR8-M3/GGR8-M3) residues changes the efficiency to 
functionally deliver M3 to its cytosolic GFP1-10 target expressed in SCL1 cells. In 
order to test the compatibility of these peptides to complement with GFP1-10, 
complementation was first investigated using the improved in vitro assay where 
peptides are mixed with cell lysate of SCL1 cells containing GFP1-10. 80 µM of M3 
containing peptide was mixed with cell lysate of 0.8x105 SCL1 cells expressing GFP1-
10 and GFP complementation was monitored on a microplate reader over 24 h at 
4ºC. Figure 5-7 shows the time dependent increase of GFP fluorescence of M3 
containing peptides with GFP1-10. R8 itself did not have the ability to rescue GFP 
fluorescence. GFP complementation of R8-M3 was slightly increase at each time 
point compared to FR8M3, FFR8-M3, GR8-M3 and GGR8-M3. Complementation of 
FFR8-M3, GR8-M3 and GGR8-M3 was similar between the samples. Only 
complementation of FR8-M3 was decreased until the 4 h time point compared to other 
samples. All samples showed a time dependent complementation of GFP1-10 that 
was contained in the SCL1 cell lysate and the CPP-M3 peptides. Importantly, there 
was no significant difference found when peptides containing M3 were compared 
regarding their ability to complement with SCL1 cell lysate in vitro at time points 120 
min or 7h. Overall, Phenylalanine or Glycine additions to R8-M3 did not alter the ability 
to complement with M3 significantly.  
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Figure 5-7 In vitro complementation of R8-M3 peptides with a Phenylalanine or Glycine residue addition with SCL1 cells. 
(A) In vitro complementation of lysed SCL1 cells with peptides. SCL1 cells were trypsinised and lysed using 0.1% Triton-X100 in PBS. Cell lysate of 0.8X105 
cells was mixed with 80 µM M3 and CPP-M3 peptides to obtain a final concentration of 40 µM in 0.05% Triton-X-100/PBS. Lysate mixture was left under 
constant agitation at 4ºC. The fluorescent signal resulting from GFP complementation was monitored over 24 h using a microplate reader. DMSO only control 
was subtracted as the sample background. n=3. Error bars present SEM. For statistical analysis data was tested using a One way Annova followed by multiple 
comparison using a Turkey HSD (honest significant difference) test. Data was tested at two time points, 120min and 7h. No significant difference of fluorescence 
was found between peptides containing M3. n.s.: not significant.  
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After the ability of R8 containing M3 peptides to complement with GFP1-10 was 
confirmed in vitro, the different R8 derived peptides were evaluated regarding their 
ability to deliver M3 in a live experiment. To explore this, SCL1 cells were washed 
once in serum free media and incubated with DMSO, R8-M3 or 
Phenylalanine/Glycine added versions of R8-M3 at concentration range of 10-40 µM 
for 2h at 37ºC. Then cells were washed in 0.5 mg/ml Heparin for 3 times in order to 
remove membrane bound CPP-M3 peptide. Cells were detached from the cell culture 
dish using trypsin and washed with PBS twice. Cells were then transferred into a 
FACS tube in a volume of 500 µl of PBS and kept on ice until flow cytometry 
measurements. GFP fluorescence of 20,000 cells were detected using flow cytometry 
and cells were gated for morphologically intact cells and green fluorescence of the 
population was measured using the geometric mean of samples. The geometric mean 
of all samples was normalised to the DMSO control that was set to a value of 1 to 
display a fold change in GFP fluorescence.  
Single addition of Phenylalanine (FR8-M3) or Glycine (GR8-M3) residues to R8-
M3 did not result in an increased delivery of M3 into SCL1 cells compared to R8-M3 
(Figure 5-8 A). Nevertheless, FR8-M3 and GR8-M3 did show peptide delivery activity 
in a concentration dependent manner. GR8-M3 delivered M3 half as effective as R8-
M3 and followed the same trend seen for R8-M3 that delivery increased linear when 
used at 10 µM, 20 µM or 30 µM (1.02, 1.04, 1.07 fold respectively) and a higher 
increase was seen at 40 µM when delivery increased by 1.2 fold compared to the 
DMSO control (1 fold). The delivery efficiency of FR8-M3 was decreased compared 
to GR8-M3 and R8-M3 and only reached a 1.11 fold change when applied at 40 µM 
compared to R8-M3 (1.36 fold) or GR8-M3 (1.2 fold). No significant difference was 
seen between functional delivery of M3 by R8, FR8 or GR8.  
However, when two Phenylalanine residues were added to R8-M3 (FFR8-M3), 
M3 delivery dramatically increased (Figure 5-8 B) compared to R8-M3. M3 delivery 
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was concentration dependent and rapidly increased from 1.1 fold at 10 µM to 1.86 
fold at 20 µM, 2.54 fold at 30 µM and reached 3.13 fold at 40 µM. Hence, M3 delivery 
using FFR8-M3 was 6 times higher at a 40 µM than R8-M3. In contrast, addition of 
two Glycine residues (GGR8-M3) decreased M3 delivery compared to R8-M3 and M3 
delivery was similar to the peptide with a substitution of a single Glycine (GR8-M3) 
and did not decrease M3 delivery further.   
This increase in M3 delivery when FFR8-M3 is used as a drug delivery vector 
was further shown to be significantly different to R8-M3 and GGR8-M3 at 
concentrations of 30 µM and 40 µM.  
 
In addition to the fold change of GFP fluorescence within the SCL1 cell 
population, the percentage of GFP positive cells was calculated using histograms 
obtained from flow cytometry measurement. Figure 5-9 A shows an example of a 
histogram that describe the green fluorescence of the cell population when SCL1 cells 
were incubated with 40 µM of the different peptides. Figure 5-9 B displays the same 
histogram with a staggered offset so that every condition is clearly visible. It can be 
seen that the cell population of SCL1 cells treated with M3 or L-M3 did have the same 
distribution of green fluorescence as the DMSO control across the cell population and 
the histograms are overlayed. When cells were treated with R8-M3, GR8-M3 or 
GGR8-M3, the peaks of the histograms were shifted to the right, meaning that M3 
was delivered to these cells and increased green fluorescence was detected. The 
histogram of F-R8-M3 was only slightly shifted to the right, indicating a small change 
of green fluorescence and M3 delivery by FR8. In contrast, when FFR8-M3 was 
incubated with SCL1 cells at 40 µM, there is a clear shift of the cell population towards 
higher green fluorescence.  
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Figure 5-8 Effect of Phenylalanine or Glycine residue addition to R8-M3 on functional 
delivery of M3  
Live split GFP complementation assay to monitor M3 delivery. SCL1 cells were washed once 
in serum free media and incubated with DMSO, R8-M3, FR8-M3, GR8-M3, FFR8-M3 or 
GGR8-M3 at 10-40 µM for 2h at 37ºC. Cells were prepared for flow cytometry measurement. 
In total 20,000 cells were measured. Cells were gated for morphologically intact cells using 
SSC and FSC measurements and green fluorescence within this cell population was 
measured using the 488 nm excitation laser and the FITC emission filter. Fold change is 
shown compared to the DMSO control which was set to the value 1. (A) Comparison of single 
amino acid additions to R8-M3. For statistical analysis data was tested using a One way 
Annova followed by multiple comparison using a Turkey HSD (honest significant difference) 
test. No significant difference was seen for M3 delivery by FR8-M3 or GR8-M3 compared to 
R8-M3. (B) Comparison of addition of two amino acid additions to R8-M3.For statistical 
analysis data was tested using a One way Annova followed by multiple comparison using a 
Turkey HSD (honest significant difference) test. Significance is shown for FFR8-M3 compared 
to the corresponding concentrations of GGR8-M3 and R8-M3. *: p<0.05, **: p<0.01, ***: 
p<0.001, n.s.: not significant. Error bars: standard error of the mean n=3. 
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This change of green fluorescence within the cell population was further 
calculated to display the percentage of GFP positive cells (Figure 5-9 C). It can be 
seen that SCL1 cells were not positive for GFP complementation when they were 
incubated with M-3 or L-M3 at concentrations ranging from 10-40 µM. Treatment of 
SCL1 cells with R8-M3 showed a concentration dependent increase of cells that were 
positive for M3 delivery ranging from 5% at 10 µM to 28% at 40 µM. When cells were 
incubated with FR8-M3 no change was seen at 10 µM and the cell population was 
11% positive at 40 µM. The highest increase of positive cells was seen for FFR8-M3. 
At 10 µM, 10% of the cell population were detected as GFP positive. This rapidly 
increased to 51% when 20 µM were applied and further increased to 65% and 72% 
for when incubated with 30 µM and 40 µM, respectively. Substitution of one or two 
Glycine residues had a similar effect on delivery efficiency of M3 into SCL1 cells. For 
both conditions the percentage of GFP positive cells was decreased at each 
concentration compared to R8-M3 and both peptides achieved a 17% GFP positive 
SCL1 cell population at the maximum concentration of 40 µM.  
 
This shift in percentage positive cells correlates with the fold change of GFP 
fluorescence seen for the different peptides when incubated with SCL1 cells. This 
data demonstrated that functional cytosolic M3 delivery is most efficient using FFR8 
as a drug delivery vector. The second efficient delivery vector was shown to be R8 
followed by GR8-M3 and GGR8-M3. The least effective drug delivery vector in this 
study was FR8-M3.  
This experiment clearly shows that the SCL1 cell line can be utilised to evaluate 
different CPPs regarding their ability to deliver M3 peptide cargo into cells.  
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Figure 5-9 Shift of green fluorescence in SCL1 cell population when treated with 
different peptides.  
Live split GFP complementation assay to monitor M3 delivery. SCL1 cells were washed once 
in serum free media and incubated with DMSO, M3, L-M3, R8-M3, FR8-M3, GR8-M3, FFR8-
M3 or GGR8-M3 at 10-40 µM for 2h at 37ºC. Cells were washed in 0.5 mg/ml Heparin 3 times 
and detached from the cell culture dish using trypsin and prepared for flow cytometry 
measurement. In total 20,000 cells were measured. Cells were gated for morphologically intact 
cells using SSC and FSC measurements and green fluorescence within this cell population 
was measured using the 488 nm excitation laser and the FITC emission filter. (A) Example 
histogram shown when SCL1 cells were incubated with 40 µM of peptide. (B) Histogram with 
a staggered offset to emphasize shift of populations. (C) Percentage positive cells were 
determined using the population comparison tool in the FlowJo software. DMSO control 
samples were used for the corresponding concentration to compare populations. Error bars: 
SEM. n=3. 
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5.5 Delivery of M3 by different DDSs using mCherry-SCL51 cells 
After it was seen that two phenylalanine residues can significantly increase M3 
delivery into cells, the different M3 containing peptide formulations were further tested 
using the stable cell line mCherry-SCL51. 
However, before M3 delivery by R8 containing drug delivery systems was 
investigated in a live cell assay, the compatibility of the M3 containing peptides to 
complement to full length GFP with mCherry-GFP1-10 expressed by mCherry-SCL51 
cells was first tested in an in vitro assay.  
 
5.5.1 In vitro complementation of peptides with mCherry-SCL51 lysate 
To investigate GFP complementation in vitro, mCherry-SCL51 cells were 
trypsinised and pelleted. The cell pellet was resuspended in 0.1% Triton-X-100 and 
left to lyse the plasma membrane for 4 min. 80 µM of M3 containing peptides in PBS 
were then mixed with cell lysate of mCherry-SCL51 cell expressing mCherry-GFP1-
10 to a obtain a final mix of lysate in 0.05% Triton-X100 in PBS with 40 µM of M3 
containing peptides. mCherry-GFP1-10 lysate with the peptides was then left at room 
temperature under constant agitation and GFP complementation was monitored 
using a microplate reader every hour for 7 h (Figure 5-10). The in vitro 
complementation assay revealed that cell lysate from mCherry-SCL51 only 
complemented to form full length GFP when M3 was present. The drug delivery 
system R8 alone did not rescue GFP fluorescence. In vitro complementation using 
40 µM R8-M3 showed a time dependent increase of GFP complementation with 
mCherry-GFP1-10. An N-terminal addition of Phenylalanine (F) or Glycine (G) 
residue to R8-M3 did not alter complementation dynamics, nor did an addition of two 
Phenylalanine (FF) or Glycine (GG) residues.  
For all peptides a similar amount of GFP fluorescence was detected at each time 
point and the GFP complementation was not significantly different between the M3 
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containing peptides at time points 2h and 7h. This shows that addition of 
Phenylalanine or Glycine residues to R8-M3 did not inhibit or enhance the ability to 
complement with mCherry-GFP1-10 in vitro as it was seen before when peptides 
were tested with SCL1 cell lysate in vitro.  
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Figure 5-10 In vitro complementation of peptides with mCherry-SCL51.  
In vitro complementation of lysed mCherry-SCL51 cells with peptides. Cells were trypsinised and lysed using 0.1% Triton-X100 in PBS. Cell lysate of 0.8X105 
cells was mixed with 80 µM M3 and CPP-M3 peptides to obtain a final concentration of 40 µM in 0.05% Triton-X-100/PBS. Lysate mixture was left under 
constant agitation at room temperature. The fluorescent signal resulting from GFP complementation was minored over 24 h using a microplate reader. DMSO 
only control was subtracted as the sample background. n=3. Error bars present SEM. For statistical analysis data was tested using a One way Annova followed 
by multiple comparison using a Turkey HSD (honest significant difference) test. Data was tested at two time points, 120min and 7h. No significant differences 
were detected between M3 containing peptides at time points 2h and 7h. n.s.: not significant.  
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5.5.2 Effect of Phenylalanine or Glycine substitution to R8 on the efficiency 
to deliver M3 to the cytosol 
It was next explored if a concentration dependent as well as DDS dependent 
delivery of M3 by different R8 based peptides can be observed in a live split GFP 
complementation assay using mCherry-SCL51 by flow cytometry. To test this, 
mCherry-SCL51 cells were washed once in serum free media and incubated with 
DMSO, M3, L-M3, R8-M3 or Glycine/ Phenylalanine added versions of R8-M3 
(G/GG/F/FF) at a concentration range of 10-40 µM for 2h at 37ºC. The cells were then 
washed in 0.5 mg/ml Heparin for 3 times in order to remove membrane bound CPP-
M3 peptide. Cells were detached from the cell culture dish using trypsin and washed 
with PBS twice. Cells were then resuspended in PBS and transferred into a FACS 
tube and kept on ice until flow cytometry measurements. GFP fluorescence of 10,000 
cells was detected using flow cytometry and cells were gated for morphologically 
intact cells using FSC and SSC measurements. (For the 40 µM R8-M3 sample, GFP 
fluorescence of 20,000 cells were accidently collected.) The geometric mean of all 
samples was normalised to the DMSO control that was set to a value of 1 to display 
a fold change in GFP fluorescence. Figure 5-12 A displays the concentration 
dependent delivery of M3 by R8 compared to mCherry-SCL51 cells that were 
incubated with M3 or L-M3 only. M3 and L-M3 were not able to access the cytosol 
when incubated at concentrations of 10-40 µM. When mCherry-SCL51 cells were 
incubated with 10 µM R8-M3, GFP fluorescence was increased to 1.02 fold compared 
to the DMSO control (1 fold) indicating functional delivery of the M3 peptide to the 
cytosol. GFP fluorescence increased to 1.05 fold at 20 µM and remained at that 
fluorescence when incubated at 30 µM. Incubation with 40 µM R8-M3 resulted in 1.08 
fold change compared to the DMSO control (1.0 fold). Hence, R8 was able to delivery 
M3 to the cytosol of SCL1 cells at each concentration but a concentration dependent 
increase was not observed when mCherry-SCL51 cells were incubated with 30 µM 
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R8-M3. In contrast, when single amino acids F or G were added to the N-terminus of 
R8-M3, a concentration dependent delivery was observed for both of the peptides 
(Figure 5-11 B). GR8-M3 showed no functional delivery of M3 at 10 µM but increased 
to 1.14 fold at 40 µM and was therefore more efficient to deliver M3 than R8-M3. 
Compared to that, FR8-M3 delivered M3 to an even greater extend, starting at the 
same efficiency like R8-M3 at 10 µM (1.03 fold) and achieving a 1.19 fold change at 
30 µM and a 1.3 fold change of GFP fluorescence at 40 µM.  
Figure 5-11 C displays the M3 delivery efficiency of peptides with addition of two 
amino acid residues, FFR8-M3 and GGR8-M3. N-terminal substitution of FF to R8-
M3 had a great effect on functional delivery of M3 and achieved a 1.06 fold change 
in GFP fluorescence at 10 µM and 1.5 fold and 2.5 fold at 20 µM 30 µM, respectively. 
When cell were incubated with 40 µM, GFP fluorescence even changed by 3.1 fold. 
In contrast, substitution of GG to R8-M3 did not result in the same enhancement for 
M3 delivery. M3 delivery using GGR8-M3 increased compared to GR8-M3 and R8-
M3 and fold change in GFP fluorescence was comparable to FR8-M3 at every 
concentration.  
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Figure 5-11 Effect of Phenylalanine or Glycine substitution 
to R8 on M3 delivery using mCherry-SCL51. 
mCherry-SCL51 cells were washed once in serum free media 
and incubated with DMSO, M3, L-M3, R8-M3, FR8-M3, GR8-
M3, FFR8-M3 or GGR8-M3 at 10-40 µM for 2h at 37ºC. Cells 
were washed in 0.5 mg/ml Heparin for 3 times and detached 
from the cell culture dish using trypsin and prepared for flow 
cytometry measurement. In total 10,000 cells were measured 
(20,000 cells for 40 µM R8-M3 treated cells). Cells were gated 
for morphologically intact cells using SSC and FSC and then 
for mCherry positive cells using the red signal detected through 
the PerCP-Cy5-5 filter. Within that population, green 
fluorescence was measured using the 488 nm excitation laser 
and the FITC emission filter. Fold change is shown compared 
to the DMSO control which was set to the value 1. n=1. 
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The efficiency of the different peptides to deliver M3 was also reflected in the 
histograms of the fluorescence of the whole population. Figure 5-12 A shows an 
example histogram that resulted when mCherry-SCL51 cells were incubated with 40 
µM peptides. The same histogram is shown using a staggered offset in Figure 5-12 
B. It can be seen that histograms of M3 and L-M3 were overlaid with the histogram 
obtained from the DMSO sample and histograms of GR8-M3, FR-M3, GGR8-M3 and 
FFR8-M3 were shifted to the right, indicating higher green fluorescence of cell 
populations demonstrating M3 delivery. The peak obtained from R8-M3 was higher 
compared to others because 20,000 cells were measured compared to 10,000 for 
other samples.  
When the shift of histograms was calculated as percentage positive cells 
compared to the DMSO control, the same trend as when fold change of GFP 
fluorescence was calculated was seen. Cell populations of M3 and L-M3 were 
negative for GFP complementation and M3 delivery. A small change can be detected 
for R8-M3 at all concentrations but the change of percentage positive cells is not 
concentration dependent between 20 µM and 30 µM but reaches 8.33% of GFP 
positive cells at 40 µM. F-R8-M3, GR8-M3 and GGR8-M3 all show a concentration 
dependent increase in percentage positive cells of M3 delivery reaching 29.43% 
15.79% and 29.08% when incubated with 40 µM, respectively. FFR8-M3 delivers M3 
most efficient and achieves a 67.58% positive cell population when cells are 
incubated with 40 µM. The highest increase in percentage positive cells can be 
observed when FFR8-M3 concentration increases from 10 µM (8.58%) to 20 µM 
(39.37%). 
This data obtained using mCherry-SCL51 cells indicates that FFR8-M3 delivered 
M3 most efficient followed by FR8-M3 and GGR8-M3. Substitution of one Glycine 
resulted in decreased efficiency to deliver M3 compare to GGR8-M3 but it was more 
efficient than R8-M3. R8-M3 did not show a concentration dependent increase in 
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delivery and the delivery efficiency was the least effective compared to all delivery 
systems that were investigated.  
However, this data was obtained from a single experiment and should be 
repeated in order to confirm these results.  
 
 
Figure 5-12 Shift of green fluorescence in mCherry-SCL51 cell population when treated 
with different peptides.  
Live split GFP complementation assay to monitor M3 delivery. mCherry-SCL51 cells were 
washed once in serum free media and incubated with DMSO, M3, L-M3, R8-M3, FR8-M3, 
GR8-M3, FFR8-M3 or GGR8-M3 at 10-40 µM for 2h at 37ºC. Cells were washed in 0.5 mg/ml 
Heparin for 3 times and detached from the cell culture dish using trypsin and prepared for flow 
cytometry measurement. In total 10,000 cells were measured (20,000 cells for 40 µM R8-M3). 
Cells were gated for morphologically intact cells using SSC and FSC measurements and then 
for mCherry positive cells using the red signal detected through the PerCP-Cy5-5 filter. Within 
that population, green fluorescence was measured using the 488 nm excitation laser and the 
FITC emission filter. (A) Example histogram shown when mCherry-SCL51 cells were 
incubated with 40 µM of peptides. (B) Histogram with a staggered offset to emphasize shift of 
populations. (C) Percentage positive cells were determined using the population comparison 
tool in the FlowJo software. DMSO control samples were used for the corresponding 
concentration to compare populations. n=1. 
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5.6 Discussion 
Split GFP has recently been utilised by several research groups in order to prove 
M3 peptide delivery and thereby evaluate the delivery efficiency of different peptide 
delivery vectors (Kim et al. 2015; Milech et al. 2015; Schmidt et al. 2015a; Lönn et al. 
2016). In this Chapter it was demonstrated that the split GFP system that was 
developed here can also be utilised to determine a concentration dependent delivery 
of M3 by a DDS. Moreover it allows evaluation of DDSs and their efficiency to 
functionally deliver peptide cargo to an intracellular target.  
Testing the delivery efficiency of functional M3 by different R8 derived peptides 
on two stable cell lines, SCL1 and mCherry-SCL51, showed a clear trend that a 
substitution of two Phenylalanine residues can enhance functional delivery of M3 
peptide cargo compared to R8-M3. One Phenylalanine residues did not result in an 
enhancement of functional delivery compared to R8 on SCL1 cells. A single 
experiment on mCherry-SCL51 cells indicated that FR8-M3 could have an increased 
delivery compared to R8-M3. It was also demonstrated that this increased delivery is 
specific to the hydrophobic Phenylalanine residue because functional M3 delivery 
was not increased with GR8-M3 or GGR8-M3 in SCL1 cells.  
Importantly, the effect of substitution of Phenylalanine residues on functional 
delivery in a live cell assay can be specifically shown by comparing the live cell assay 
data obtained from the in vitro assay. In the in vitro assay it was shown that every 
peptide has the same ability to complement with SCL1 expressed GFP1-10 to form 
full length GFP, with the complementation even being slightly increased for R8-M3 
compared to FFR8-M3. In contrast, in the live cell assay FFR8-M3 delivered the M3 
peptide highly increased compared to R8-M3. Because the two peptides 
complemented to the same degree with GFP1-10 in vitro, increase in GFP 
complementation in the live assay is specific to the delivery efficiency of the peptide. 
Hence, it was demonstrated that the improved in vitro system allows us to compare 
227 
 
complementation rates and degree of complementation of different peptides. This 
improvement is of high importance when different DDS-M3 peptides will be compared 
with each other to confirm that the effect seen in live uptake experiments is due to the 
DDS and not varying complementation ability of the peptides.   
 
In other GFP complementation studies, the intracellular GFP1-10 target was 
either expressed stably (Milech et al. 2015; Lönn et al. 2016) or transiently as a fusion 
protein to the expression marker mCherry (Schmidt et al. 2015a).  Here it was shown 
that the generated cell line SCL1 stably expressing GFP1-10 can be utilised to 
investigate concentration dependent and DDS dependent delivery of M3. One 
experiment also indicated that mCherry-SCL51 can be utilised to evaluate DDSs to 
deliver M3 is a dose dependent manner.  
It was seen on both cell lines that FFR8-M3 delivered M3 to a higher degree than 
the other peptides that were tested. FR8-M3 delivered M3 less efficiently than R8-M3 
on SCL1 cells but on the mCherry-SCL51 cell line it was indicated that FR8 could 
increase M3 delivery into cells. Results obtained from the mCherry-SCL51 cells 
should be confirmed, however, the reason for varying performance of the peptides on 
different cell lines can be hypothesised. The two factors that could influence the 
delivery performance in this assay are the peptides themselves as well as the two cell 
lines.  
When the R8 based peptides were purchased they were received as 1.0 mg 
powder aliquots. EZBiolabs reassured that the accuracy of the measured weight is to 
the best of their performance. Different batches of peptides were consistently diluted 
with the same amount of DMSO to a final concentration of 10 mM. However, slight 
batch to batch variations are possible and factors like long term storage and freeze 
thaw cycles could have influenced peptide performance.  
SCL1 cells and mCherry-SCL1 cells both stably express a protein in their cytosol. 
The site of integration of the DNA into the genome could be critical and uptake 
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mechanisms between the cell lines could be altered between the cell lines which 
could lead to different performance of the peptides on the cell lines.  
In Chapter 4 it was shown that even though the GFP1-10 target is expressed in 
every cell in the SCL1 cell line, only selected cells showed M3 delivery. It was 
hypothesised that a cellular factor (e.g. mitotic cells, plasma membrane composition) 
could be responsible to determine in which cells delivery takes place. If that 
mechanism is revealed in the future, the mCherry-SCL51 and SCL1 cell line should 
be characterised regarding that factor.  
 
Most importantly, the split GFP assay was not limited by the amount of 
intracellular expressed GFP1-10, even though it was demonstrated in Chapter 4 that 
the amount of expressed GFP1-10 was low compared to the levels that can be 
achieved using transient transfection. The expressed levels of GFP1-10 were 
sufficient to achieve a dose response for all R8 based delivery vectors used in this 
study.  
 
R8 and its function as a peptide delivery vector has not been investigated before 
by other groups utilising the split GFP system. One Arginine rich peptide similar to R8 
that has been characterised regarding its ability to deliver peptide cargo to the cytosol 
is nonaarginine (R9) (Milech et al. 2015; Schmidt et al. 2015a). Delivery efficiency of 
M3 by R9 was tested at a concentration range of 5-20 µM in both studies and in total 
three cell lines were investigated; CHO-K1 and HCC827 stably expressing GFP1-10 
and HEK293Tcells transfected with mCherry-GFP1-10. In all cell lines, delivery of M3 
was shown to be least efficient at concentrations of 5 and 10 µM. When the 
concentration was increased to 20 µM, a large increase in delivery efficiency was 
seen. In this chapter it was demonstrated that R8 efficiently acts as a drug delivery 
vector at concentrations of 10-40 µM and M3 was delivered to 28% of the cell 
population when incubated at 40 µM on SCL1 cells. R8 was able to deliver M3 at 
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concentrations as low as 10 µM. It would be interesting to investigate if delivery can 
also be detected down to 5 µM as it was shown in other studies for different CPPs.  
 
Two mechanisms are proposed by which CPPs like R8 can enter cells: by direct 
translocation or uptake via endocytic pathways. It was shown that R8 enters the cell 
by endocytic pathways like clathrin-mediated endocytosis or micropinocytosis at 
concentrations below 10 µM (Kaplan et al. 2005; Ikuhiko Nakase et al. 
2006(Kawaguchi et al. 2016). If they enter through endocytic mechanism it is critical 
for the peptide to escape the endosome to reach the cytosol and avoid degradation 
in the lysosome.  
The direct transduction efficiency of fluorophore conjugated polyarginines has 
been assessed. For R8 and longer polyarginines it was shown that direct transduction 
of the cells started as low as 5 µM (Tunnemann et al. 2008). This study was based 
on a phenotypic analysis where endocytic uptake was scored when fluorescent signal 
was enclosed in vesicles and direct transduction was accounted for when both, 
completely cytosolic distribution of the fluorophore was seen as well as a combination 
of cytosolic fluorescent signal and endosome enclosed CPP. A study by (Tunnemann 
et al. 2006) also suggested that CPPs with smaller cargos like non globular peptides 
can enter the cell through direct penetration. 
How uptake of R8-M3 is facilitated across the plasma membrane, through 
endocytic uptake followed by endosomal escape or direct translocation remains 
unknown. However, considering the high concentrations of R8 of 10-40 µM that have 
been used in this assay and the relatively small size of the M3 peptide cargo (1.8 
kDa) could suggest that direct translocation across the plasma membrane is possible. 
Lönn et al., 2016 have shown that the limiting factor for cargo delivery is 
endosomal escape and have shown that M3 delivery by Tat upon treatment with the 
endosomolytic agent chloroquine was greatly enhanced (Lönn et al. 2016). It would 
be interesting to investigate if treatment of chloroquine could enhance R8-M3 
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delivery. This could lead to the model that R8-M3 can cross the plasma membrane 
directly as well as via endocytosis. The direct entry is seen in 28% of the cell 
population, in other cells R8-M3 remains entrapped in endosomes.  
This would also explain the heterogeneous delivery of M3 across the cell 
population. It was seen that M3 was not functionally delivered into every cell of the 
SCL1 cell population. This cannot be attributed to the lack of expression of the 
intracellular GFP1-10 target protein because it was shown that SCL1 cells express 
even amounts of GFP1-10 across the cell population. Hence, another cellular 
mechanism is suggested that could be underlying that favours direct translocation or 
endocytic uptake. Interaction with the plasma membrane is critical for the uptake of 
CPPs and Schmidt et al., 2015 have shown that treatment of the plasma membrane 
with bacterial sphingomyelinase which leads to conversion from sphingomyelin into 
ceramide, increases M3 cargo delivery into cells by R9. Lipid composition and 
localisation is also changed during mitosis (Atilla-Gokcumen et al. 2014). It would be 
interesting to investigate the change of lipid composition throughout the cell cycle and 
test if direct M3 delivery by R8 is dependent of the stage of the cell cycle of the target 
cell.  
 
Popular strategies to enhance uptake of CPPs are the substitution or 
modification of single amino acids to enhance cell penetration. Especially 
hydrophobic residues like Phenylalanine or Tryptophan have been used to increase 
uptake of CPPs (Takayama et al. 2009; Rydberg et al. 2012; Takayama et al. 2012; 
Sayers et al. 2014; Lönn et al. 2016). A study by the group of Shiroh Futaki identified 
a penetration acceleration sequence (pas) consisting of the amino acid sequence 
FFLIPKG. N-terminal conjugation of that sequence to Alexa 488 labelled R8 highly 
increased its uptake in HeLa cells (Takayama et al. 2012). In that study, uptake of 
Alexa 488 labelled R8 with the N-terminal addition of two Phenylalanine residues via 
a Glycine residue (FFGR8) was investigated. Uptake of FFGR8 was examined at 1 
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µM and 15 min incubation time but was not of further interest because in only yielded 
a low increase of uptake compared to R8 and substitution of four Phenylalanine 
residues achieved even more increased uptake.  
However in that study Alexa 488 labelled FFGR8 was investigated using flow 
cytometry. Hence, the uptake of the peptide was investigated, not the ability of 
functional delivery of a cargo. In this chapter it was clearly shown that substitution of 
two phenylalanine residues to R8 (FFR8) enhances the functional delivery of the M3 
cargo peptide compared to R8 at concentrations between 10 and 40 µM. This effect 
is specific to the hydrophobic Phenylalanine residues and was not achieved when 
conjugating two Glycine residues to the CPP R8. Conjugation of one Phenylalanine 
did not result in an enhancing effect compared to R8-M3 when investigated on SCL1 
cells. Based on the previous study that FFFFGR8 uptake was more enhanced that 
FFGR8 (Takayama et al. 2012), it would be interesting to test if the addition of four 
phenylalanine residues to R8-M3 could have an even more enhancing effect on 
delivery than FFR8-M3.   
 
Steven Dowdy’s group has utilised the split GFP assay to determine endosomal 
escape domains (EEDs) attached to the CPP TAT  to enhance the functional delivery 
of GFP11 to intracellular GFP1-10 by enhancing endosomal escape (Lönn et al. 
2016). EEDs consisted of either Phenylalanine or Tryptophan residues were 
investigated in his study. The EEDs which was identified to increase cytosolic delivery 
of the cargo peptide was a residue consisting of two Phenylalanine residues with a 
central Tryptophan residue (FWF). An EED consisting of four Phenylalanine residues 
was shown to increase delivery but was also associated with severe cytotoxic effects. 
When Shiroh Futaki’s group tested the enhanced uptake of FFFFGR8 it was reported 
that this peptide was not accompanied by sever cytotoxicity monitored by the live cell 
impermeable stain propidium iodide (PI) (Takayama et al. 2012).  
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Membrane integrity and cytotoxicity is an important factor to consider when 
evaluating drug delivery vectors because in addition to their ability to deliver cargo 
into cells, they should not affect the viability of the target cell. Especially when working 
with CPPs this is critical because they have the ability to penetrate the plasma 
membrane. Hence, it will be critical to evaluate the cytotoxic effects of FFR8-M3 in 
order to fully characterise this peptide as a delivery vector for peptides.  
 
In a study by Gisela Tuennemann the penetration ability of polyarginines with 
respect to their cytotoxicity was tested (Tunnemann et al. 2008). For R8 it was seen 
that cells where direct translocation of the fluorophore tagged R8 took place were 
stained for PI from a concentration of 10 µM. However concentration up to 50 µM only 
showed a PI staining of under 10% of the cell population. In this study a concentration 
range of 10-40 µM was used. However R8 was also conjugated to a 2.4 kDa cargo 
peptide (including the linker between cargo and R8) which could have an influence 
on membrane integrity when this cargo is delivered across the plasma membrane.  
 
The selection of morphologically intact cells was aimed to be achieved by flow 
cytometry measurements. Gating of morphologically intact cells by flow cytometry 
and measurement of green fluorescence of viable cells was based on the Split GFP 
study published by Schmidt and his colleagues (Schmidt et al. 2015a). Using a 
Live/Dead cell stain, data collected from a single experiment suggested which FSC 
and SSC measurements correlate with morphologically intact cells. It was shown that 
cells that small and less granular included cells that were positive for the cells stain. 
However this experiment should be repeated including an experimental control with 
cells where the plasma membrane has been permeabilised.  
A different method to assess the integrity of the plasma membrane includes the 
treatment of cells with the nuclear counterstain propidium iodide (PI). This a popular 
stain to determine membrane damage by CPPs (Tunnemann et al. 2008; Takayama 
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et al. 2012). The stain is not permeable to live cells and only stains cells with a non-
intact plasma membrane. However, PI (excitation/emission: 535 m/617nm) has 
similar fluorescent characteristics like mCherry and it would not have been possible 
to distinguish the fluorescent signal from cells that were expressing mCherry-GFP1-
10 or cells that were permeable for the PI stain. In order to perform the flow cytometry 
experiments consistently between cell lines SCL1 and mCherry-SCL51, this method 
was not followed up on further.  
Milech and colleagues have included the violet Live/Dead cell stain within their 
M3 delivery studies by CPPs (Milech et al. 2015).  However, this cell stain requires 
incubation of 30 min according to the manufactures instructions which delays flow 
cytometry measurements additional to the time that is needed for the sample 
preparation. Because this method is supposed to be a real time assessment of M3 
delivery so that the time between the end of incubation of the DDS-M3 peptide until 
flow cytometry measurements should be kept minimal.   
 
Retrospective, it would have been beneficial to add the cell stain PI to assess 
membrane integrity of SCL1 cells when treated with different CPP-M3 compounds. 
This would have given valuable information about the influence on membrane 
integrity depended on the type of CPP as well as on the concentration dependent 
influence on membrane integrity. For this reason it is inevitable to assess the 
cytotoxicity of the peptides used in this study to be able to correlate cytotoxicity data 
with the ability to delivery M3 cargo into cells.  
 
 
In summary, in this chapter it was shown that the generated cell line SCL1 can 
be utilised to investigate DDS dependent as well as concentration dependent delivery 
of the M3 peptide and allows characterisation of the DDSs. To obtain the full picture 
of the performance of the DDS this should be correlated with cytotoxicity studies.  
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Moreover it was shown that the substitution of two Phenylalanine residues to R8-M3 
can significantly increase delivery of the M3 peptide and this effect can be specifically 
attributed to the Phenylalanine residue.  
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6 Microscopic analysis of M3 delivery by R8 based 
peptides  
6.1 Introduction 
Thus far, it is has been established that the split GFP assay developed within 
this study can be utilised to evaluate the M3 peptide delivery efficiency of different R8 
based peptides. In order to gain information of delivery in a large number of cells and 
to be able to assess multiple conditions within the same experiment, flow cytometry 
measurement was chosen as a detection method. This detection method was also 
utilised by other research groups that have developed the split GFP assay as a 
method to characterise novel DDSs to functionally deliver M3 peptide (Milech et al. 
2015; Schmidt et al. 2015b; Lönn et al. 2016).  
One aim of this project was utilise the split GFP as a microscopy based technique 
to not only show if the M3 peptide has been functionally delivered to its cellular target 
but also to investigate its subcellular localisation. This will help to examine if DDSs 
have an influence on the localisation of their cargo.  
Detailed microscopic analysis of M3 peptide delivery by DDSs has not been 
shown by other research groups so far. One figure including microscopy images was 
published by the group of Roland Brock to confirm GFP complementation using R9 
as a delivery vector is increased in bacterial sphingomyelinase treated cells (Schmidt 
et al. 2015a). However, those images did not add any further information to the assay 
other than confirming that the M3 peptide had been delivered and GFP 
complementation had occurred.  
Microscopic analysis has the potential to add more valuable information in order 
to characterise DDSs than just answering the question if a cargo has reached the 
cytosol of a cell. Utilising widefield microscopy, it was shown in Chapter 3 and Chapter 
4 that real time delivery of M3 peptide by a DDS can be observed in live cells which 
allows us to image an effect of cargo and target interaction in real time.  Furthermore, 
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it was seen that complemented GFP localises to the nucleolus when R8 is used as a 
DDS to deliver the peptide. In a study by Giesela Tuennemann, fluorophore 
conjugated R8 has been characterised to be able to act as a nucleolar live cell marker 
for imaging (Martin et al. 2007).  
Subcellular localisation of a delivered peptide cargo is critical when it has to 
function at a specific site of action. For this reason it is important to not only be able 
to monitor if and when the peptide is delivered into the intracellular target but also 
where the target-cargo complex is localised inside the cell and what influence a drug 
delivery system has on subcellular localisation of a peptide cargo and its associated 
target.  
 
The aim of this chapter is to analyse and characterise the localisation of M3 
delivery by R8 based peptides with Glycine and Phenylalanine residue addition using 
microscopy as the detection method for split GFP complementation. It is hypothesised 
that microscopy can add further information as to where complemented GFP localises 
inside the cell and what influence a drug delivery vector can have on the peptide-
cargo complex localisation.   
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6.2 Localisation of complemented GFP  
6.2.1 Localisation of complemented GFP using R8-M3 as a DDS 
In chapter 3 and 4, complemented GFP was noticed to be localised to the 
nucleolus when cells were treated with R8-M3. In order to confirm the subcellular 
localisation of complemented GFP when R8 is utilised as a DDS to deliver M3, SCL1 
cells were washed once with serum free media, incubated with 40 µM R8-M3 for 2h 
at 37ºC and the nucleus was stained with Hoechst. In chapter 5 it was shown that 
green fluorescence from GFP complementation was highest when SCL1 cells were 
incubated with 40 µM peptide. Furthermore, it was previously shown that untreated 
SCL1 cells are green fluorescent as a result of GFP1-10 expression. Hence, a 
concentration of 40 µM was chosen to achieve the highest GFP complementation 
signal in order to visualize the subcellular localisation of GFP and obtain a sufficient 
signal over the green fluorescent background of SCL1 cells.  
Figure 6-1 shows a typical image of cells where GFP has complemented as a 
result of M3 delivery to the cytosol by R8. It can be seen that the GFP fluorescence 
is mainly localised in two compartments: the cytosol and the nucleus (Figure 6-1 C). 
Enlargement of a cell that exhibits GFP fluorescence reveals that fluorescence is not 
distributed in the entire nucleus but concentrated as round structures at specific 
localisations that remind of nucleolar labelling (red arrow heads).  
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Figure 6-1 Localisation of complemented GFP using R8-M3. 
SCL1 cells were incubated with R8-M3 at 40 µM in serum free media for 2 hours at 37˚C. 
Cells were counterstained with Hoechst nuclear dye and kept in phenol red free RPMI for 
imaging. GFP fluorescence was detected using a widefield fluorescent microscope. (A-C) 
Representative image that shows GFP complementation achieved by M3 delivery by R8. Cell 
in red square is enlarged in images D-E. (F) Red arrow heads point out nucleolar localisation 
of GFP. Scale bar: 10µm.n=3.  
 
 
 
Figure 6-2 Comparison of localisation of complemented GFP using R8 or FFR8 to 
deliver M3. 
SCL1 cells were incubated with R8-M3 or FFR8-M3 at 40 µM in serum free media for 2 hours 
at 37˚C. Cells were counterstained with Hoechst nuclear dye and kept in phenol red free RPMI 
for imaging. GFP fluorescence was detected using a widefield fluorescent microscope. 
Representative images show GFP complementation achieved by M3 delivery by R8 (A-D) or 
FFR8 (E-H). Cells in red squares are enlarged in images D and H. (D) Red arrow heads point 
out nucleolar localisation of GFP. Scale bar: 10µm.n=3.  
239 
 
6.2.2 Localisation of complemented GFP using FFR8-M3 as a DDS 
It was next investigated if the N-terminal addition of Glycine or Phenylalanine 
residues to R8-M3 influences the subcellular localisation of complemented GFP 
compared to R8-M3. We have previously shown that substitution of two 
Phenylalanine residues (FFR8-M3) had the most dramatic effect to increase M3 
delivery to the cytosol of SCL1 cells. Hence, it was first compared if a difference in 
complemented GFP localisation can be seen when cells are incubated with R8-M3 of 
FFR8-M3. To investigate this, SCL1 cells were washed once with serum free media, 
incubated with 40 µM R8-M3 or FFR8-M3 for 2h at 37ºC and the nucleus was stained 
with Hoechst. 
Comparison of the localisation of complemented GFP using R8-M3 or FFR8-M3 
to deliver M3 cargo to the cytosol reveals that complemented GFP is distributed 
differently inside the cells (Figure 6-2). Complemented GFP is again localised in the 
cytosol and concentrated as punctate structures in the nucleus (red arrow heads) 
when R8-M3 served as a delivery vector for M3 (Figure 6-2 C, D). When FFR8-M3 
was utilised for delivery, complemented GFP signal is evenly distributed throughout 
the entire cell (Figure 6-2 G). When the image is enlarged in the area where the 
nucleus is localised, no distinct nuclear structure can be seen and even distribution 
of GFP signal between the nuclear area and the cytosol is observed (Figure 6-2 H). 
When comparing the two samples, it is striking that the exact localisation of the 
nucleus can be determined on the basis of complemented GFP distribution when 
incubated with R8-M3. There is a clear separation of the GFP signal between the 
cytosol and the nucleus which emphasizes the outline of the nucleus within the cell. 
Complemented GFP signal is excluded from the nucleus and only localises to the 
nucleolus inside the cell.  
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6.2.3 Influence of N-terminal amino acid substitutions to R8-M3 on the 
localisation of complemented GFP 
It was next explored if the change of localisation of complemented GFP that is 
seen between R8-M3 and FFR8-M3 is specific to the addition of two Phenylalanine 
residues or whether this is an effect of N-terminally ‘capping’ of R8. To investigate 
this, cytosolic localisation of complemented GFP was investigated when cells were 
treated with either R8-M3 or the amino acid substituted versions of R8-M3, FR8-M3, 
FFR8-M3, GR8-M3 or GGR3-M3. This experiment was carried out using cells 
transiently expressing GFP1-10 because it was previously shown that stable GFP1-
10 expression in SCL1 cells results in a high amount of green fluorescence.  
Moreover, delivery efficiency of M3 by peptides with one addition of a 
Phenylalanine or Glycine residue the amino acid was not as great as seen with FFR8-
M3. Hence, green fluorescence in SCL1 cells could be confused with low signal of 
GFP complementation resulting from treatment with non-efficient peptide when 
localisation is visually analysed.  In order to ensure that the green fluorescence that 
is seen in localisation experiments can be certainly attributed to the fluorescence of  
complemented GFP further localisation experiments were performed using HeLa 
cells transiently expressing GFP1-10.  
To explore the intracellular localisation of complemented GFP when cells were 
treated with different peptides, cells transiently expressing GFP1-10 were washed 
once with serum free media and incubated with 40 µM R8-M3 or amino acid 
substituted versions, FR8-M3, FFR8-M3, GR8-M3 or GGR3-M3 for 2h at 37ºC. After 
incubation the nucleus was stained with Hoechst. Figure 6-3 shows representative 
images obtained from analysing cells using a widefield microscope.  It is again visible 
that cells incubated with R8-M3 show a distribution of complemented GFP in the 
cytosol as well as localised to the nucleolus (Figure 6-3 G, H). Only weak green 
fluorescence can be seen for the DMSO control that is likely to be a source of GFP 
fluorescence resulting from transient GFP1-10 expression (Figure 6-3 C, D). Addition 
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of one or two Glycine residues to R8-M3 (GR8-M3/GGR8-M3) showed the same 
distribution of complemented GFP as it was seen when cell were incubated with R8-
M3. When cells were treated with 40 µM GR8-M3 and GGR8-M3, the GFP signal was 
localised at the nucleolus or the cytosol (Figure 6-3 L, P). For cells treated with R8-
M3, GR8-M3 and GGR8-M3, a clear separation of GFP fluorescence can be seen 
between the nucleus and the cytosol and almost no green fluorescence is detected 
at the nucleus apart from GFP localised at the nucleolus (red arrow heads). Addition 
of Phenylalanine residues changed the localisation of complemented GFP and this 
effect is seen for a single substitution (FR8-M3) or a double substitution (FFR8-M3). 
Incubation of 40 µM FR8-M3 or FFR8-M3 resulted in an even distribution of GFP 
signal throughout the cell and no separation can be seen between the cytosol and 
the nucleus (Figure 6-3 T,X).  
This data shows that complemented GFP is localised at different places inside 
the cell depending on which drug delivery vector was chosen. Furthermore, N-
terminal ‘capping’ of R8-M3 with one or two Glycine residues did not have an 
influence on subcellular localisation compared to R8-M3. Thus, relocalisation of 
complemented GFP to be distributed evenly throughout the cell is an effect that can 
be specifically attributed to the addition of Phenylalanine residues. The main 
difference between Phenylalanine substituted R8-M3 and R8-M3 or Glycine 
substituted versions was this distinct separation of complemented GFP signal from 
the nucleus and the cytosol for R8-M3 and Glycine substituted R8-M3. However, 
these images were taken with a widefield microscope. In order to confirm that there 
is a localisation difference seen within the plane of the nucleus inside the cell, this 
experiment was repeated on a confocal microscope.   
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Figure 6-3 Influence of substitution of Glycine or Phenylalanine 
residues to R8-M3 on complemented GFP localisation. 
HeLa cells transiently expressing GFP1-10 were incubated with DMSO, 
R8-M3, FR8-M3, FFR8-M3, GR8-M3 or GGR8-M3 at 40 µM in serum free 
media for 2 hours at 37˚C. Cells were counterstained with Hoechst nuclear 
dye and kept in phenol red free RPMI for imaging. GFP fluorescence was 
detected using a widefield fluorescent microscope. Representative images 
show GFP complementation achieved by M3 delivery. Cells in red squares 
are enlarged in images D, H, L, P, T and X. Red arrow heads point out 
nucleolar localisation of GFP. Scale bar: 10µm.n=2.  
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6.2.4 Confocal analysis of complemented GFP localisation  
For confocal analysis of complemented GFP distribution inside the cell, HeLa 
cells transiently expressing GFP1-10 were washed once with serum free media and 
incubated with 40 µM R8-M3 or amino acid substituted versions, FR8-M3, FFR8-M3, 
GR8-M3 or GGR3-M3 for 2h at 37ºC. The nucleus was stained with Hoechst and cells 
were imaged on a confocal microscope. Images of single planes through the cells 
were taken. The nucleus served as an orientation point to visualize different samples 
at comparable z localisation within the cell. Representative images for each condition 
are shown in Figure 6-4 A. The exact localisation of complemented GFP can be seen 
in Figure 6-4 B where images obtained from the GFP channel are enlarged. These 
images confirm the results observed with a widefield microscope and show that 
complemented GFP is localised in the cytosol and at the nucleolus when incubated 
with R8-M3, GR8-M3 or GGR8-M3 (Figure 6-4 B). For all three conditions a clear 
separation of complemented GFP from the nucleus can be seen. Compared to these 
samples, the complemented GFP fluorescence is evenly distributed within the cells 
when cells were incubated with F8-M3 or FFR8-M3; and this observation is 
independent on the amount of complemented GFP (brightness of the cell). 
Observation of the GFP channel of the samples incubated with F8-M3 or FFR8-M3 
does not give a hint of where the nucleus or nucleolus could be localised within the 
cell (Figure 6-4 B). Even though the GFP intensity is not highly increased compared 
to the DMSO control, a difference between these samples can be seen suggesting 
that fluorescence is indeed derived from GFP complementation. The DMSO sample 
shows two cells with increased fluorescence compared to other cells in the field of 
view (marked with red stars). This fluorescence is suggested to be derived from 
GFP1-10 expression in cells as it was previously shown to occur when GFP1-10 is 
expressed in HeLa cells. Green fluorescence in those cells is localised in the cytosol 
and the nucleus but not at the nucleolus which can be seen as punctate structures 
without GFP fluorescence. Compared to that green fluorescence, GFP fluorescence 
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derived from complementation for cells treated with 40 µM FR8-M3 and FFR8-M3 is 
increased and no nucleolar structures can be seen.  
 
The data obtained from confocal microscopy confirms that distribution of 
complemented GFP is altered depending on the type of drug delivery vector used to 
deliver M3 into the cell.  
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Figure 6-4 Confocal analysis of complemented GFP localisation. 
HeLa cells transiently expressing GFP1-10 were incubated with DMSO, R8-M3, FR8-M3, 
FFR8-M3, GR8-M3 or GGR8-M3 at 40 µM in serum free media for 2 hours at 37˚C. Cells were 
counterstained with Hoechst nuclear dye and kept in phenol red free RPMI for imaging. GFP 
fluorescence was detected a confocal microscope. (A) Representative images for each 
condition show GFP complementation achieved by M3 delivery. (B) GFP channels shown for 
each condition. Red arrows point out nucleolar localisation of GFP. n=1.  
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6.3 GFP complementation at the Golgi membrane  
In Chapter 3 it was mentioned that the expression construct GRASP65-GFP1-
10 had been generated to obtain GFP1-10 expression that is retained at the Golgi 
membrane.  
Using the GRASP65-GFP1-10 expression construct, it was investigated in a final 
experiment if the M3 peptide can be delivered to the outside of the Golgi membrane 
(cytosolic access) to complement with GFP1-10. To test this, Hela cells were 
transiently transfected with 125 ng DNA coding for GRASP65-GFP1-10. The next 
day, cells were incubated with 40 µM of M3 peptides for 2h at 37ºC. The peptides that 
were chosen to be investigated were M3, as a non-DDS conjugated version; R8-M3, 
representing the peptides that localised complemented GFP to in the cytosol and the 
nucleolus and FF-R8M3, a peptide highly efficient at delivering M3 to the cytosol and 
locating complemented GFP in the cytosol. Figure 6-5 shows the result of the 
experiment suggesting that M3, not conjugated to a DDS was not able to enter the 
cells (Figure 6-5 III). R8-M3 did deliver M3 to the cytosol of cells, however only cells 
were found where the whole cytosol was found to be positive for GFP 
complementation (Figure 6-5 VI). No cell was found where complemented GFP was 
localised to the Golgi apparatus. When FFR8-M3 was incubated with the cells, clear 
complementation of Golgi retained GRASP65-GFP1-10 with M3 was seen (Figure 
6-5 IX).   
 
This was an interesting finding which could indicate that, even though R8-M3 
and FFR8-M3 both deliver the M3 peptide to the cytosol, the delivery vector however 
can influence cargo localisation and delivery to cytosolic targets of intracellular 
organelles.   
However, more work has to been done to confirm these findings and elucidate if 
the delivery of the M3 peptide to the Golgi apparatus can be enhanced by attachment 
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of a Phenylalanine residues to R8-M3 and if this effect is specific to the Phenylalanine 
substitution.  
 
 
 
 
 
 
Figure 6-5 M3 delivery to the Golgi apparatus.  
HeLa cells transiently expressing GRASP65-GFP1-10 were incubated with M3, R8-M3 or 
FFR8-M3 at 40 µM in serum free media for 2 hours at 37˚C. Cells were counterstained with 
Hoechst nuclear dye and kept in phenol red free RPMI for imaging. GFP fluorescence was 
detected using a widefield fluorescent microscope. Representative images show GFP 
complementation achieved by M3 delivery. Scale bar: 10µm.n=1. 
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6.4 Discussion 
Cytosolic delivery of macromolecules bears the huge potential for these drugs to 
act at specific intracellular targets. Their high specificity has the potential to result in 
increased therapeutic efficacy and reduced toxicity (Panyam and Labhasetwar 2004).  
Hence, it is not only important to deliver the macromolecule to the cytosol of a cell but 
also ensure that it reaches its site of action within the cell. Intracellular targets include 
the cytosol to target kinases or other enzymes, apoptotic factors residing in the 
mitochondria or modulators of gene expression (e.g. transcription factors) within the 
nucleus (Panyam and Labhasetwar 2004; Mitragotri et al. 2014). For this reason drug 
delivery vectors are designed to not only overcome the plasma membrane barrier but 
to also enter intracellular organelles like the mitochondria or the nucleus (Jensen et 
al. 2003; Cardarelli et al. 2008; Horton et al. 2008; Horton et al. 2012; Cerrato et al. 
2015).  
For penetrating peptides it was shown that their intracellular localisation can be 
changed when altering amino acid residues or substitutions of additional amino acid 
residues. Modification with Phenylalanine residues is a popular choice to impart 
lipophilicity and to target conjugated CPPs for mitochondrial delivery. Targeting of 
penetrating peptides was monitored by conjugation with fluorophores like thiazole 
orange or 5(6)-carboxyfluorescein (Horton et al. 2008; Cerrato et al. 2015). These 
studies are important to characterise CPPs and shed light on their intracellular 
localisation. However, these utilise fluorophore conjugated peptides to visualize 
intracellular localisation. Conjugated fluorophores can alter uptake dynamics and 
could also have an effect on the intracellular localisation (Jones and Sayers 2012). 
Furthermore, these studies do not give information about cargo delivery, e.g. 
subcellular localisation of a delivered cargo and its activity once it has reached its site 
of action.  
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Split GFP enables us to investigate the localisation of the delivered M3 peptide 
and there is huge potential to investigate intra-organelle delivery by the expression of 
GFP1-10 inside an organelle to detect GFP complementation once M3 has reached 
the same location. This investigation would not necessarily require microscopy and 
flow cytometry measurement would be sufficient to detect green fluorescence of 
complemented GFP in order to determine if M3 had been delivered to the organelle.  
 
However, in this chapter it was shown that even though the intracellular GFP1-
10 target was expressed in the same localisation (cytosol), two different DDSs 
localised complemented GFP to different places inside the cell after delivery into the 
cytosol. When R8-M3 and Glycine added versions GR8-M3 or GGR8-M3 were 
utilised to deliver the M3 peptide, localisation of complemented GFP was found to be 
localised in the cytosol and the nucleolus. There was a clear separation of 
complemented GFP from the nucleus. When FR8-M3 or FFR8-M3 served as delivery 
vectors for the M3 peptide, complemented GFP was evenly localised throughout the 
cell. This important information would have been missed if GFP complementation had 
only been measured using flow cytometry.  
Hence, using microscopic analysis of the split GFP assay developed within this 
project allows us to visualize the intracellular localisation of a peptide cargo delivered 
by DDSs once it has complemented with its intracellular GFP1-10 target.  
 
Whether the preferential recruitment of R8-M3 into the cytosol or nucleus takes 
place before or after complementation with GFP1-10 remains unknown. GFP1-10 
was generated as a cytosolic expression construct meaning it was not fused to a 
protein or a sequence that specifically targets GFP1-10 to a subcellular location within 
the cell. It was shown that transient expression of non-targeted EGFP in HeLa cells 
is located at in the cytosol as well as the nucleus. It reaches the nucleus via diffusion 
through the nuclear pore and it was shown that even a fusion proteins consisting of 
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four GFPs (110 kDa) can enter the nucleus through the nuclear pore (Wang and 
Brattain 2007).   Hence, it is suggested that GFP1-10 that is expressed in the cytosol 
diffuses through the nuclear pore and is also present in the nucleus, therefore being 
present in both compartments. Nucleolar and cytosolic localisation of complemented 
GFP when R8-M3 is used as a drug delivery vector can thought to be achieved in 
different scenarios. Once R8-M3 crosses the plasma membrane it complements with 
cytosolic GFP1-10 which diffuses into the nucleus and localises to the nucleolus. R8-
M3 could also diffuse into the nucleus and localise at the nucleolus where it 
complements with GFP1-10 already located in the nucleus through diffusion. It is also 
possible that a combination of both scenarios takes place in a live cell.  
 
Independent of one or the other, one important question is: why does R8 localise 
to the nucleolus and the cytosol but not to the rest of the nucleus?  
 
The nucleolus is the site of ribosomal biogenesis where the ribosomal RNA 
(rRNA) is generated which is the building block of ribosomes (Scheer and Hock 1999). 
Furthermore, it is known that RNA binding proteins are enriched with arginine 
residues (Bayer et al. 2005) and Arginine residues strongly interact with negatively 
charged phosphate groups of the RNA (Treger and Westhof 2001; Woods and Ferré 
2005).  
The laboratory of Christina Cardoso has first published in 2006 that FITC labelled 
Decaarginine (FITC-R10) can act as a nucleolar marker in living cells such as HeLa 
cells, mouse fibroblasts or rat cardiomyocytes (Martin et al. 2007). In 2016 their 
protocol to stain the nucleolus with FITC-R10 was published in the Springer series 
The Nucleus Methods and Protocols (Martin et al. 2016). Furthermore, they 
investigated the principle of protein targeting to the nucleolus (Martin et al. 2015). 
They identified that Polyarginines labelled with FITC (R6 – R12) localised to the 
nucleolus while Polylysines of the same length did not specifically localise to the 
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nucleolus but were distributed within the whole nucleus. It was found that the 
nucleolar environment is more acidic compared to the surrounding nucleoplasm 
providing an ideal environment to bind poly-arginine containing proteins. Hence, it is 
likely that interaction between highly positively charged Arginine residues and the 
nucleolus where negatively charged rRNA resides is via electrochemical interaction 
(Martin et al. 2015).  
 
N-terminal addition of one or two Phenylalanine residues to R8-M3 can change 
the intracellular distribution of the delivered cargo peptide and its intracellular target 
GFP1-10 when they have reassembled to GFP. When Phenylalanine was attached 
to R8-M3, there was no separation of complemented GFP from the nucleus. Confocal 
analysis confirmed that it was distributed evenly throughout the cell.  
Phenylalanine is a basic amino acid and is added to peptides to increase the 
lipophilicity. It has been reported to be associated with targeting mitochondrial 
membranes (Horton et al. 2008; Cerrato et al. 2015). The data in this chapter does 
not show specific localisation of complemented GFP to mitochondria, however it 
remains unknown if FFR8-M3 enters the mitochondrial membrane. It would be 
interesting to test this, in fact, there are GFP1-10 DNA constructs available that 
ensure GFP1-10 expression localised to the outer mitochondrial membrane 
(accessible in the cytosol) as well as GFP1-10 expression in the mitochondrial matrix 
where translocation of M3 into the mitochondria would be necessary (Cali et al. 2014).  
Furthermore, GFP does not enter the mitochondria and these are seen as dark 
structures within cytosolic expressed GFP. Further experiments could investigate if 
these dark structures are still visible when R8-GFP or FFR8-GFP is expressed in the 
cytosol (both of which expression constructs are available in our lab).  
The general increase in lipophilicity when Phenylalanine residues are attached 
to R8-M3 could enhance its interaction with intracellular membranes which could be 
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an explanation why FFR8-M3 complemented with GFP1-10 localised at the Golgi 
membrane.  
 
This Chapter highlights the influence that a chosen DDS can have on subcellular 
localisation of the cargo peptide (and its target). This can be disadvantageous when 
the cargo-target complex needs to act in the cytosol but a large portion is located at 
the nucleolus. Microscopic analysis of the split GFP complementation will help to gain 
information about this and indicate whether intracellular cleavage mechanisms that 
separate the cargo from the DDS have to be incorporated. A popular tool to achieve 
this is the linkage of DDS and cargo via a disulfide bond that can be cleaved in the 
reducing environment of the cytosol (reviewed in (Saito et al. 2003)) and it was shown 
that gene silencing by delivered siRNA can be increased using this strategy (Kam et 
al. 2005; Breunig et al. 2008). Another strategy that has been utilised is the co-
incubation of cell penetrating peptides with the cargo that also led to the uptake of the 
co-incubated cargo molecule (Lee et al. 2010; Pinaud and Dahan 2011). 
 
However, targeting a cargo-target complex to a specific subcellular localisation 
also bears opportunities. R8 as a drug delivery system would be of interest if a 
peptide-target complex that assembled in the cytosol should be located to a specific 
subcellular localisation (e.g. nucleolus) to carry out their function. CPPs could then 
not only act as Trojan horses in order to guide cargo into the cytosol but also to locate 
cargo-target complex to a subcellular localisation.  
In fact, this has very recently been achieved and published (Herce et al. 2017). 
In this publication nanobodies against GFP (13-14 kDa) were delivered by 
tetramethylrhodamine labelled cyclic R10 (cR10) into cell expressing full length GFP. 
When full length GFP is expressed in the cytosol it is not found at the nucleolus. 
However, the nanobody against GFP was able to bind to GFP upon cytosolic delivery 
by cR10 and was able to target it to the nucleolus. Utlising this strategy they have 
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further shown that the polymerase clamp PCNA (proliferating cell nuclear antigen) 
and tumour suppressor p53 were located to the nucleolus.  
 
In summary, this data shows that microscopic analysis of GFP complementation 
by M3 delivery can add additional information about the localisation of complemented 
GFP. This is valuable information when characterising a drug delivery system and 
should be included in addition to flow cytometry measurements when analysing 
delivery efficiency of M3 peptides by DDSs using the split GFP system.  
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7 General Discussion 
7.1 Summary of findings 
In this thesis a method has been established to investigate cytosolic delivery of 
a functional peptide cargo to its intracellular target by different drug delivery systems. 
Peptides require drug delivery vectors for their intracellular delivery, hence, it is critical 
to be able to evaluate their ability to functionally deliver their peptide cargo to its 
intracellular target in order to select the most efficient drug delivery systems. Our 
method utilising the split GFP system allows us to investigate real time peptide 
delivery and to assess if the peptide cargo is still functional and whether it interacts 
with its intracellular target. Furthermore subcellular localisation of the peptide cargo 
and its target can be investigated using this method. 
 
7.1.1 Development of the Split GFP complementation assay  
Chapter 3 describes the development of the split GFP system in HeLa cells to 
investigate M3 peptide delivery to its intracellular GFP1-10 target by a drug delivery 
system. It was shown that the expression of the intracellular GFP1-10 target protein 
can be detected using immunofluorescence with an anti GFP antibody. Not every 
anti-GFP antibody was able to detect GFP1-10 expression, possibly due to their 
epitope specificity and the fact that GFP1-10 misses its 11th beta sheet from its 
structure. However, an anti GFP antibody has been identified that can prove that 
GFP1-10 is expressed in the cytosol of a target cell and this can be observed using 
immunofluorescent staining or western blot analysis.  
Initial testing of split GFP complementation can be performed using co-
expression of the DNA coding for the M3 peptide and GFP1-10 within the same cell. 
The GFP complementation can be monitored in fixed cells using a widefield 
fluorescent microscope or in live cells using a microplate reader.  
255 
 
Most importantly, a method has been developed that proves the in vitro 
complementation of GFP1-10 originated from cellular expression and M3 peptide 
conjugated to its drug delivery vector. By mixing cell lysate of cells expressing GFP1-
10 and with DDS-M3 peptide, it was possible to show concentration dependent as 
well as time dependent complementation of the two fragments. This is a critical step 
because the in vitro complementation can give insight if conjugation of the DDS to 
the M3 peptide influences ability to complement with GFP1-10. Furthermore, when 
comparing two DDSs, the in vitro assays can give information if GFP 
complementation is impaired or enhanced in vitro which allows correlation to the data 
obtained from live experiments to define if delivery efficiency is more or less efficient 
compared to the other DDS.  
 
7.1.2 The transient GFP1-10 expression system 
It was shown that the developed techniques can be utilised to characterise the 
split GFP assay and allowed the successful development of a transient expression 
systems to determine delivery of M3 by a drug delivery system. Functional and 
cytosolic M3 delivery was shown to be achieved using the drug delivery vectors R8 
as well as RhodamineR8 (Rh-R8).  
Labelling of R8 with the fluorescent tag Rhodamine showed that uptake of the 
RhR8-M3 peptide is heterogeneous across the cell population. It was also 
demonstrated that functional delivery of M3 was not observed in every cell, even 
though cells had taken up similar amounts of RhR8-M3 peptide shown by the 
fluorescence of rhodamine. However, the attachment of rhodamine to R8-M3 not only 
labelled the peptide but also increased uptake into the cells. It has been reported that 
the attachment of fluorophores can to changed uptake dynamics of CPPs into the cell 
(Jones and Sayers 2012) and especially for rhodamine it was recently shown that it 
increases the hydrodynamic radius of the CPPs significantly enhances cellular uptake 
into cells (Hyrup Moller et al. 2015). 
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Hence, attachment of rhodamine did not give a detailed insight of how the 
unlabelled peptide R8-M3 enters the cell. However, it gave important detail about the 
heterogeneous uptake of peptide across the cell population and that a transient 
expression system was not sufficient in order to show drug delivery system specific 
effect on M3 delivery. 
This highlighted the need to improve the split GFP method so that DDS specific 
effects can be seen on functional M3 delivery and the method is not dependent on 
intracellular expression levels of the GFP1-10 target protein.  These findings led to 
the generation of two stable cell lines; one expressing GFP1-10 (SCL1) and a second 
cell line including the fluorescent expression marker mCherry to express mCherry-
GFP1-10 (mCherry-SCL51).  
 
7.1.3 Stable cell line SCL1 
The stable cell line SCL1, expressing GFP1-10, has been fully characterised 
utilising the methods developed in order to characterise the split GFP system. This 
included the detection of GFP1-10 expression using immunofluorescence, 
expression of the DNA of the M3 fragment (H6-Xa-R8-M3) in SCL1 as well as in vitro 
complementation with M3 containing peptides. It was revealed that the cell line SCL1 
expresses even amounts of GFP1-10 across the cell population that can complement 
with the M3 fragment when expressed in the cell or in vitro when incubated with 
synthetic M3 peptides.  
Stable cell lines expressing GFP1-10 have been utilised by two other research 
groups who developed the split GFP method to determine functional delivery of the 
M3 peptide by DDSs (Milech et al. 2015; Lönn et al. 2016). These groups have only 
used flow cytometry as a detection method for GFP complementation. In our study 
we have utilised flow cytometry as well as microscopy. Utilising both techniques it 
was shown that the stable cell line SCL was more fluorescent than HeLa cells that 
did not express GFP1-10. This enhanced green fluorescence was examined by 
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spectral analysis of the emission spectrum and it is suggested that this fluorescence 
originates from autofluorescence of the cell as well as GFP fluorescence. This 
hypothesis was further confirmed when this enhanced green fluorescence was also 
detected in cells transiently expressing GFP1-10. Furthermore, this green 
fluorescence in stable cell lines was also described by (Milech et al. 2015) and was 
also attributed to the expression of GFP1-10.  
Moreover, the morphology of SCL1 cells was changed compared to HeLa cells 
which was seen by flow cytometry analysis of the cell line. The cells were bigger and 
more granular compared to HeLa cells. The granularity can be influenced by the 
shape of the nucleus and it was found by Alexander Dudziak that the shape of the 
nuclei were changed in SCL1 cell compared to HeLa cell which would be an 
explanation for this finding. Importantly, no morphological changes to the actin or 
tubulin skeleton were detected which is critical when the delivery M3 by the CPP R8 
is investigated that may deliver the M3 cargo by micropinocytosis which is dependent 
on the actin skeleton.  
In summary, the SCL1 cell line can be utilised to investigate functional M3 
delivery by DDSs. However, the high green fluorescent background in this cell line in 
combination with weak signal of GFP complementation (due to insufficient delivery) 
make it challenging to obtain a sufficient fluorescent signal on the microscope. Flow 
cytometry measurement is more representative of GFP complementation across the 
cell population.  It would be a major improvement to the assay if a cell line could be 
obtained that emits less green fluorescence whilst maintaining sufficient expression 
levels of GFP1-10.  
 
7.1.4 Stable cell line mCherry-SCL51 
Introducing an expression marker for GFP1-10 expression improves the split 
GFP method, so that it can be visualised which cells are expressing the GFP1-10 
target protein in their cytosol when transient expression is used. This approach has 
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also been utilised by Schmidt and his colleagues in order to investigate M3 delivery 
by the CPP R9. (Schmidt et al. 2015a). Utlising this technique using transient 
transfection will give insight if the M3 peptide has been delivered to the cytosol. 
Howerver, it has been previousely shown that uptake of CPPs is dependent on the 
peptide to cell ratio rather than the absolute peptide concentration (Hallbrink et al. 
2004). As a results of transient expression of mCherry-GFP1-10, some cells will not 
express the mcherry-GFP1-10 target protein. This will result in a number of cells that 
are investigated in the split GFP assay and will take up peptide but they cannot give 
a readout about functional peptide delivery.  
Hence, the generation of a stable cell line expressing mCherry-GFP1-10 was 
advantageous when investigating functional delivery of the M3 peptide. The 
generated stable cell line, mCherry-SCL51 was found to be a polyclonal cell line with 
86% of the cells expressing mCherry-GFP1-10 which was confirmed by 
immunofluorescent staining to detect GFP1-10 expression. mCherry-SCL51 was 
further found to be able to complement with M3 by transfection of DNA coding for M3 
or in vitro when mCherry-SCL51 cell lysate was used to complement with synthetic 
M3 containing peptides.  
Cytosolic green fluorescence was also found to be increased in mCherry-SCL51 
cells compared to HeLa cells, as seen in the SCL1 cell line. No spectral analysis of 
emitted green fluorescence was perfromed on this cell line. However, it is suggested 
that this green fluorescence is derived from GFP1-10 expression like it was shown 
for SCL1 cells.  
In summary, it was shown that a stable cell line has been created expressing 
mCherry-GFP1-10 and this cell line can be utilised to determine M3 delivery by 
different DDS. Resulting GFP complementation can be monitored by flow cytometry 
as well as microscopy. The stable cell line can further be improved in order to obtain 
a clonal cell line where all cells expressing even amounts of mCherry-GFP1-10 
across the cell population.  
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The expression marker mCherry that labels GFP1-10 expression also has the 
potential to allow us to obtain a quantitative readout of how much M3 peptide is 
delivered in the cytosol of target cells and correlate mCherry and GFP fluorescence.  
 
7.1.5 Octaarginine and its performance as a peptide delivery vector 
In this study octaarginine (R8) was utilised as a drug delivery vector to facilitate 
functionally delivery of the M3 peptide cargo. It was shown that R8-M3 enhances GFP 
fluorescence compared to L-M and M3 when incubated at 10-40 µM with SCL1 for 2 
h. This demonstrated that R8 is able to act as a drug delivery vector to functionally 
deliver M3 peptide cargo which leads to GFP complementation and increase of GFP 
fluorescence compare to M3 peptides that are not conjugated to drug delivery 
systems. M3 delivery was shown to be significantly different (p<0.001) at 40 µM and 
M3 was delivered to 28% of the SCL1 cell population. When the split GFP assay was 
utilised by other research groups, functional delivery of M3 by arginine rich peptides 
like R9 and Tat was shown at concentrations between at 5-20 µM and 5-60 µM, 
respectively (Milech et al. 2015; Schmidt et al. 2015a; Lönn et al. 2016). The mode of 
uptake of R8-M3 through direct penetration or endocytosis followed by endosomal 
escape remains unknown and is subject to future studies.  
In this study, we have also shown that M3 delivery by R8 can be enhanced by 
the N-terminal addition of two Phenylalanine residues. M3 delivery using FFR8-M3 
was significantly enhanced compared to R8-M3 at concentrations of 30 µM and 40 
µM (p<0.001). Addition of two Glycine residues (GGR8-M3) did not result in enhanced 
M3 delivery, nor did the addition of one Phenylalanine residue (FR8-M3).  
 
Moreover, it was found that an addition of Phenylalanine residues to R8-M3 not 
only enhanced the functional delivery of the M3 peptide but also influenced the 
localisation of complemented GFP in the cytosol. When M3 was delivered using 40 
µM R8-M3, complemented GFP was localised in the cytosol as well as located at the 
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nucleolus. The addition of one or two Phenylalanine residues to R8-M3 resulted in an 
even distribution of complemented GFP thought the cell. This effect was also specific 
to Phenylalanine residues and was not seen for the addition of one or two Glycine 
residues.  
Other research groups have also demonstrated enhanced uptake of M3 by 
modified CPPs to increase intracellular stability or enhance endosomal escape 
(Schmidt et al. 2015a; Lönn et al. 2016). However, the influence of the CPP or 
modified CPP on the intracellular localisation of the cargo has not been shown before 
utilising GFP. The importance of this effect and the chances of targeted re-localisation 
of intracellular protein to compartments (e.g. the nucleolus) has recently been 
demonstrated  (Herce et al. 2017) and is of high importance when characterising 
DDSs. 
 
Importantly, in this study compared to other split GFP systems that have been 
developed, it is shown that functional M3 delivery can be captured in real time using 
a widefield fluorescent microscope and functional delivery and GFP complementation 
was seen to be as fast as 5 minutes. Visualisation of real time delivery using a 
microscope can give important information about M3 peptide delivery and allows us 
to investigate live dynamics of functional M3 delivery within the same cell over time 
which is not possible using flow cytometry.  
 
Key to a perfect DDS is the ability to efficiently deliver cargo with minimal 
cytotoxicity. Much effort has been put into identifying new CPPs or modify existing 
CPPs so that a maximal delivery of cargo is achieved with decreased cytotoxicity 
(Lönn et al. 2016; Schmidt et al. 2017). In this study, the cytotoxicity or the effect on 
membrane integrity of R8-M3 or Phenylalanine or Glycine modified versions of R8-
M3 has not been investigated. This data will be critical in order to characterise these 
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DDSs and their ability to functionally deliver cargo into live cells and will be 
investigated in the future.  
 
7.1.6 Limitations of the Split GFP system 
The developed methods and resources are an important advance in order to 
investigate functional M3 peptide delivery by novel DDSs and assess their ability to 
functionally deliver peptide cargo. However, this method can further be improved. 
Complemented GFP fluorescence was only weak to be detected on the microscope. 
This is likely to be due to insufficient delivery of the M3 peptide to the cytosol. The 
weak green fluorescence could also be due to limited GFP1-10 expression in the 
cytosol of the stable cell line. However, when concentration dependent delivery of the 
M3 peptide by different CPPs was investigated no saturation of complemented GFP1-
10 was seen. If the weak fluorescence is due to insufficient delivery of the M3 peptide 
to the cytosol it would be advantageous to increase the sensitivity of this method by 
an intracellular enhancing cascade resulting in increased fluorescence.  
Kim and colleagues have introduced an enhanced split GFP system (Kim et al. 
2015). In their method, the short M3 fragment was delivered by a penetrating antibody 
to cells expressing GFP1-10 in order to prove the cytosolic delivery of the antibody. 
They utilised an enhanced split GFP system where GFP1-10 is expressed as a fusion 
to streptavidin (SA) which naturally forms tetramers connecting GFP1-10 in the cell. 
The penetrating antibody-M3 peptide complex was fused to an SBP2 peptide. One 
tetramer of streptavidin bind two molecules of SBP2 peptide which leads to enhanced 
GFP complementation through SBP2-SA interaction. In their publication they state 
that it was possible to measure GFP fluorescence in a 96 well format on a 
spectrofluorometer which suggests high fluorescent signal of complemented GFP in 
these cells (which could be due to the enhanced split GFP assay or the great 
penetrating ability of the antibody utilised in this study).  
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It is also known that the size of a cargo attached to DDS like CPPs changes the 
mode of uptake into the cell (Maiolo et al. 2005; Tunnemann et al. 2006). Using the 
split GFP system it is possible to investigate the functional delivery of a peptide cargo 
of the size of 1.8 kDa. However, once a DDS is selected to functionally delivery 
peptides, the conjugation of a different peptide cargo could lead to unpredicted 
change in delivery of that cargo to its intracellular target.   
 
7.2 Future directions  
7.2.1  Use of split GFP assay to determine peptide delivery into organelles 
The use of the split GFP assay to investigate functional delivery of the M3 peptide 
has the great potential to be utilised to not only characterise DDSs and their ability to 
delivery functional cargo into the cytosol, but also determine the ability to functionally 
deliver the peptide into organelles. Recently Split GFP has developed into a popular 
tool, not only regarding DDS characterisation but also to determine orientation or 
localisation of proteins (Cali et al. 2014; Hyun et al. 2015). Thus a range of subcellular 
split GFP expression constructs have been generated and published (Cali et al. 2014; 
Hyun et al. 2015). Utilising split GFP in a co-expression study with an endoplasmatic 
reticulum (ER) based membrane protein it was shown that the orientation of the 
membrane protein can be determined by co-expression with cytosolic GFP1-10 or 
luminal GFP1-10 (Hyun et al. 2015). Luminal localisation of GFP1-10 was ensured 
by attachment of an ER retention sequence. Furthermore, GFP1-10 can be 
expressed at the outer membrane of mitochondria (cytosolic access) and the 
mitochondrial matrix (Cali et al. 2014). It would be interesting to investigate M3 
peptide delivery to these organelles using novel drug delivery vectors and this would 
open up new possibilities for macromolecular therapeutics to not only gain access to 
cytosolic targets but to targets located in specific organelles which could help to cure 
disease with even higher specificity and less side effects.    
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7.2.2 Colour variants 
GFP is a fluorescent protein that can easily be genetically manipulated to exhibit 
changed excitation and emission characteristics. Point mutations in the fluorophore 
allows us to utilise it as a yellow (T203Y) or cyan (Y66W) fluorescent probe named 
YFP (yellow fluorescent protein) and CFP (cyan fluorescent protein), respectively 
(Heim et al. 1994; Heim and Tsien 1996; Ormo et al. 1996). All mutations that result 
in a shift of fluorescence spectra are located within the amino acid sequence of the 
GFP1-10 fragment. Hence it has been possible to introduce these mutations to obtain 
YFP1-10 and CFP1-10 (Kamiyama et al. 2016). This has great potential because the 
same M3 peptide (GFP11) can rescue the fluorescence of GFP1-10, YFP1-10 or 
CFP1-10. This opens up new opportunities in the field of drug delivery. Different 
colour variants could be expressed in different subcellular localisation within the same 
cell and functional delivery to a certain position would be indicated by which colour 
fluorescence is rescued.  
 
In addition to that another split fluorescent colour variant is available: split Cherry 
(sfCherry1-10). mCherry has a different precursor than GFP and is derived from a 
tetrameric protein found in reef corals, DsRed (Matz et al. 1999). In a stepwise 
process a monomeric protein was created and a range of red colour fluorescent 
variants were developed by mutation of critical residues. mCherry has 
excitation/emission peaks at 587nm/610nm wavelength (Campbell et al. 2002; 
Shaner et al. 2004) and the development of super-folder Cherry (sfCherry) has led to 
creation of split mCherry. sfCherry1-10 requires a different small peptide fragment 
compared to the M3 peptide that rescues its fluorescence and is called sfCherry11. 
Its fluorescence is not yet rescued as efficiently as seen for split GFP but once this 
issue is overcome, a second split peptide cargo is available to test functional delivery 
of peptides into cells.  
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7.2.3 Split GFP as a high throughput imaging technique 
The split GFP as a microscopy based technique has the potential to be utilised 
as a fully automated high throughput screening platform to determine novel DDSs to 
functionally deliver peptide cargo into cells. In order to pursue this goal sensitivity 
issued have to be overcome. Thus far, the split GFP system developed in this thesis 
lacks brightness so that imaging in a 96 well format at low magnification is 
challenging. However, the lack of brightness could also be attributed to poor delivery 
of the M3 peptide into the cytosol and therefore GFP fluorescence is low.  In order to 
utilise the split GFP system as a high throughput imaging technique it is probably 
necessary to improve both, the efficiency of M3 delivery by vectors and a cell line that 
expresses maximal amounts of GFP1-10 in the cytosol. Multiple stable cell lines 
expressing GFP1-10 have been generated by different research groups investigating 
M3 delivery by DDSs (Milech et al. 2015; Schmidt et al. 2015b; Lönn et al. 2016). It 
would be interesting to compare the delivery of M3 by the same DDS utilising those 
different cell lines to gain information if there is a cell line available that is more 
promising to be utilised on a high throughput imaging platform.  
 
7.2.4 Delivery into organoids and animal models 
In this thesis, the split GFP complementation was developed using a two 
dimensional (2-D) tissue culture model in the cell line HeLa. Other groups have used 
different cell types to investigate M3 delivery to cells expressing GFP1-10, however, 
all of them were adherent 2-D cell models (Milech et al. 2015; Schmidt et al. 2015b; 
Lönn et al. 2016). The choice of a 2-D cell model was the best choice to develop the 
split GFP complementation assay because 2-D cell models like HeLa cells are well 
characterised and more importantly, easy to genetically modify their protein 
expression using transfection. However peptide drugs are designed to be 
administered in humans where cells grow in 3 dimensional structures. Hence, a better 
description of the cell barrier that a DDS with its peptide cargo has to overcome are 
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three dimensional (3-D) cell models like spheroids or organoids (reviewed in (Breslin 
and O'Driscoll 2013) (Fatehullah et al. 2016)). These cell models would have been 
challenging to develop the split GFP complementation assay because they can be 
hard to transfect and the cell models themselves are still being characterised. 
Nevertheless, it should be pursued to integrate the split GFP complementation assay 
into spheroid models and ultimately in organoid models. In the future, the split GFP 
system could even be utilised to investigate tissue specific delivery in a genetically 
modified mouse model.   
 
7.3 Concluding remarks 
An increased understanding of functional delivery of macromolecules such as 
peptides and their access to their intracellular targets is important and comes with the 
great opportunity to develop biopharmaceutical drugs with increased specificity and 
reduced side effects. In order ensure intracellular peptide delivery novel drug delivery 
vectors are needed. The successful development of novel drug delivery vectors relies 
on a technique that allows us to assess their ability to deliver functional peptide cargo 
to their intracellular targets.  
Within this project, a method based on split GFP complementation has been 
developed that allows us to evaluate drug delivery vectors regarding their ability to 
functionally deliver peptide cargo into the cytosol. In this thesis it is highlighted that 
microscopy analysis can give insight as to when peptide cargo is delivered to its target 
as well as where it is delivered to. This adds valuable information to the 
characterisation of novel DDSs and has not been shown before by other groups 
utilising this assay to characterise peptide delivery vectors. Hence, the split GFP 
complementation system presented in this study is a great method to characterise 
DDSs regarding their ability to functionally deliver M3 peptide cargo and gives insight 
as to if, when and where peptide cargo is delivered to.  
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9 Appendices 
9.1 Recipes and buffers 
Mowiol 
Mowiol 4-88 2.4 g  
 Glycerol 6 g  
 H2O 6 ml  
 0.2M Tris pH 8.5 12 ml 
 
Non- denaturing lysis buffer 
50mM Tris-Cl 
150mM NaCl,  
1%Triton-X-100,  
Protease inhibitor (cOmplete™, EDTA-free) 
 
Loading Buffer (gel electrophoresis)  
 
Glycerol 30%(v/v) 
Bromophenol Blue (0.25%) 
In TE (10mM Tris, pH7.4, 1mM EDTA) 
Final conc of 0.1mg/ml ethidium bromide 
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9.2 Vector map EGFP-N2 
 
Figure 9-1 Vector map of EGFP-N2.  
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9.3 Appendix Chapter 3 
 
 
Figure 9-2 Comparison of two anti-GFP antibodies 
HeLa cells were transiently transfected with DNA constructs coding for GRASP65-GFP or 
GRASP65-GFP1-10 expression. The transfection mix of mock transfected cells did not contain 
DNA. Cells were incubated in transfection mix overnight and PFA fixed the next day. The 
plasma membrane was permeabilised with 0.1 % Triton-X-100. (A) GRASP65-GFP or 
GRASP65-GFP1-10 expression was detected using a primary anti-GFP antibody (Roche) 
raised in mouse. A secondary anti-mouse antibody conjugated to Alexa-568 was used to 
visualise GFP expression (Anti GFP). (B) GRASP65-GFP or GRASP65-GFP1-10 expression 
was detected using a primary anti-GFP antibody (Vectorlaboratories) raised in goat. A 
secondary anti-goat antibody conjugated to Alexa-647 was used to visualise GFP expression 
(Anti GFP). Representative images shown for each condition. Nuclei were counterstained with 
DAPI. Scale bars: 30 µm. N=1.  
D 
 
 
 
Figure 9-3 Detection of GRASP65-GFP1-10 expression in HeLa cells using 
immunofluorescence.  
HeLa cells were transiently transfected with DNA constructs coding for GRASP65-GFP1-10 
or full length GRASP65-GFP. The transfection mix of mock transfected cells did not contain 
DNA. Cells were incubated in transfection mix overnight and PFA fixed the next day. The 
plasma membrane was permeabilised with 0.1 % Triton-X-100 and GRASP65-GFP1-10 or full 
length GRASP65-GFP expression was detected using a primary anti-GFP antibody raised in 
goat. A secondary anti-goat antibody conjugated to Alexa-647 was used to visualise GFP 
expression (Anti GFP). Nuclei were counterstained with DAPI. Representative images are 
shown for each condition. Scale bars: 30 µm. n=3.  
 
 
 
 
Figure 9-4 Detection of GRASP65-GFP complementation after co-tranfection using a 
microplate reader. 
Single transfections or co-transfections of HeLa cells were performed with DNA encoding for 
GRASP65-GFP, GRASP65-GFP1-10, mCherry-H6-Xa-R8-M3 and mCherry. The transfection 
mix of mock transfected cells did not contain DNA. Cells were left in transfection mix overnight. 
The next day, cells were detached from their dish using trypsin, washed and transferred into 
a clear bottom, black walled microwell plate. Green fluorescence was monitored using a 
microplate reader. n=2.  
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Figure 9-5 Excitation and emission spectrum of Rhodamine (TMR) and GFP. 
The graph shows GFP excitation (light green) and emission (dark green) spectrum and TMR-
Rhodamine excitation (light red) and emission (dark red) spectrum. Spectra were obtained 
from the Chroma website.  
 
 
 
9.4 Appendix Chapter 4 
 
Figure 9-6 mCherry-SCL34 
mCherry-SCL34 was obtained after the first round of limiting dilution was expanded and used 
for the second round of limiting dilution. Images show the polyclonal cell line before the second 
round of limiting dilution was performed.  
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9.5 Appendix Chapter 5 
 
Figure 9-7 Form factor of the nucleus of SCL1 and HeLa cells 
This figure was copied from the report Characterisation of a stable cell line expressing the 
large component of a split GFP system by Alexander Dudziak, University of Duisburg-Essen, 
2015. All experiments were performed under my supervision.  
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Figure 9-8 Labelling of the plasma membrane of SCL1 and HeLa cells.  
This figure was copied from the report Characterisation of a stable cell line expressing the 
large component of a split GFP system by Alexander Dudziak, University of Duisburg-Essen, 
2015. All experiments were performed under my supervision.  
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Figure 9-9 Immunofluorescence of the actin cytoskeleton in HeLa and SCL1 cells. 
This figure was copied from the report Characterisation of a stable cell line expressing the 
large component of a split GFP system by Alexander Dudziak, University of Duisburg-Essen, 
2015. All experiments were performed under my supervision.  
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Figure 9-10 Immunofluorescence of tubulin in HeLa and SCL1 cells. 
This figure was copied from the report Characterisation of a stable cell line expressing the 
large component of a split GFP system by Alexander Dudziak, University of Duisburg-Essen, 
2015. All experiments were performed under my supervision.  
 
